Scientific Programme

Sunday, 30 August 2020

Non-Profit Symposium
08:30 - 10:00

IS1, How does MRD impact outcome of stem cell transplantation in AML, now and in the future? - AML Hub non-profit symposium

Chairs:
Gert Ossenkoppele (Netherlands)

Welcome and introduction 08:30 - 08:35
Gert Ossenkoppele (Netherlands)

Challenges in MRD measurement by Multiparameter Flow Cytometry (MFC) in AML 08:35 - 08:50
Jacqueline Cloos (Netherlands)

New developments in molecular MRD assessment in AML 08:50 - 09:05
Christian Thiede (Germany)

Does current evidence support the use of MRD guided treatment before transplant in patients with AML? 09:05 - 09:20
Adriano Venditti (Italy)

Why should we use MRD assessment post hematopoietic stem cell transplantation? 09:20 - 09:35
Charles Craddock (United Kingdom)

Round table discussion: Use of MRD guided treatment decisions before and after transplantation 09:35 - 09:50

Summary and conclusions: Establishing MRD as surrogate endpoint in AML, and what does the future hold 09:50 - 10:00
Gert Ossenkoppele (Netherlands)

Non-Profit Symposium
08:30 - 10:00
Hall A (Exhibition Area)

IS2, Dilemma in allogeneic hematopoietic transplantation for myelofibrosis - Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) non-profit symposium

Chairs:
Jacques Olivier Bay (France)
Marie-Thérèse Rubio (France)

Impact of HSCT in ruxolitinib area 08:30 - 09:00
Marie Robin (France)

Transplantation with an alternative donor: Results and perspectives 09:00 - 09:30
Nicolaus Kröger (Germany)
Liver specificities in myelofibrosis and impact on transplantation procedure
Audrey Payance (France)

IS3, Latest developments in hematopoietic cell transplantation - Sorbonne University (ATERHIT) non-profit symposium

Chairs:
Arnon Nagler (Israel)
Bipin Savani (United States)

Haplo transplant for AML
Arnon Nagler (Israel)

Haplo transplant for the elderly
Didier Blaise (France)

Monoclonal antibodies in ALL
Eolia Brissot (France)

Monoclonal antibodies in Hodgkin lymphoma
Ali Bazarbachi (Lebanon)

Allogeneic transplantation after CAR T-cell therapy
Bipin Savani (United States)

Round table discussion

IS4, Multiple Myeloma in 2020: The IFM global perspective - IFM non-profit symposium

Chairs:
Mohamad Mohty (France)
Jean-Luc Harousseau (France)

What's new for induction prior to ASCT?
Philippe Moreau (France)

What's new in the elderly setting?
Thierry Facon (France)

Monoclonal antibodies for relapse after ASCT
Mohamad Mohty (France)

Requirements for functional cure in myeloma
Jean-Luc Harousseau (France)

Round table discussion
**Scientific Programme**

**CME Symposium**  
*08:30 - 10:00*  
*Sala Retiro*

**IS5, GMMG CME Symposium: Stem cell transplantation in Multiple Myeloma**

**Chairs:**  
Hartmut Goldschmidt (Germany)

- **Role of allo-TPX in Multiple Myeloma**  
  Nicolaus Kröger (Germany)  
  *08:30 - 08:45*

- **Impact of age on the decision of auto-TPX in Multiple Myeloma**  
  *08:45 - 09:00*

- **Predictive factors in Multiple Myeloma**  
  Hartmut Goldschmidt (Germany)  
  *09:00 - 09:15*

- **Treatment of high-risk Multiple Myeloma**  
  Katja Weisel (Germany)  
  *09:15 - 09:30*

- **Role of antibodies in the treatment of Multiple Myeloma**  
  Igor-Wolfgang Blau (Germany)  
  *09:30 - 09:45*

- **Cellular Therapy in Multiple Myeloma**  
  Christoph Scheid (Germany)  
  *09:45 - 10:00*

**Nurses Group**  
*08:30 - 10:00*  
*Sala Colón*

**NG01, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can’t live without them**

**Chairs:**  
Caroline Bompoint (France)  
Julia Ruiz (Spain)

- **Welcome and introduction**  
  John Murray (United Kingdom)  
  *08:30 - 08:35*

- **Overview: Indications and implications**  
  Jörg Halter (Switzerland)  
  *08:35 - 09:00*

- **How does it work? Mechanisms of action**  
  Agnès Bonnin (France)  
  *09:00 - 09:30*

- **Use in paediatrics**  
  Alberto Castagna (Italy)  
  *09:30 - 10:00*

**EBMT Exam**  
*09:00 - 12:00*  
*Sala Neptuno*

**EBMT Exam**
Scientific Programme

Statistics
09:00 - 12:00

Stat1, Statistical Course: Basic Statistics

Basic Statistics
Antonella Santucci (Italy)
Richard Szydlo (United Kingdom)

Patient, Family Donor Day
09:15 - 09:30

PFD0, Patient, Family and Donor Day: Welcome

Chairs:
Bregje Verhoeven (Netherlands)
Lola Manterola (Spain)

Welcome from Madrid
Rafael Duarte (Spain)

Welcome from Patient Advocacy Committee
Bregje Verhoeven (Netherlands)

Housekeeping
Lola Manterola (Spain)

Patient, Family Donor Day
09:30 - 11:00

PFD1, Patient, Family and Donor Day: General introduction

Chairs:
Guy Bouguet (France)
Lola Manterola (Spain)

My Experience with cGVHD
Ángela Gómez (Spain)

Overview of haematopoietic stem cell transplantation
Miguel Ángel Díaz Pérez (Spain)

Chronic GVHD: The Daily Impact
Régis Peffault de Latour (France)

Questions & Answers

Page 4 / 203
Scientific Programme

Industry Symposium
10:30 - 12:00

**IS6, GVHD: What's new in 2020? - Sanofi Genzyme Industry Symposium**

**Chairs:**
Mohamad Mohty (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30 - 10:40 | Welcome and introduction  
Mohamad Mohty (France) |
| 10:40 - 10:55 | The mycobiota: A new player in GVHD pathophysiology  
Florent Malard (France) |
| 10:55 - 11:10 | ATG and/or post-Cy for GVHD prophylaxis  
Mohamad Mohty (France) |
| 11:10 - 11:25 | Personalized ATG dosage: The PARACHUTE trial  
Jaap Jan Boelens (United States) |
| 11:25 - 11:40 | Nutritional support for GVHD patients  
Zinaida Peric (Croatia) |
| 11:40 - 12:00 | Round table discussion                                                   |

Industry Symposium
10:30 - 12:00

**IS7, Practical considerations for CAR-T Cell Therapy use in lymphomas - Novartis**

**Industry Symposium**

**Chairs:**
Anna Sureda (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30 - 10:35 | Introduction and opening remarks  
Anna Sureda (Spain) |
| 10:35 - 10:55 | CAR-T Cell Therapy in the DLBCL continuum of care: Efficacy and safety in key clinical trials and the real world  
Matthew Frigault (United States) |
| 10:55 - 11:10 | Patient selection for CAR-T Cell Therapy: What we know and what we have yet to find out  
Anna Sureda (Spain) |
| 11:10 - 11:30 | Treatment landscape in DLBCL: New developments, and when to take the CAR instead?  
Edmund K Waller (United States) |
| 11:30 - 11:45 | How to apply CAR-T Cell Therapy in DLBCL: Interactive case-based panel  
Pere Barba (Spain) |
| 11:45 - 11:55 | Panel discussion and Q&A  
Anna Sureda (Spain) |
| 11:55 - 12:00 | Closing remarks  
Anna Sureda (Spain) |
Industry Symposium
10:30 - 12:00
Hall B (Exhibition Area)

IS8, Maintenance of complete remission in AML - Celgene Industry Symposium

**Chairs:**
Martin Bornhäuser (Germany)

**Welcome and introduction**
Martin Bornhäuser (Germany)  
10:30 - 10:40

**Kinetics of clonal evolution and relapse in AML patients in complete response**
Maria Teresa Voso (Italy)  
10:40 - 11:15

**Current and upcoming pharmacological options to prolong complete response in AML**
Charles Craddock (United Kingdom)  
11:15 - 11:50

**Closing remarks**
Martin Bornhäuser (Germany)  
Maria Teresa Voso (Italy)  
Charles Craddock (United Kingdom)  
11:50 - 12:00

Industry Symposium
10:30 - 12:00
Sala Retiro

IS9, Case Studies on Innovative Treatment Approaches for CMV in HCT: A Clinical Forum - Industry Symposium supported by an educational grant from Takeda

**Chairs:**
Jan Styczynski (Poland)

**Welcome and Introductions**
Jan Styczynski (Poland)  
10:30 - 10:35

**HCT CASE 1 - Patient with Refractory or Resistant Disease and Panel Discussion**
Per Ljungman (Sweden)  
10:35 - 11:05

**Audience Q&A**  
11:05 - 11:10

**HCT CASE 2 - Patient with Late CMV Disease and Panel Discussion**
Johan Maertens (Belgium)  
11:10 - 11:40

**Audience Q&A, Closing Remarks**  
11:40 - 12:00
NG02, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can’t live without them

Chairs:
Caroline Bompoint (France)
Isabel Salcedo (Spain)

Psychologic aspects: Compliance and survivorship 10:30 - 11:00
Sarah Dwinger (Germany)

Avascular necrosis and osteoporosis 11:00 - 11:30
Nicola Chesman (United Kingdom)

Effects on immune system: Infections 11:30 - 12:00
Lucrecia Yáñez San Segundo (Spain)

LT1, Lab Technicians Day: Specialized cell processing

Chairs:
Harry Dolstra (Netherlands)

Bone marrow processing: Techniques and results 10:30 - 11:00
Boris Calmels (France)

Technical aspects and performance TCRab depletion 11:00 - 11:30
Kasper Westinga (Netherlands)

Donor selection and GMP-compliant manufacturing of virus-specific T-cells 11:30 - 12:00
Britta Eiz-Vesper (Germany)

PFD2, Patient, Family and Donor Day: New developments

Chairs:
Guy Bouguet (France)
Bregje Verhoeven (Netherlands)

Patient experience on CAR T 11:30 - 11:40
Mar Agudo (Spain)

Could CAR T-cell therapy save my life? 11:40 - 12:10
Jürgen Kuball (Netherlands)

HSCT for autoimmune disease and novel indications 12:10 - 12:40
John Snowden (United Kingdom)
Scientific Programme

Questions & Answers 12:40 - 13:00

Industry Symposium
12:30 - 14:00

IS10, Improving outcomes: Transplant and beyond in patients with high-risk AML - Jazz Pharmaceuticals Industry Symposium

Industry Symposium
12:30 - 14:00

IS11, Steroid-refractory GVHD: Current challenges and future advances - Novartis Industry Symposium

Chairs:
Franco Locatelli (Italy)

Welcome and introduction 12:30 - 12:35
Franco Locatelli (Italy)

GVHD and steroid-refractory GVHD in 2020 12:35 - 12:55
Jeff Szer (Australia)

Today's challenges in managing acute and chronic steroid-refractory GVHD 12:55 - 13:05
Franco Locatelli (Italy)

Panel discussion 13:05 - 13:10

The future of steroid-refractory GVHD: Acute and chronic GVHD 13:10 - 13:40
Madan Jagasia (United States)
Robert Zeiser (Germany)

Panel discussion 13:40 - 13:55

Concluding remarks 13:55 - 14:00
Franco Locatelli (Italy)

Industry Symposium
12:30 - 14:00

IS12, Current status and potential of CAR T cell therapies in B-cell malignancies - Celgene Industry Symposium

Chairs:
Catherine Thieblemont (France)

Welcome and introduction 12:30 - 12:35
Catherine Thieblemont (France)

CAR T in DLBCL: The latest data and future perspectives 12:35 - 13:00
Leo Gordon (United States)
Scientific Programme

Beyond DLBLC: CAR T in high-risk or relapsing B-cell malignancies 13:00 - 13:25
Tom van Meerten (Netherlands)

The impact of CAR T on patient care organization 13:25 - 13:50
Catherine Thieblemont (France)

Discussion, Q&A and close 13:50 - 14:00
Catherine Thieblemont (France)

Industry Symposium
12:30 - 14:00
N105

IS13, Established and cutting-edge applications for cell therapies - Miltenyi Biotec

Industry Symposium
Chairs:
Rafael Duarte (Spain)

Welcome and introduction 12:30 - 12:40
Rafael Duarte (Spain)

Picking your favorite tapas: Which cell populations to include in the allograft 12:40 - 12:50
Miguel-Angel Perales (United States)

TCRα/β CD19 depleted haploidentical HSCT in adult patients - Final results of the TCRalpha/beta-Haplo2010 study 12:50 - 13:00
Wolfgang Bethge (Germany)

Improved survival rate in T cell-depleted haploidentical hematopoietic cell transplantation utilizing CD45RA-depleted grafts 13:00 - 13:10
Brandon Triplett (United States)

Semi-automated CAR T cell manufacturing: focus on the UCL CAR T-cell programme 13:10 - 13:20
Claire Roddie (United Kingdom)

Nurses Group
12:30 - 14:00
Sala Colón

NG03, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can’t live without them

Chairs:
Caroline Bompoint (France)
Julia Ruiz (Spain)

Steroids and sugar - Much ado about nothing? 12:30 - 13:00
Matthias Hepprich (Switzerland)

Well-being on and off steroids: Practical tips for nurses 13:00 - 13:30

Patient testimony: Weight gain, information, diabetes, relationships 13:30 - 14:00
Agnès Huet-Vicens (France)
**Scientific Programme**

**Lab Technicians Day**  
12:30 - 14:00  

**LT2, Lab Technicians Day: Cell product testing, validation and characterization**  

**Chairs:**  
Britta Eiz-Vesper (Germany)

- **Phenotyping and functional testing by flow cytometry**  
  12:30 - 13:00  
  Harry Dolstra (Netherlands)

- **Flow cytometry-based CD34 enumeration**  
  13:00 - 13:30  
  Harry Dolstra (Netherlands)

- **Flow cytometric in-process and quality control for CAR T-cell manufacturing**  
  13:30 - 14:00  
  Ulrike Köhl (Germany)

**Statistics**  
13:00 - 16:00  

**Stat2, Statistical Course: Survival Analysis**  

- **Survival Analysis**  
  13:00 - 16:00  
  Antonella Santucci (Italy)  
  Richard Szydlo (United Kingdom)

**Patient, Family Donor Day**  
14:00 - 15:30  

**PFD3, Patient, Family and Donor Day: Post-transplant care**  

**Chairs:**  
Lola Manterola (Spain)  
Isabel Salcedo (Spain)

- **Patient experience on post-transplant**  
  14:00 - 14:10
- **A pathway for post-transplant care**  
  14:10 - 14:30  
  Fiona Dignan (United Kingdom)
- **Dealing with psychological effects**  
  14:30 - 14:50  
  Anna Barata (United States)
- **What about fertility?**  
  14:50 - 15:05  
  Mara Andrés Moreno (Spain)
- **The impact of stem cell transplants on sexuality, sexual functioning and sexual relationships**  
  15:05 - 15:20  
  Justin Grayer (United Kingdom)
- **Questions & Answers**  
  15:20 - 15:30
IS14, Curative treatment intent in R/R DLBCL: The role of CAR T-cell therapy - Kite

Industry Symposium
14:30 - 16:00

Chairs:
Álvaro Urbano-Ispizua (Spain)

Welcome and introduction
Álvaro Urbano-Ispizua (Spain)
14:30 - 14:35

How has the DLBCL patient pathway evolved?
Álvaro Urbano-Ispizua (Spain)
14:35 - 14:45

Can we redefine treatment goals in DLBCL?
Peter Dreger (Germany)
14:45 - 15:00

Curative intent for DLBCL patients at 3rd-line: What is the current data?
Michael Bishop (United States)
15:00 - 15:20

Which patients should be referred for CAR T-cell therapy?
Maeve O'Reilly (United Kingdom)
15:20 - 15:45

Answering the big questions about CAR T-cell therapy for DLBCL
Álvaro Urbano-Ispizua (Spain)
15:45 - 16:00

IS15, From kilometre zero - Navigating the myeloma treatment journey - Amgen

Industry Symposium
14:30 - 16:00

Chairs:
Mohamad Mohty (France)

Introduction
Mohamad Mohty (France)
14:30 - 14:40

Off to a good start - Optimal induction regimen for transplant eligible patients
Francesca Gay (Italy)
14:40 - 15:05

The road beyond relapse - Therapeutic options for hard-to-treat patients
Mohamad Mohty (France)
15:05 - 15:30

Panel discussion
15:30 - 16:00

IS16, Targeted therapy for adult ALL: New horizons in the setting of alloHSCT - Amgen Industry Symposium

Industry Symposium
14:30 - 16:00
Scientific Programme

Welcome and introduction 14:30 - 14:35
Josep M. Ribera (Spain)

Overview of conventional approaches 14:35 - 14:45
Josep M. Ribera (Spain)

Antibody-drug conjugates 14:45 - 15:05
Matthias Stelljes (Germany)

T-cell engaging immuno-oncology (BiTE® and CAR T) 15:05 - 15:35
Nicola Gökbuget (Germany)

Panel discussion 15:35 - 15:55

Summary and meeting close 15:55 - 16:00
Josep M. Ribera (Spain)

Industry Symposium
14:30 - 16:00

IS17, The role of ECP in the treatment of GVHD - Therakos Industry Symposium

Chairs:
Andrea Bacigalupo (Italy)

Introduction 14:30 - 14:35
Andrea Bacigalupo (Italy)

GVHD: Treatment goals and current definitions 14:35 - 15:00
Madan Jagasia (United States)

ECP role in GVHD treatment 15:00 - 15:25
Hildegard Greinix (Austria)

Combinatorial approaches in GVHD 15:25 - 15:50
Robert Zeiser (Germany)

Q&A 15:50 - 16:00

Industry Symposium
14:30 - 16:00
Sala Retiro

IS18, Targeted interventions in the natural history of Hodgkin Lymphoma - Takeda Industry Symposium

Chairs:
Anton Hagenbeek (Netherlands)

Welcome and introduction 14:30 - 14:40
Anton Hagenbeek (Netherlands)

Latest developments in frontline treatment of Hodgkin lymphoma 14:40 - 15:00
Martin Hutchings (Denmark)
Scientific Programme

**Panel discussion: Current trends and controversies in treatment of relapsed/refractory Hodgkin lymphoma with first salvage therapy**  
15:00 - 15:30  
Anton Hagenbeek (Netherlands)  
Martin Hutchings (Denmark)  
Anna Sureda (Spain)

**Prolongation of remission with post-ASCT strategies in Hodgkin lymphoma**  
15:30 - 15:55  
Anna Sureda (Spain)

**Closing**  
15:55 - 16:00  
Anton Hagenbeek (Netherlands)

Industry Symposium  
14:30 - 16:00  
Sala Colón

**IS19, Nurse Symposium: Power of knowledge: Nurses at the forefront of patient survival of severe hepatic VOD - Jazz Pharmaceuticals Industry Symposium**

Lab Technicians Day Industry Symposium  
14:30 - 16:00  
N107

**IS20, Get moving with your CAR T-cell production - Establish your manufacturing with Miltenyi Biotec - Miltenyi Biotec Lab Technicians Workshop**

Welcome and introduction  
14:30 - 14:35

Technical Live Demo  
14:35 - 15:00

The evolving role of automation in CAR T cell manufacturing  
15:00 - 15:20  
Martha Luevano Salinas (Germany)

Establishing point-of-care manufacturing of CAR T cells  
15:20 - 15:50  
Michael Aigner (Germany)

What’s coming next?  
15:50 - 16:00

Social Events  
15:30 - 16:00  
N101

**Abracadabra Show, Abracadabra: The therapeutic power of magic / El poder terapéutico de la magia**
Scientific Programme

Patient, Family Donor Day
16:00 - 16:45

**PFD4, Patient, Family and Donor Day: Focus on the donor**

**Chairs:**
Lola Manterola (Spain)
Julia Ruiz (Spain)

- **Donor Registry: “A lifesaver”. General and Spanish situation**
  Enric Carreras (Spain)  
  16:00 - 16:10

- **Donor and receiver from the paediatric point of view**
  Antonio Pérez-Martínez (Spain)  
  16:10 - 16:20

- **Donor – receiver: A child-focused testimony**
  Daniel Guerrero (Spain)  
  16:20 - 16:30

- **Questions & Answers**
  16:30 - 16:45

Industry Symposium
16:30 - 18:00

**IS21, Cellular immune therapies for multiple myeloma - Celgene Industry Symposium**

**Chairs:**
María-Victoria Mateos Manteca (Spain)

- **Welcome and introduction**
  María-Victoria Mateos Manteca (Spain)  
  16:30 - 16:35

- **State-of-the-art therapy in multiple myeloma and unmet needs in 2020**
  María-Victoria Mateos Manteca (Spain)  
  16:35 - 17:00

- **Overview of CAR T cell treatment strategies in multiple myeloma**
  Michel Delforge (Belgium)  
  17:00 - 17:25

- **Management and optimization of CAR T cell therapy**
  17:25 - 17:50

- **Discussion and Q&A**
  17:50 - 18:00

Industry Symposium
16:30 - 18:00

**IS22, CMV prophylaxis in transplantation - From implementation to follow up - MSD Industry Symposium**

**Chairs:**
Catherine Cordonnier (France)

- **Welcome and introduction**
  Catherine Cordonnier (France)  
  16:30 - 16:35
Scientific Programme

CMV prophylaxis in allogeneic stem cell transplantation: How to optimize clinical care?  
Rafael Duarte (Spain)  
16:35 - 16:55

Real-life experience with CMV prophylaxis in allogeneic stem cell transplantation  
Michael Schmitt (Germany)  
16:55 - 17:15

Evolving strategies in CMV prevention  
Miguel-Angel Perales (United States)  
17:15 - 17:35

Panel discussion & closing remarks  
17:35 - 18:00

Industry Symposium
16:30 - 18:00 Sala Colón

IS23, Nurse Symposium: Optimising the patient journey: The role of the specialist nurse in CAR T-cell therapy - Kite Industry Symposium  
Chairs:  
Michelle Kenyon (United Kingdom)

Welcome and introduction  
Michelle Kenyon (United Kingdom)  
16:30 - 16:40

An introduction to CAR T-cell therapy  
Rose Ellard (United Kingdom)  
16:40 - 16:50

The importance of early identification and awareness of CAR T-cell related toxicity  
Michael Bishop (United States)  
Ruth Clout (United Kingdom)  
16:50 - 17:15

Long-term follow-up of patients after CAR T-cell therapy: What can we learn from the US experience?  
Michael Bishop (United States)  
17:15 - 17:30

Patient and caregiver hopes and fears: Helping them navigate the CAR T-cell treatment journey  
Corien Eeltink (Netherlands)  
17:30 - 17:55

Meeting summary and closing  
Michelle Kenyon (United Kingdom)  
17:55 - 18:00

Special Session
16:45 - 17:45 N101

SS1, The integration of patient voices in research in HSCT  
Chairs:  
Hélène Schoemans (Belgium)  
Bregje Verhoeven (Netherlands)
Scientific Programme

**Patient’s perspective**  
Chris Lewis (United Kingdom)  
16:45 - 16:57

**Physician’s perspective**  
Linda Burns (United States)  
16:57 - 17:09

**Nurse’s perspective**  
Sarah Liptrott (Italy)  
17:09 - 17:21

**Regulatory perspective**  
Cristina Avendaño-Solá (Spain)  
17:21 - 17:33

**Patient and public involvement: An essential strategy for effective implementation of innovative care models in stem cell transplantation**  
Sabina De Geest (Switzerland)  
17:33 - 17:45

Patient, Family Donor Day  
17:45 - 18:00  
N101

**PFD5, Patient, Family and Donor Day: Closing Remarks**

**Chairs:**  
Bregje Verhoeven (Netherlands)

- **Closing remarks**  
  Bregje Verhoeven (Netherlands)  
  17:45 - 17:55

- **Welcome to Prague 2021**  
  Pavel Jindra (Czech Republic)  
  17:55 - 18:00

General  
18:30 - 19:45  
N103

**GS1, Opening Ceremony**

**Chairs:**  
Nicolaus Kröger (Germany)  
Rafael Duarte (Spain)  
John Murray (United Kingdom)

- **Welcome and introduction**  
  Nicolaus Kröger (Germany)  
  18:30 - 18:35

- **Welcome and introduction to Madrid and the conference**  
  Rafael Duarte (Spain)  
  18:35 - 18:40

- **Welcome from the Nurses Group**  
  John Murray (United Kingdom)  
  18:40 - 18:44

- **EBMT Patient Advocacy Committee: Welcome note**  
  Bregje Verhoeven (Netherlands)  
  18:44 - 18:48
Honorary Member Awards  18:48 - 19:18
Ernst Holler (Germany)
Alejandro Madrigal (United Kingdom)
Dietger Niederwieser (Germany)
Andrea Bacigalupo (Italy)

Introduction of the Keynote speaker  19:18 - 19:20
Rafael Duarte (Spain)

Keynote Lecture: How the treatment is evolving in transplant-eligible newly diagnosed Multiple Myeloma?  19:20 - 19:45
María-Victoria Mateos Manteca (Spain)
Scientific Programme

Monday, 31 August 2020

Meetings
07:00 - 09:00

Cellular Therapy and Immunobiology Working Party Business Meeting

Chairs:
Christian Chabannon (France)

Meetings
07:00 - 09:00

Severe Aplastic Anaemia Working Party Business Meeting

Chairs:
Régis Peffault de Latour (France)

Meetings
07:00 - 09:00

Acute Leukaemia Working Party Business Meeting

Chairs:
Mohamad Mohty (France)

Meetings
07:00 - 09:00

Lymphoma Working Party Business Meeting

Chairs:
Silvia Montoto (United Kingdom)

Meetings
07:00 - 09:00

Inborn Errors Working Party Business Meeting

Chairs:
Arjan Lankester (Netherlands)

Meet the Expert
08:00 - 09:00

MTE1, Meet the Expert session 1 - Room A10.01
Scientific Programme

Viral infections in HSCT recipients: The challenges in 2020
Francisco Marty (United States)

Meet the Expert Rooms
MTE2, Meet the Expert session 2 - Room A10.05
Extracorporeal photopheresis in the management of acute and chronic GVHD
Daniel Couriel (United States)

Meet the Expert Rooms
MTE3, Meet the Expert session 3 - Room A10.06
The role of donor registries in the changing landscape of allogeneic HSCT in 2020
Enric Carreras (Spain)

Meet the Expert Rooms
MTE4, Meet the Expert session 4 - Room A10.07
How to manage chronic GVHD in 2020 and beyond
Steven Pavletic (United States)

Meet the Expert Rooms
MTE5, Meet the Expert session 5 - Room A10.12
The role of cord blood banks in the changing landscape of allogeneic HSCT in 2020
Sergio Querol Giner (Spain)

Meet the Expert Rooms
MTE6, Meet the Expert session 6 - Room A10.13
How to establish a CAR T-cell Delivery Centre
Claire Roddie (United Kingdom)
Scientific Programme

Meet the Expert
08:00 - 09:00

**MTE7, Meet the Expert session 7 - Room A10.15**

**How to manage acute promyelocytic leukaemia in 2020. Current role of haematopoietic cell transplantation**
Miguel Ángel Sanz Alonso (Spain)

Statistics
08:30 - 10:30

**Stat3, Statistical consulting**

Psy Day
08:45 - 10:30

**Psy1, Workshop I: Survivorship programme**

**Chairs:**
Frank Schulz-Kindermann (Germany)
Alexandra Carpentier (Spain)

**Introduction**
Anna Barata (United States)

**Survivorship**
Karen Syrjala (United States)

**Working therapeutically with despair: Supporting patients with prolonged hospital admissions post-BMT**
Surabhi Chaturvedi (United Kingdom)

Workshop
09:00 - 10:30

**W1, Unusual GVHD manifestations**

**Chairs:**
Carmen Martínez Muñoz (Spain)
Zinaida Peric (Croatia)

**Neurologic aspects of cGVHD**
Ervina Bilic (Croatia)

**The kidney and GVHD - Is the kidney a target organ?**
Sangeeta Hingorani (United States)

**Late acute GVHD and steroid refractory GVHD**
Robert Zeiser (Germany)
Scientific Programme

Educational  
09:00 - 10:30  
Hall A (Exhibition Area)

E1, Educational forum on microbiota and allogeneic HSCT

Chairs:  
Ernst Holler (Germany)  
Sergio Giralt (United States)

- Current understanding of the impact of microbiome on HSCT alloreactive phenomena and outcome  
  Daniela Weber (Germany)  
  09:00 - 09:30

- Gut microbiota and GVHD in children  
  Riccardo Masetti (Italy)  
  09:30 - 10:00

- Preventive and therapeutic interventions in the microbiota  
  Florent Malard (France)  
  10:00 - 10:30

Nurses Group  
09:00 - 10:30  
Hall B (Exhibition Area)

NG04, Nurses Programme Opening Session

Chairs:  
John Murray (United Kingdom)  
Julia Ruiz (Spain)

- Welcome and overview  
  John Murray (United Kingdom)  
  09:00 - 09:10

- Presentation of the 12th Distinguished Merit Award  
  John Murray (United Kingdom)  
  09:10 - 09:20

- Extensive role of nurses  
  José Luis Cobos Serrano (Spain)  
  09:20 - 09:50

- Keynote lecture: Artificial Intelligence in health care  
  Shahrurk Hashmi (United States)  
  09:50 - 10:30

Workshop  
09:00 - 10:30  
N105

W2, Controversies in T-cell NHL

Chairs:  
Dolores Caballero (Spain)  
Luca Castagna (France)

- Are we improving first-line therapy in TCL?  
  Eva Domingo Domenech (Spain)  
  09:00 - 09:25

- Is HSCT the way forward for PTCL?  
  Norbert Schmitz (Germany)  
  09:25 - 09:50
Scientific Programme

Insights in CAR T therapy for T-cell lymphomas 09:50 - 10:15
Karl Peggs (United Kingdom)

Round table discussion 10:15 - 10:30

Cell therapy
09:00 - 10:30

N101

CTD1, Cell Therapy Day: Large-scale access to marketed CAR T-Cells

Chairs:
Olaf Penack (Germany)
Manel Juan (Spain)

Collecting autologous MNC for industry manufactured CAR T-cells: When and how 09:00 - 09:30
Elad Jacoby (Israel)

Adressing bottlenecks in CAR T-cell manufacturing 09:30 - 10:00
Ulrike Köhl (Germany)

Management of OOS CAR T-cell products 10:00 - 10:30
Alexey Bersenev (United States)

Oral Session
09:00 - 10:30

Sala Retiro

OS1, Oral session 1 - Early complications after transplantation 1

Chairs:
Jose Luis Piñana (Spain)
Grzegorz Basak (Poland)

METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY 09:00 - 09:11

IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION 09:11 - 09:22
Maria M Cuadrado, Chloe Anthias, Raymond Fernando, Richard M Szydlo, Steven GE Marsh, Neema P Mayor, Ronjon Chakraverty, J Alejandro Madrigal, Katy Latham (United Kingdom)

ELTROMBOAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA 09:22 - 09:33
Fei Gao, Yanmin Zhao, Jimin Shi, Yi Luo, Yanmin Tan, Jian Yu, Xiaoyu Lai, He Huang (China)
Scientific Programme

IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES
Diana Tran, Dongyun Yang, Janny M. Yao, Salman Otoukesh, Haris Ali, Shukaib Arslan, Amandeep Salhotra, Ibrahim Aldoss, Karamjeet Sandhu, Vinod Pullarkat, Tony Stein, David Snyder, Guido Marcucci, Auaporn Nademanee, Stephen J. Forman, Ryotaro Nakamura, Monzr M. Al Malki (United States)

INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS
Christopher Dandoy, Seth Rotz, Priscila Badia, Anna Klunk, Christine Higham, Christopher Dvorak, Christin Duncan, Michelle Schoettler, Leslie Lehmann, Maria Cancio, James Killinger, Blachy Davila, Zoe Ann Kasprzyk, Rachel Phelan, Kris Mahadeo, Sajad Khazal, Mahal Vissa, Deepika Bhatla, Nicholas Gloude, Eric Anderson, Jefferey Hoo, Philip Roehrs, Jeffrey Auletta, Stella Davies, Ranjit Chima, Sonata Jodele (United States)

USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT

REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Remy Dulery, Claire Goudet, Antonio Bianchessi, Angela Granata, Samia Harbi, Valerio Maisano, Christian Chabannon, Florent Malard, Eolia Brissot, Simona Sestili, Clemence Medavilla, Anne Banet, Zöe Van de Wyngaert, Annalisa Pavignaniti, Ramdane Belhocine, Stéphane Ederhy, Thomas Pagliardini, Faezeh Legrand, Lucas Castagna, Didier Blaise, Mohamad Mohy, Sabine Surst, Raymond Devillier (France)

ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Eleni Gavrilaki, Ioanna Sakellari, Natassa Konstantinou, Despina Mallouri, Zoi Bousiou, Marianna Masmanidou, Ioannis Batsis, Aliki Xochelli, Athanasios Anastasiadis, Maria Gkanidou, Achilles Anagnostopoulos (Greece)

Working Party Session
09:00 - 10:30 Sala Colón

IDWP, Infectious Diseases Working Party Session

Chairs:
Jan Styczynski (Poland)
Malgorzata Mikulska (Italy)

IDWP activity 2019-2020 and highlights of ECIL
Jan Styczynski, Nina Knelange, Lotus Wendel, Gloria Tridello, Diana Averbuch, Lidia Gil, Malgorzata Mikulska (Poland)

Current scientific proposals of IDWP
Malgorzata Mikulska, Nina Knelange, Lotus Wendel, Gloria Tridello, Diana Averbuch, Lidia Gil, Jan Styczynski (Italy)
Infections after CAR T therapy 09:10 - 09:25
Lidia Gil (Poland)
Dina Averbuch (Israel)

Highlights of ECIL: Recommendations in community-acquired respiratory virus infections 09:25 - 09:45
Hans H Hirsch, Anne Bergeron-Lafaurie, Michael Boeckh, Roy Chemaly, Francesca Compagno, Hermann Einsele, Dan Engelhard, Per Ljungman, David Navarro, Christine Robin, Marie von Lilienfeld-Toal (Switzerland)

Highlights of ECIL: Recommendations in invasive fungal disease in children 09:45 - 10:05
Andreas H. Groll, Dina Averbuch, Elio Castagnola, Simone Cesaro, Carolina Garcia-Vidal, Fanny Lanternier, Alessio Messini, Zoi-Dorothea Pana, Nicole Ritz, Jan Styczynski, Adilia Warris, Thomas Lehrnbecher (Germany)

Highlights of ECIL: Recommendations in pediatric febrile neutropenia 10:05 - 10:25
Thomas Lehrnbecher, Dina Averbuch, Elio Castagnola, Simone Cesaro, Carol Garcia-Vidal, Fanny Lanternier, Alessio Messini, Malgorzata Mikulska, Dorothea Pana, Nicole Ritz, Monica Slavin, Jan Styczynski, Adilia Warris, Andreas H. Groll (Germany)

Summary and Conclusions 10:25 - 10:30
Jan Styczynski (Poland)

Working Party Session
09:00 - 10:30  N107

CMWP, Chronic Malignancies Working Party Session

Chairs:
Stéphanie Nguyen Quoc (France)
Christoph Scheid (Germany)

Welcome and introduction 09:00 - 09:10
Patrick Hayden (Ireland)

Allogeneic haematopoietic cell transplantation in aggressive mastocytosis 09:10 - 09:40
Gandhi Damaj (France)

Round table: Implication of Artificial Intelligence in HC transplantation and cellular therapy approaches 09:40 - 10:30
Tamim Alsuliman (France)
Ramana Reddy (United States)
Layth Sliman (France)

Working Party Session
09:00 - 10:30  N109

ADWP, Autoimmune Diseases Working Party Session

Chairs:
John Snowden (United Kingdom)
Tobias Alexander (Germany)
Scientific Programme

**Introduction**
John Snowden (United Kingdom)  
09:00 - 09:05

**Autologous HSCT in MS: Will delivery early in the disease course improve outcomes? How can we work with the neurological community to select the most appropriate patients?**
Giovanni Mancardi (Italy)  
09:05 - 09:20

**Questions**  
09:20 - 09:25

**Autologous HSCT in SSc: Will delivery early in the disease course improve outcomes? What disease markers should we use to select patients?**
Jacob M. van Laar (Netherlands)  
09:25 - 09:40

**Questions**  
09:40 - 09:45

**Autologous HSCT in Crohn’s disease: Will delivery early in the disease course improve outcomes? What disease markers should we use to select patients?**
10:00 - 10:05

**Questions**
10:05 - 10:20

**HSCT in Immune Cytopenias: Is there still a role alongside modern management strategies? How should we select patients?**
Nichola Cooper (United Kingdom)  
10:20 - 10:25

**Questions**  
10:25 - 10:30

**Close and summary**
Tobias Alexander (Germany)  
10:30 - 10:45

---

**OS2, Oral session 2 - Aplastic anaemia**

**Chairs:**
Lucrecia Yáñez San Segundo (Spain)  
Austin Kulasekararaj (United Kingdom)

**LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY**
Antonio M. Risitano, Alexander Roth, Juliette Soret, Camilla Frieri, Flore Sicre de Fontbrune, Luana Marano, Izabella Rozenberg, Julie Milojevic, Peter End, Prasanna K Nidamarthy, Guido Junge, Regis Peffault de Latour (Italy)  
09:00 - 09:11

**PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA**
Alexander Kulagin, Tatiana Bykova, Tatiana Rudakova, Olesya Klimova, Irina Golubovskaya, Anna Ospova, Alexandra Lapina, Elena Babenko, Maria Estrina, Alexander Alyanskiy, Sergey Bondarenko, Ivan Moiseev, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)  
09:11 - 09:22
EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE
Rotana Alsaggaf, Shilpa Katta, Stephen Spellman, Tao Wang, Belynda D. Hicks, Youjin Wang, Sharon A. Savage, Bin Zhu, Stephanie J. Lee, Steve Horvath, Shahinaz M. Gadalla (United States)

GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT

FLUDARABINE/MELPHALAN VS. FLUDARABINE/CYCLOPHOSPHAMIDE CONDITIONING REGIMEN FOR BONE MARROW TRANSPLANTATION IN PEDIATRIC ACQUIRED BONE MARROW FAILURE: A REPORT FROM THE JSHT PEDIATRIC APLASTIC ANEMIA WORKING GROUP

REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA

OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA
Satya Prakash Yadav, Revathi Raj, Dharmendra Choudhary, Ramya Uppuluri, Divya Doval, Vikas Dua, Sunil Bhat, Gaurav Kharya, Rajesh Patil, Shweta Bansal, M Deenadayalan, Intezar Mehdi, Vikram Mathews, Aby Abraham, Biju George (India)
Scientific Programme

**Introduction and Overview**
Machteld Oudshoorn (Netherlands)

**Debate: Do we still need Verification Typing (VT) of the donor?**

**No, rely on initial high resolution typing**
Matthias Stelljes (Germany)

**Yes, safety first**

Panel discussion

**Data Management**
09:00 - 10:30

**DM1, Education session 1**

**Chairs:**
Lucas Stolarczyk (United Kingdom)

**Discussion forum - Cell therapy**
Chiara Bonini (Italy)
Jürgen Kuball (Netherlands)
Álvaro Urbano-Ispizua (Spain)
Lawrence Vermeir (United Kingdom)

**Data Management**
09:00 - 10:30

**DM13, Training session 1 (pre-registration required)**

**Chairs:**
Asterios Kasmiris (United Kingdom)

**MACRO data entry**
Asterios Kasmiris (United Kingdom)

**Joint Session**
09:00 - 10:30

**JS1, Joint session ASTCT/CIBMTR: Bridging the gap in BMT and cellular therapy between North America and Europe**

**Chairs:**
Navneet Majhail (United States)
Robert Soiffer (United States)
Nicolaus Kröger (Germany)

**A tale of two continents: Differences and similarities in BMT practices in North America and Europe**
Robert Soiffer (United States)
Scientific Programme

Landscape of CAR T-cell therapy in North America and Europe: Lessons learned and future directions
Miguel-Angel Perales (United States)

Looking back and moving forward: Blueprint for collaborative international studies in BMT and Cellular therapy
Anna Sureda (Spain)

Poster Sessions

Acute leukaemia

ALLOGENIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT
Johanna Waidhauser, Myriam Labopin, Jordi Esteve, Nicolaus Kröger, Jan Cornelissen, Tobias Gedde-Dahl, Gwendolynian, Jan Gorkam, Jürgen Finke, Montserrat Rovira, Nicolaas Schaap, Eelke Petersen, Dietrich Beelen, Donald Bunjes, Christoph Schmid, Arnon Nagler, Mohamad Mohy (Germany)

GENETIC CHARACTERISTICS AND LONG-TERM OUTCOMES OF ADULTS WITH ETP-ALL VERSUS NON-ETP-ALL: MYELOID-DERIVED CHEMOTHERAPY FOLLOWED BY ALLOGENEIC HCT MAY OVERCOME THE POOR PROGNOSIS OF ETP-ALL
Seok Lee, Nack-Gyun Chung, Seong-Kyu Park, Jae-Yong Kwak, Jeong-A Kim, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Jae-Ho Yoon (Korea, Republic of)

GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT
Annalisa Ruggeri, Myriam Labopin, Emanuele Angelucci, Didier Blaise, Fabio Ciceri, Yener Koc, Jose Luiz Diez-Martin, Luca Castagna, Benedetto Bruno, Zafer Gülbas, Andrea Bacigalupo, Arnon Nagler, Mohamad Mohy (Italy)

IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES

DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
David I Marks, Shamyla Siddique, Ronjon Chakraverty, Aimee Jackson, Victoria Potter, Ram Malladi, Andy Peniket, Paresh Vyas, Pamela Kears, Charles Craddock (United Kingdom)

DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1
Su-Peng Yeh, Ming Yao, Bor-Sheng Ko, Jyh-Pyng Gau, Tzeon-Jye Chiou, Tran-Der Tan, Po-Nan Wang, You-Chin Chen, Chieh-Lin Teng, Ci-yuan-Jheng Wang, Tsai-Yun Chen, Ta-Chih Liu, Ming-Sun Yu, Wei-Han Huang (Taiwan, Republic of China)

A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKAEMIA
Shuichi Ota, Akio Shigematsu, Ryoji Kobayashi, Takeshi Kondo, Tomoyuki Endo, Yutaka Tsutsumi, Hajime Kobayashi, Yasutaka Kakinoki, Satoshi Yamamoto, Yuichi Konuma, Takuto Miyagishima, Tetsuyauki Igarashi, Takani Oda, Hajime Sakai, Toshihichii Ishihara, Masahiro Yoshida, Takahiro Nagashima, Kazuya Sato, Yuji Kanisawa, Yoshihito Haseyama, Yasuo Hirayama, Mitsutoshi Kuosawa (Japan)
PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS
Niels Jacobsen, Tina Frisch, Niels Keiding, Carsten Heilman, Henrik Sengeløv, Hans Madsen, Hanne Marquart, Mette Andersen, Claus Christiansen, Lars Ryder (Denmark)

EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS

PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML IN CR1
Igor Novitzky Basso, Shiyi Chen, Jeffrey Lipton, Dennis Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios Michelis (Canada)

IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT

DIFFERENT FREQUENCY OF GENETIC SUBTYPES AND NON-INFERIOR LONG-TERM OUTCOMES OF KOREAN ADULTS WITH PH-LIKE ALL VERSUS NON-PH-LIKE ALL
Seok Lee, Naky-Gyun Chung, Seong-Kyu Park, Jae-Yong Kwak, Jeong-A Kim, Byung-Sik Cho, Ki-Seong Eom, Yoo-jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Jae-Ho Yoon (Korea, Republic of)

COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Zeynep Arzu Yeğin, Asena Dikyar, Lale Aydin Kaynar, Zübeyde Nur Özkurt, Münci Yağcı (Turkey)

SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT

FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Olga Pirogova, Ksenia Afanaseva, Elena Morozova, Sergey Bondarenko, Inna Markova, Ivan Moiseev, Boris Afanasyev (Russian Federation)

ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)
Guldane Cengiz Seval, Eliz Bahar Ulas, Selami Kocak Toprak, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Pervin Topcuoglu, Klara Daiva, Onder Arslan, Muhit Ozcan, Taner Demirer, Osman Ilhan, Hamdi Akan, Meral Beksac, Gunhan Gurman (Turkey)

SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION
Carmine Liberatore, Matteo Giovanni Carrabba, Federica Ardizzoia, Andrea Assanelli, Carlo Messina, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri, Maria Teresa Lupo Stanghellini (Italy)

PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)

MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY

WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?
Emilia Jaskula, Mariola Sedzimirska, Monika Mordak-Domagala, Janusz Lange, Krzysztof Suchnicki, Anna Sobczynska-Konefal, Marta Lemieszewska, Helena Pakos, Agnieszka Tarnowska, Andrzej Langa (Poland)
**Scientific Programme**

**COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA**

Eshrak Al-Shaibani, Sunu Cyriac, Shiyi Chen, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios V. Michelis (Canada)

**GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS**

Bella Ayubova, Sergey Bondarenko, Ivan Moiseev, Olga Uspenskaya, Elena Karyagina, Elena Misurina, Evgeniya Zhelnova, Alexander Alyanskiy, Elena Babenko, Ildar Barkhatov, Tatjana Gindina, Alexander Kulagin, Boris Afanasyev (Russian Federation)

**THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES**

Maria Rhida Bautista, Shiyi Chen, Wilson Lam, Fotios Michelis, Dennis Kim, Jeffrey Lipton, Auro Viswabandya, Rajat Kumar, Ivan Pasic, Armin Gerbitz, Jonas Mattson, Zeyad Al-Shaibani, Arjun Law (Canada)

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE**

Posttransplantation Bendamustine for GVHD prophylaxis in refractory acute leukemia patients

Ivan Moiseev, Sergey Bondarenko, Elena Darskaya, Alexandr Alyanskiy, Anastasiya Beynarovich, Evgeniya Borzenkova, Anna Dotcenko, Olga Kudyasheva, Varvara Ovechkina, Olga Pirogova, Valentina Porunova, Tatjana Rudakova, Olesya Smikova, Boris Afanasyev (Russian Federation)

**IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE**

Flat regimen as myeloablative conditioning with limited toxicities for autologous stem cell transplantation in patients with acute myeloid leukemia: results in 30 patients

Tyrosine kinase inhibitor treatment after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

Yu-Hsiang Chang, Xiu-Wen Liao, Jia-Hau Liu, Ming Yao, Bor-Sheng Ko, Chi-Cheng Li, Cheng-Hong Tsai, Shang-Ju Wu, Hui-Hsuan Huang, Tai-Chung Huang, Hsin-An Hou, Wen-Chien Chou, Feng-Ming Tien, Yun-Chu Lin, Meng-Yao Lu, Kai-Hsin Lin, Jih-Luh Tang (Taiwan, Republic of China)

Outcomes of allogeneic transplantation for cytogenetic intermediate-risk AML according to the molecular risk based on ELN 2017 risk stratification system; single center experience in Korea

Haerim Chung, Ji Eun Jang, Soojeong Kim, Jin Seok Kim, Yoo Hong Min, June-Won Cheong (Korea, Republic of)

The prognostic significance of minimal residual disease monitoring by WT1 gene expression in peripheral blood before and after allogeneic stem cell transplantation in AML patients

Impact of posttransplant tyrosine kinase inhibitors administration on long term outcomes of allogeneic hematopoietic stem cell transplantation in Ph-positive acute lymphoblastic leukemia patients

Kseniia Afanaseva, Elena Morozova, Olga Pirogova, Yulia Vlasova, Anna Smirnova, Sergey Bondarenko, Ivan Moiseev, Boris Afanasyev (Russian Federation)
THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION
Guldane Cengiz Seval, Ekin Kircali, Mehmet Akif Baltaci, Sinem Civriz Bozdog, Meltem Kurt Yuksel, Pervin Topcuoglu, Klara Dalva, Onder Arslan, Muhit Ozcan, Taner Demirer, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Bekzac, Selami Kocak Toprak (Turkey)

MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL
Wei Ma, Xingyu Cao, Wei Zhang, Min Xiong, Jianping Zhang, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Yanli Zhao, Jiarui Zhou (China)

BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS
Shin Young Hyun, Eun Jung Na, Ji Eun Jang, Haerim Chung, Soo Jeong Kim, Jin Seok Kim, Yoo Hong Min, Jun-Won Cheong (Korea, Republic of)

GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?
Michael Stadler, Vanessa Oberstaedt, Elke Dammann, Lothar Hambach, Eva M. Weissinger, Catherina Lueck, Gernot Beutel, Matthias Eder, Arnold Ganser (Germany)

THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

DIFFERENT PATTERNS OF BCR-ABL EXPRESSION IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AND THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Satoshi Nishiwaki, Jeong Hui Kim, Masafumi Ito, Matsuyoshi Maeda, Yusuke Okuno, Daisuke Koyama, Yukiyasu Ozawa, Masaharu Gunji, Masahide Osaki, Kunio Kitamura, Yuichi Ishikawa, Koichi Miyamura, Isamu Sugiiura, Hitoshi Kiyoi (Japan)

HIGH INCIDENCE OF RAS PATHWAY MUTATIONS AMONG SENTINEL GENETIC LESIONS OF KOREAN PEDIATRIC BCR-ABL1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA
Nack-Gyun Chung, Jae Wook Lee, Seongkoo Kim, Bin Cho, Jaewoong Lee, Hanwool Cho, Gun Dong Lee, Myungshin Kim, Yonggoo Kim (Korea, Republic of)

AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS
Carmine Liberatore, Francesca Lorentino, Matteo Giovanni Carrabba, Carlo Messina, Luca Vago, Sara Mastaglio, Raffaella Greco, Francesca Pavesi, Sarah Marktel, Francesca Farina, Raffaella Milani, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Maria Teresa Lupo Stanghellini, Fabio Ciciri (Italy)

THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION

ALLOGENEIC TRANSPLANT IMPROVES OUTCOMES OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ALL
Melinda Tan, Hein Than, Jeffrey Quek, Yeh Ching Linn, William Hwang, Yvonne Loh, Francesca Lim, Yeow Tee Goh, Jing Jing Lee, Aloysius Ho (Singapore)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS
THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
Sergey Bondarenko, Ivan Moiseev, Elena Morozova, Olga Pirogova, Elena Darskaya, Anna Smirnova, Nikolai Tsvetkov, Anastasiya Beynarovich, Irina Samorodova, Tatyana Gindina, Elena Babenko, Ildar Barkhatov, Alexander Alyanskly, Alexander Kulagin, Boris Afanasyev (Russian Federation)

IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE
Fahad Shaikh, Ganapathi Bhat, Suresh Advani, Samir Shah, Reetu Jain (India)

DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE
William Hayhurst, Asterios Giotas, Chloe Anthias, Sandra Easdale, David Taussig, Mike Potter, Mark Ethell, Joy Brennan, Maria Mulligan, Kim Davis, Emma Thistlethwayte, Emma Nicholson (United Kingdom)

EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES
Zeynep Tugba Guven, Serhat Çelik, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, Ali Unal (Turkey)

ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Aplastic anaemia

ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS

SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA

INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA
Carlos Vallejo, Ana Rosell, Blanca Xicoy, Carmen García, Carmen Albo, Marta Polo, Isidro Jarque (Spain)

ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA

OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE

OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
30 August - 2 September 2020,
Madrid, Spain

Scientific Programme

IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY
Rashit Bogdanov, Mareike Gocht, Amin Turki, Markus Ditschkowski, Dietrich W. Beelen (Germany)

HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA
Gilbert Wilfred, Sen Mui Tan, Tee-Chuan Ong, Sh. Shahnaz Syed Kadir, Kim Wah Ho, Boon Liaw Kian, Jameela Sathar (Malaysia)

HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER

EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN

IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE

CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES
Nilesh Wasekar, Girish Badarkhe, Sudarshan Pandit, Raj Nagarkar (India)

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Autoimmune diseases

THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW
Owain Greaves, Amit Patel (United Kingdom)

RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS

HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS
Maynara Santana, Djulio Zanin, Deisy Silva, Marianna Vasconcelos, Daniela Moraes, Juliana Dias, Vanessa Leopoldo, Marília Oliveira, Alvaro Henrique-Neto, Kelen Farias, Leandra Ramalho, Maria Carolina Oliveira (Brazil)

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD
Ellen P.A. Kramer, Bram Platel, Frederike J.A.E Ambagsheer, Gerald J.D. Hengstman, Otto Visser (Netherlands)

ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES
Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaojie Han (United States)
Scientific Programme

AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET'S DISEASE: A RETROSPECTIVE STUDY
Mathieu Puyade, Amit Patel, Yeong Ler Lim, Norbert Blank, Manuela Badoglio, Francesca Gualandi, David Ma, Natalia Maximova, Tobias Alexander, John Snowden (France)

SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE
Pawan Kumar Singh, Isha Gambhir, Ragesh Radhakrishnan Nair, Rohan Halder, Zahier Ahmad Shekib, Manish Mahajan, Sumit Singh (India)

OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY
Maiken Schultz, Øyvind Midtvedt, Øyvind Molberg, Tobias Gedde-Dahl, Ragnar Gunnarsson, Yngvar Flæsland (Norway)

THE USE OF AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS
Claudia Sossa, Javier Figueroa, Juan Manuel Herrera, Angela M Peña, Luis A Salazar, Manuel Rosales, Enrique Pedraza, Elena Mora, Xueyi Chen, Maria Luna-Gonzalez, Jose Patricio Lopez-Lopez (Colombia)

A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE
Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaoliang Han (United States)

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

CAR-based Cellular Therapy – clinical

NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)
Caroline Louise Furness, Rachael Hough, Michelle Cummins, Gillian Murphy, Sara Ghorashian, Persis Amrolia, Claire Roddie, Maeve O'Reilly, Robert Wynn, Denise Bonney, David Marks, Sridhar Chaganti, Geoff Shenton, Anna Castleton, Eleni Tholoulis, Deborah Yallop, Peter Clark, John Snowden (United Kingdom)

REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA
Shafqat Inam, Sean Apap Mangion, Victoria Potter, Reuben Benjamin, Andrea Kuhnrl, Robert Hadden, Robin Sanderson (United Kingdom)

CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY
Rawan Faramand, Michael Jain, Verena Staedtke, Hiroshi Kotani, Renyuan Bai, Saebom Lee, Kayla Reid, Kristen Spliter, Julio Chavez, Farhad Khimani, Aleksandr Lazaryan, Bijal Shah, Christina Bachmeier, Marian Dam, Brigitte Brandjes, Ricardo Gonzalez, John Mullinax, Xuefeng Wang, Mohammad Hussaini, Frederick Lock, Marco Davila (United States)
EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)

ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS

Francis Ayuk, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Dominic Wichmann, Nicolaus Kröger, Boris Fehse (Germany)

SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS

Martina Pennisi, Miriam Sanchez-Escamilla, Jessica Flynn, Roni Shouval, Yakup Batlevi, Mari Lynn Silverberg, Connie Batlevi, Renier Brentjens, Parastoo B Dahi, Sean M Devlin, Claudia Diamonte, Sergio Giral't, Elizabeth Halton, Tania Jain, Molly Maloy, Elena Mead, Maria Lia Palomba, Bianca D Santomasso, Craig Sauter, Micheal Scordo, Gunjan Shah, Jae H Park, Lucrecia Yanez San Segundo, Miguel Angel Perales (United States)

NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL

SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)

Houli Zhao, Yongxian Hu, Wei Ding, Arnon Nagler, He Huang (China)

A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

Boris Fehse, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Nicolaus Kröger, Francis A. Ayuk (Germany)

FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHoblastic LEUKEMIA

AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT

Robin Sanderson, Reuben Benjamin, Piers Patten, Victoria Potter, Deborah Yallup, Kirsty Cuthill, Orla Stewart, Tony Pagliuca, Pramila Krishnamurphy, Shaqat Inam, Mili Shah, Shu Wong, Catherine Hockings, Victoria Metaxa, Andrea Kuhnli (United Kingdom)

MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDEC-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19

Nela Klein-González, E. Azucena González-Navarro, Ariadna Bartoló-Ibars, Valentin Ortiz-Maldonado, Montserrat Torrebada, Maria Castellà, Daniel Benítez, Miguel Caballero- Baños, Raquel Cabezon, Marta España-Régio, Tycho Baumann, Eva Ginetè, Pedro Castro, Jordi Esteve, Jordi Yagüe, Susana Rives, Álvaro Urbano-Ispizua, Manel Juan (Spain)
REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA
Shu Min Wong, Mili Shah, Shafqat Inam, Andrea Kuhnl, Robin Sanderson (United Kingdom)

SENEGSCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES
CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-C19 CAR-T THERAPY
Catherine Hockings, Andrea Kuhnl, Shu Wong, Mili Shah, Shafqat Inam, Piers Patten, Kirsty Cuthill, Tony Pagliuca, Deborah Yallop, Reuben Benjamin, Victoria Potter, Robin Sanderson (United Kingdom)

CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO
IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL

IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING
CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL
Felix Korell, Sascha Laier, Sandra Sauer, Sonia Jaramillo-Segura, Elisabeth Lasitschka, Kaya Veelken, Hannah Hennemann, Marie-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt (Germany)

NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS
Adrián Fernández, Lucía Fernández, Isabel Mirones, Adela Escudero, Leila Cardoso, Gloria Esteso, Raquel De Paz, Joaquín Martínez-López, Mar Valés, Antonio Pérez-Martínez (Spain)

EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY
Christian B Schultz-Florey, Victoria Panagiota, Ivan Odak, Sultan Bektas, Tabea C Froehlich, Aleksandra Gladysz, Zhixiong Li, Gernot Beutel, Matthias Eder, Immo Prinz, Reinhold Foerster, Arnold Ganser, Christian Koeneccke (Germany)

EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A
Francis Ayuk, Boris Fehse, Dietlinde Janson, Carolina Berger, Kristoffer Riecken, Nicolaus Kröger (Germany)

A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS
CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE
LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE
Giovanna Del Principe, Giovanna Leone, Annalisa Ruggeri, Simone Biagini, Elia Girolami, Stefania Lazzaro, Antonella Meschini, Francesca Del Bufalo, Manuel Broglia, David Malaspina, Katia Feri, Federica Galaverna, Pietro Merli, Valentina Bertaina, Mattia Algeri, Mauro Montanari, Andrea Onetti Muda, Giuseppina Li Pira, Franco Locatelli (Italy)

BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE
Ignacio Gómez-Centurión, Saskia Burridge, Juliana Silva, Arina Lazareva, María Gabelli, Oana Miric-Danicar, Giovanna Lucchini, Robert Chiesa, Kanchan Rao, Sujith Samarasinghe, Paul Veys, Ajay Vora, Persis Amrolia, Sara Ghorashian (Spain)

THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
Fang Ni, Yongxian Hu, Alex Hong Chang, He Huang (China)

CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION
Madiha Iqbal, Sangeetha Gandhi, Abdullah Alselah, Muhamad Alhaj Moustafa, Ernesto Ayala, Hemant Murthy, Allison Rosenthal, Jilan Kubusek, Justin Haynes, Tuan Truong, Patrick Johnston, Stephen Ansell, Nora Bennani, Jonas Paludo, Jose Villasboas Binsneto, Breana Etsby, Eva Brandes, Gina Lange, Januario Castro, Yi Lin, Mohamed Kharfan-Dabaja (United States)

COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION
Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, Sultan Bektas, Tabea C Froehlich, Aleksandra Gladysz, Zhixiong Li, Gerot Beutel, Matthias Eder, Immo Prinz, Reinhold Foerster, Arnold Ganser, Christian Koenecce (Germany)

NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS

NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN’S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS
Katie Ahern, Shafqat Inam, Katie Walker, Orla Stewart, Victoria Potter, Piers Patten, Andrea Kuhnli, Deborah Yallop, Reuben Benjamin, Robin Sanderson (United Kingdom)

EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES

DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT
Scientific Programme

CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL
Francesco Paolo Tambaro, Sajad Khazal, Drishti Ragoonanan, Priti Tewari, Demetrios Petropolous, Jeffrey A Miller, William G Wierda, Richard E Champlin, Kris M Mahadeo (Italy)

PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA
Georg-Nikolaus Franke, Eberhard Schleyer, Konstantin Weibl, Hansjakob Fries, Sophia Michel, Rosmarie Pointner, Dominic Brauer, Sandra Otto, Uwe Platzbecker, Vladan Vucinic (Germany)

EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

CAR-based Cellular Therapy - preclinical

BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS
Franziska Blaeschke, Antonia Apfelbeck, Dana Stenger, Jasmin Mahdawi, Mareike Lepenies, Felicitas Rataj, Semjon Willier, Theresa Kaeuferle, Thomas G. P. Gruenewald, Robbie G. Majzner, Dirk H. Busch, Sebastian Kobold, Tobias Feuchtinger (Germany)

ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING
Federico Simonetta, Toshihito Hirai, Juliane K. Lohmeyer, Kristina Maas-Bauer, Maite Alvarez, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, Samuel Haile, Crystal L. Mackall, Robert S. Negrin (United States)

DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL

NKGD2 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS

CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL
Katrin Mestermann, Marie Eichler, Markus Machwirth, Kati Kebbel, Ulrike Köhl, Hermann Einsele, Claudia Müller, Jörg Lehmann, Tamás Raskó, Felix Lundberg, Zsuzsanna Ízsvák, Gerno Schmiedeknecht, Michael Hudecek (Germany)

LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA
Tobias Bexte, Stephan Müller, Veronika Gebel, Franziska Kalensee, Eva Stolzenberg, Jessica Hartmann, Ulrike Koehl, Axel Schambach, Wels Winfried S., Ute Modlich, Evelyn Ulrich (Germany)

NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT
Miriam Alb, Jonathan Moggs, Lars Wallstabe, Benedikte Hatz, Hermann Einsele, Peter Loskill, Andries van der Meer, Scott Wagers, Ulrike Köhl, Michael Hudecek (Germany)
Scientific Programme

ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS
Lara Herrera, Silvia Santos, Miguel Ángel Vesga, Juan Anguita, Itziar Martín-Ruiz, Tomás Carrascosa, Manel Juan, Cristina Eguizabal (Spain)

ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS

TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Sessions
09:00 - 18:00

Cellular Therapies other than CARs

OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY

ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENIC HSCT: AN ACADEMIC NETWORK FRAMEWORK THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION

HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES
Francesco Manfredi, Lorena Stasi, Danilo Abbati, Sara Mastaglio, Fabio Ciceri, Eliana Ruggiero, Chiara Bonini (Italy)

EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY

COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS
Eshrak Al-Shaibani, Jeffrey H. Lipton, Dennis D. Kim, Auo Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Giosué V. Michelis (Canada)

AUTOMATED APPLICATION FOR DEPLETION OF TCRAB+, CD19+ AND CD45RA+ CELLS FROM APERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)
Julia Dzionek, Carina Thießen, Felix Hebbeker, Stephanie Soltenborn, Joanna Justyna Stenzel, Burgund Kauling, René Meißner, Nikolas Kaltz, Kirsten Langeveld, Michaela Malchow, Mario Assenmacher, Andreas Bosio, Eleni Papanikolaou (Germany)

THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCES

GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD
Silvia Torrents, Laura Alonso, Joaquim Vives, Luciano Rodríguez, Georgina Morón-Cazalilla, Izaskun Elorza, Maria Luz Uría, Maria Isabel Benítez, Rocío Parody, Guillermo Ortí, María Trabazo, Jesús Fernandez-Sojo, Margarita Codinach, Laura Medina, Isabel Badell, Cristina Díaz de Heredia, Sergi Querol (Spain)

AN ’ALL IN ONE’ T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY
Scientific Programme

CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!
Kira Inkari Thies, Michael Kramer, Friedrich Stölzel, Martin Bornhäuser, Johannes Schetelig, Simone von Bonin, Ralph Schneider, Kristina Hölig (Germany)

IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS

OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER
Vania Lo Presti, Ester Dunnebach, Maud Plantinga, Annelisa Cornel, Jurgen Kuball, Jaap Jan Boelens, Niek van Til *, Stefan Nierkens * (Netherlands)

DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE

CHRONIC leukaemia and other myeloproliferative disorders

INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS
Isik Kaygusuz Atagunduz, Anita Badbaran, Gaby Zeck, Christine Wolschke, Francis Ayuk, Maximilian Christopeit, Nicolaus Kröger (Germany)

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME
Yadanar Lwin, Simon He, Andrew Spencer, Duncan Purtill, Ashley Mcewan, Peter Browett, Andrew Butler, John Carter, Peter Bardy, Glen Kennedy, Jeffrey Szer, David Ritchie, Matthew Greenwood, Stephen Larsen, Sam Milliken, Hock Lai, David Gottlieb, John Kwan, Donna Aarons, Steven Tran, Nada Hamad (Australia)

CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME
Dunja Kampelmann, Dietrich W. Beelen, Rashit Bogdanov, Vesna Klisanin, Michael Koldehoff, Lambros Kordelas, Rudolf Trenschel, Markus Ditschkowski (Germany)

CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS

REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE
Claire Horgan, Shereef Elmoamly, Alex Kanellopoulos, Richard Lovell, Shankara Paneesha, Bhuvan Kishore, Mary Dillon, Katie O'Collins, Kathy Holder, Emmanouil Nikolousis (United Kingdom)
**Scientific Programme**

**ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS**
Christoph Buhl, Emin Abdullayev, Johanna Kerschbaum, Herrad Baermann, Andreas Reiter, Bertram Glaß (Germany)

**ALLOGENIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE**

**TARGETING AUTOPHAGY IS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME BCR-ABL DEPENDENT- AND INDEPENDENT-IMATINIB RESISTANCE THROUGH THE INHIBITION OF HISTONE DEACETYLASES**
Eun Sun Yoo, Yeung-Chul Mun, Jee-Young Ahn, Chu-Myong Seong (Korea, Republic of)

**A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA**
Nadezhda Shnalieva, Anna Melikhova, Iurii Osipov, Galina Salogub, Vladimir Ivanov, Elza Lomaia (Russian Federation)

**Conditioning regimens**

**COMBINING CLOFARABINE AND FLUĐARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN**
Anne Birgitta Versluys, Coco de Koning, Marc Bierings, Stefan Nierkens, Caroline Lindemans, Dorine Bresters, Wouter Kollen, Arjan Lankester, Jaap Jan Boelens (Netherlands)

**BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPESED DLBCL: A PHASE II STUDY**

**REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION**
Jesus Duque-Afonso, Gabriele Ihorst, Miguel Waterhouse, Robert Zeiser, Ralph Wäsch, Hartmut Bertz, Mehtap Yücel, Thomas Köhler, Joachim Müller-Quernheim, Reinhard Marks, Jürgen Finke (Germany)

**ALLOGENIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW**
Marianne Gallanagh, Amy Brown, Angharad Pryce, Richard Szydlo, Stephen Morris, Renuka Palanicawandar, Edward Kanfer (United Kingdom)

**ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT**

**A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**
Wael Saber, Patricia Steiner, Mei-Jie Zhang, Min Chen, Andrea Pope, Armand Keating, John Wingard, Karen Ballen, Patrick Stiff, Miguel-Angel Perales, Stephen Forman, Richard Champlin, Amelia Langston, Torbjörn Kullenberg, Mattias Rudebeck, Mary Horowitz (United States)
PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT
Parastoo Dahi, Andrew Lin, Jessica Flynn, Christian Uruburo, Ian Mcgeary, Ryan Schofield, Valkal Bhatt, Lauren Derespiris, Bradley Figgins, Meagan Griffin, Carmen Lau, Anthony Proli, Dean Carlow, Christina Cho, Oscar Lahoud, Miguel Perales, Craig Sauter, Michael Scordo, Gunjan Shah (United States)

MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?
Roni Tamari, Andrew Lin, Valkal Bhatt, Boglarka Gyurkocza, Esperanza Papadopoulos, Ann Jakubowski, Christina Cho, Brian Shaffer, Doris Ponce, Sergio Giralt, Gunjan Shah (United States)

COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL

DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES
Varun Mehra, Daniele Avenoso, Ximena C Castellano, Adrian Choy, Stefani Widya, Mili Shah, Shafqat Inam, Shreyans Gandhi, Austin Kulasekararaj, Pramila Krishnamurthy, Francesco Dazzi, Hugues de Lavallade, Victoria Potter, Ghulam J Mufti, Tony Pagliuca (United Kingdom)

THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Jill Boss, Arief Lalmohamed, Paul van der Linden, Jaap Jan Boelens, Erik van Maarseveen (Netherlands)

NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION
Dimana Dimitrova, Gulbu Uzel, Luigi D. Notarangelo, Amanda K. Ombrello, Deborah Stone, Mark Parta, Ellen Carroll, Jennifer Wilder, Stephanie N. Hicks, Jennifer L. Sadler, Daniel H. Fowler, Ronald E. Gress, Christopher G. Kanakry, Jennifer A. Kanakry (United States)

PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION

LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY
Sandra Serson Rohr, Raul Cavalcante Maranhao, Thauany Martins Tavoni, Aleksandra Tiemi Morikawa, Debora Fernandes Deus, Jesus Salvador Rodrigues Oliveira (Brazil)

A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TRESULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS
Simona Piemontese, Lorenzo Lazzari, Magda Marcatti, Fabio Giglio, Raffaella Greco, Daniela Clerici, Maria Teresa Lupo Stanghellini, Andrea Assaneli, Francesca Farina, Francesca Lorentino, Sara Mastaglio, Sarah Marktel, Matteo Carrabba, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri (Italy)

BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS
Antonio Grasso, Giulia Caddeo, Davide Zanon, Alessandra Maestro, Roberto Simenone, Natalia Maximova (Italy)
FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML
Kathryn Bower, Madiha Siraj, Jongphil Kim, Biwei Cao, Hany Elmariah, Lia Perez, Asmita Mishra, Taiga Nishihori, Farhad Khimani, Rawan Faramand, Aleksandr Lazaryan, Hugo Fernandez, Michael Nieder, Dan Sullivan, Joseph Pidala, Claudio Anasetti, Nelli Bejanyan (United States)

SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)

INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT
Akihito Shinohara, Michiho Ebihara, Nobuaki Nakano, Emiko Sakaida, Naoyuki Uchida, Kentaro Fukushima, Hitoshi Sakai, Takashi Ashida, Yoshinobu Kanda, Junji Tanaka, Takahiro Fukuda, Yoshiko Asuta, Hideki Nakasone (Japan)

TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA

A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE
Sharon Hyzy, Rahul Palchaudhuri, Jennifer Proctor, Bradley Pearse, Ganapathy Sarma, Geoff Gillard, Asim Saha, Tahirih Lamotho, Melissa Brooks, Katelyn Hammond, Anjali Bhat, Charlotte McDonagh, Hans-Peter Kiem, John Wagner, Bruce Blazar, Anthony Boitano, Michael Cooke (United States)

INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vaneuza Araújo Moreira Funke, Virgílio Antônio Rensi Colturato, Nelson Hamerschlag, Neysimélia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Paz, Mariana Stevenazzi, Lilian Díaz, Abraaaho Elias Hallack Neto, Gustavo Bettarello, Breno Moreno de Gusmão, Marco Aurélio Salvino, Rodolfo Froses Calixto, Maria Cláudia Rodrigues Moreira, Gustavo Machado Teixeira, Cinthya Corrêa da Silva, Anderson Simioni, Romélia Pinheiro Gonçalves Lemes (Brazil)

CONDITIONING REGIMENS IN AML: MYELOABLATIVE TREOSULFAN-BASED REGIMEN VS. CYCLOPHOSPHAMIDE/TOTAL BODY IRRADIATION AND BUSULFAN-CYCLOPHOSPHAMIDE CONDITIONING REGIMENS
Eeva Martelin, Sari Kytölä, Riitta Niittyvuopio, Vesa Lindström, Jouni Heiskanen, Anne Nihtinen (Finland)

PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION
Taiki Ando, Taisei Suzuki, Takayoshi Tachibana, Masatsugu Tanaka, Heiwa Kanamori, Hideaki Nakajima (Japan)

FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA
Herbert Gottfried Sayer, Mathias Witzens-Harig, Mohammad Wattad, Agnieszka Korfel, Inken Hilgendorf, Georg-Nikolaus Franke, Gerald Illerhaus, Michael Heinsch, Bernd Metzner, Eva Bettina Zinggrebe, Nadezda Basara, Mascha Binder, Mark Ringhoffer, Alexander Röth, Thomas Geer, Volker Schmidt, Peter Dreger (Germany)
Scientific Programme

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS

COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

Zafer Gulbas, Elif Birtas Atesoglu, Imran Dora, Cigdem Eren, Suat Celik, Gokhan Kusdemir, Kader Caliskan (Turkey)

CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA

Kristen Peterson, Andrew Lin, Josel Ruiz, Junting Zheng, Sean Devlin, Gunjan Shah, Michael Scordo, Craig Sauter, Miguel Perales, Sergio Giralt, Larry Buie, Parastoo Dahi (United States)

PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES

A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING

Ian Wu, Tangia Muquith, Yeh Ching Linn, Michelle Poon, Lip Kun Tan, Belinda Tan, Yelly Yelly, Teck Guan Soh, Davanaliz Gonzales Ramos, William Hwang, Liang-Piu Koh (Singapore)

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS

Amado Jose Karduss, Rosendo Perez, Giovanni Ruiz, Angelica Cardona, Juan Alejo Jimenez, Luis Rodolfo Gomez, Pedro Reyes (Colombia)

TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE

Frances Yeap, Chintan Tarunkumar Vyas, Cheryl Neoh, Mariflor S Villegas, Poh Lin Tan (Singapore)

COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS

Anastasiia Samoylova, Vladislav Sarzhevsky, Vladimir Melnichenko, Nikita Mochkin, Julia Dubinina, Elena Smirnova, Anna Bannikova, Vladimir Bogatyrev (Russian Federation)

ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE

Thomas Heinicke, Ana-Maria Waldeleben, Denise Wolleschak, Thomas Brunner, Günther Gademann, Thomas Fischer, Hans-Joachim Ochel (Germany)

FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACATORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS

THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA
FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?
Guldane Cengiz Seval, Ekin Kircali, Sinem Civriz Bozdağ, Selam Kocak Toprak, Meltem Kurt Yuksel, Onder Arslan, Muhtı Ozcan, Taner Demirer, Gunhan Gurman, Osman İlhan, Hamdi Akan, Meral Bekşac, Pervin Topcuoğlu (Turkey)

INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS
Antonio Grasso, Rossella Vidimari, Francesca Ciriello, Roberto Simenone, Fabrizio Cupardo, Natalia Maximova (Italy)

EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS
Carla Alves, Nuno Miranda, Pedro Sousa, Isabelina Ferreira, Gilda Teixeira, Ana Sofia Jorge, Maria Joao Gutierrez, Fernando Leal-da-Costa, Manuel Abecasis (Portugal)

THIOTEPA-BUSULFAN-FLUDARBINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN

ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES
Eva De Backer, Dries Deeren (Belgium)

IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION
Susanne Aydin, Ingo Müller (Germany)

LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN
Nabil Yafour, Faiza Serradj, Soufi Osmane, Mohamed Brahimi, Sihem Bekadhja, Amel Mihoubi, Rachid Bouhass, Abdessamad Arabi, Mohamed Amine Bekadhja (Algeria)

SEQUENTIAL HLA—HAPLOIDENTICAL TRANSPLANTATION USING PTCY IN HIGH-RISK MDS/AML OF THE ELDERLY: A MATCHED-PAIR ANALYSIS OF TWO DIFFERENT REGIMENS USING TREOSULFAN OR MELPHALAN FOR RIC

CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK
Nick Duncan, Amritpal Atwal, Sumantha Gabriel, Matthew Collin (United Kingdom)

HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE

INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD
Satoru Matsushima, Ryoji Kobayashi, Daiki Hori, Masato Yanagi, Koya Kodama, Daisuke Suzuki, Atsushi Manabe, Kunihiko Kobayashi (Japan)
Scientific Programme

THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION
Gulen Tuysuz Kintrup, Funda Tayfun Kupesiz, Hilal Akbas, Ayse Nur Akinel, Cigdem Sivrince, Elif Guler, Alphan Kupesiz (Turkey)

REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE
Vinod Patil, Reghu Sukumaran, Mita Roychowdhury, Sayak Chaudhuri, Jeevan Kumar, Saurabh Bhave, Rizwan Javed, Niharendu Ghara, Reena Nair, Vivek Radhakrishnan, Mammen Chandy (India)

HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA

REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE

DESCRIBE AND EXPLORE A PATIENTS’ OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT
Charlotte Wilson-Dewhurst, Amit Patel, Shelagh Thompson (United Kingdom)

SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS

CONDITIONING REGIMEN WITH FLUDARABIN/TREOSSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS
Alix Pianka, Peter Herhaus, Krischan Braitsch, Katrin Holzhauser, Katharina Götz, Florian Bassermann, Mareike Verbeek (Germany)

OUTCOMES OF UNRELATED DONOR STEM CELL TRANSPLANTATION WITH OR WITHOUT ANTI-THYMICSE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE
Georgina Gener Ricós,Montserrat Batlle Massana, Mirreia Morgades de la Fe, María Josefa Jiménez Lorenzo, Christelle Ferrà Coll, Juan Manuel Sancho Cia, Mirreia Franch Sarto, Mirreia Santos Gómez, Susana Vives Polo, Miriam Moreno Velázquez, Anna Torrent Catarineu, Blanca Xicoxy Cirici, Laura Abril Sabater, Gladys Ibarra Fernández, Alicia Senín Mañan, Albert Oriol Rocafiugera, Josep Maria Ribera Santasusana (Spain)

BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY

ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
Lazar Chadievksi, Aleksandra Pivkova Veljanovska, Irina Panovska Stavridis, Zlate Stojanoski, Lidija Cevreska, Nevenka Ridova, Marija Popova Labacevska, Zaklina Ancevska, Gabriela Trajkovska, Borce Georgievska (North Macedonia, the Republic of)

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Gene Therapy
EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA
Jane Kinsella, Simon Jones, Heather Church, Ceri Jones, Stuart Ellison, Claire Booth, Karen Buckland, Diego Leon Rico, Brian Bigger, Adrian J Thrasher, Robert Wynn (United Kingdom)

Graft-versus-host disease - clinical

IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION

SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE

DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ram Vasudevan Nampoothiri, Peter Riddell, Susan Chernenko, Matthew Binnie, Lianne Singer, Stephen Juvel, Jeffrey Howard Lipton (Canada)

REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD
Katarina Riesner, Steffen Cordes, Maria Bartosova, Martina Kalupa, Sarah Mertlitz, Lars Bullinger, Igor Wolfgang Blau, Claus Peter Schmitt, Gernot Beutel, Olaf Penack (Germany)

IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TRANSPLANTATION FROM UNRELATED DONORS

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IS HIGHLY EFFECTIVE AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN HLA-MISMATCHED DONOR (MMUD) HEMATOPOIETIC CELL TRANSPLANTATION: REPORT OF A PROSPECTIVE PHASE II TRIAL
Monzr M. Al Malki, Ni-Chun Tsai, Joycelynne Palmer, Thai Cao, Haris Ali, Amandeep Salhotra, Shukaib Arslan, Ibrahim Aldoss, Nicole Karras, Jasmine Zain, Saker Khaled, Anthony Stein, David Snyder, Guido Marcucci, Stephen J. Forman, Auayporn Nademanee, Ryotaro Nakamura (United States)

DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL

EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE
Nick C. Matthewews, Charlotte Burton, Arun Alfred (United Kingdom)

POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: ‘SIR-PTCY’ RESULTS IN 249 PATIENTS
Raffaella Greco, Serena Albanese, Francesca Lorentino, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Plemontese, Maqda Marcatti, Daniela Clerici, Lorenzo Lazzari, Rosamaria Nitti, Carmine Liberatore, Sara Mastaglio, Andrea Assanelli, Luca Vago, Chiara Bonini, Consuolo Corti, Massimo Bernardi, Fabio Ciceri, Jacopo Peccatori (Italy)
A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCST): RUXOLITINIB
Osman Ilhan, Guidane Cengiz Seval, Sinem Civriz Bozdag, Burak Deveci, Mustafa Pehlivian, Leylagul Kaynar, Irfan Yavasoglu, Huseyin Bekoz, Ipek Yonal Hindilerden, Zeynep Arzu Yegin, Simten Dagdas, Ayse Ausar, Atilla Hasan Ozkan, Tulin Firat Tuglular, Hakan Goker, Zafer Golbas (Turkey)

AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL

BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC

EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Abed Alahad Sarraf, Renate Schmelz, Henning Baldauf, Daniela Aust, Friedrich Stölzel, Jan Moritz Middeke, Katja Sockel, Raphael Teipel, Stefan Brückner, Marco Berning, Sebastian Zeissig, Jana Babatz, Christian Kirsch, Gustavo Bareton, Martin Bornhäuser, Jochen Hampe, Johannes Schetelig (Germany)

CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP

TRANSPANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE
Eleni Gavriilaki, Ioanna Sakellari, Zoi Bousiou, Thomas Chatzikonstantinou, Despina Mallouri, Marianna Masmanidou, Anna Vardi, Eudoxia-Evagelia Koravou, Foteini Kika, Tasoula Touloumenidou, Apostolia Papaalexandri, Evangelia Yannaki, Ioannis Batsis, Achilles Anagnostopoulos (Greece)

DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)
Georg Evers, Wolfgang Roll, Joern Christian Albring, Christian Reicherts, Rebecca Strotmann, Georg Lenz, Michael Schaefers, Matthias Stelljes (Germany)

LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS
Tatiana Bykova, Ivan Moiseev, Elena Morozova, Elena Darskaya, Olesya Paina, Anna Smirnova, Anna Dotcenko, Evgenia Borzenkova, Alexander Galimov, Yana Dudognikova, Kirill Ekushev, Polina Kozhokar, Anna Osipova, Olga Pirogova, Tatjana Rudakova, Olesya Shakeeva, Nikolay Tcvetkov, Egor Kulagin, Ludmila Zubarovskaya, Boris Afnasyev (Russian Federation)

INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Razan Mohty, Rémy Duléry, Giorgia Battipaglia, Eolia Brissot, Clémence Médiavilla, Simona Sestilli, Tounes Ledraa, Beatrice Gaugler, Agnes Bonnin, Mohamad Mohty, Florent Malard (France)

EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION
PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN
Frida Schain, Nurgul Batyrbekova, Annica Dominicus, Simona Baculea, Mats Remberger, Jonas Mattsson, Jacek Toporski (Sweden)

CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE
Olle Ringden, Mats Remberger, Johan Torlen, Sigrun Finnbogadottir, Britt-Marie Svahn, Behnam Sadeghi (Sweden)

FECA MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES
Jaroslaw Bilifksi, Karol Lis, Agnieszka Tomaszewska, Pawel Grzesiowski, Aleksandra Pechcinska, Tomasz Dzieciatkowski, Kazimierz Halaburda, Magdalena Tormanowska, Martyna Tyszka, Krzysztof Madowy, Ewa Karakulska-Prystupiuk, Alicja Walesiak, Wieslaw Wiktor Jedrzejczak, Grzegorz W. Basak (Poland)

INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS
Antonela Lelas, Ronja Langer, Michael Rittenschober, Lana Desnica, Hildegard Greinix, Anne Dickinson, Marit Inngjerdingen, Anita Lawitschka, Radovan Vrhovac, Drazen Pulanic, Stefan Klein, Jan Moritz Middeke, Matthias Edinger, Daniel Wolff (Croatia)

THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE
Hao Dai, Sivaramakrishna P. Rachakonda, Olaf Penack, Olga Blau, Aleksandar Radujkovic, Carsten Müller-Tidow, Peter Dreger, Rajiv Kumar, Thomas Luft (Germany)

EARLY INTRODUCTION OF RUXOLINITIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE
Revathi Raj, Ramya Uppuluri, Venkateswaran Vellaichamy, Nikila Ravichandran, Kesavan Iyer (India)

POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS
Irene Garcia-Cadenas, Albert Esquirol, Rahinatu Awol, Silvana Saavedra, Silvana Novelli, Ana Garrido, Jordi Lopez, Carol Moreno, Miquel Granell, Javier Briones, Salut Brunet, Jordi Sierra, Rodrigo Martino (Spain)

SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY
Ivan Pasic, Ashley Di Meo, Ioannis Prassas, Ihor Batruch, Leeann Wilson, Eletherios P. Diamandis, Fotios V. Michelas (Canada)

OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Jérome Héritérr, Michael Medinger, Dominik Heim, Helen Baldomero, Christian Arranto, Jörg Halter, Jakob R. Passweg, Martina Kleber (Switzerland)

SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSTC
Maria Teresa Lupo-Stanghellini, Francesca Lorentino, Fabio Serpenti, Andrea Assanelli, Carlo Messina, Sara Mastaglio, Stefania Girlanda, Fabio Giglio, Raffaela Greco, Sarah Marketel, Francesca Lunghi, Elena Guggiari, Magda Marcatti, Matteo G. Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciciri (Italy)
INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH
Mi Kwon, Rebeca Bailén, Maria Jesus Pascual Cascon, Lucia Lopez Corral, Arancha Bermudez, Pilar Herrera, Antonia Sampol, Inmaculada Heras, Carmen Martin Calvo, Jaime Sanz, Isabel Sanchez Ortega, Melissa Torres, Jose Rifen Roca, Kareem Humala, Cristina Muñoz, Ignacio Gomez Centurion, Gillen Qarbeacoa, Nieves Dorado, Jose Luis Diez Martin (Spain)

MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL

T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE
Aisling M Flinn, Janet Chou, Anna Ehrlich, Xiao Nong Wang, Raif S Geha, Andrew R Gennery (United Kingdom)

EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
Yanmin Zhao, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Huarui Fu, Xiaoyu Lai, He Huang (China)

RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM
Ernst Holler, Daniela Weber, Joachim Hahn, Cornelia Mittermaier, Klaus-Georg Kreitmeier, Andreas Hiergeist, Bernd Salzberger, Daniel Wolff, Andre Gessner, Wolfgang Herr, Matthias Edinger (Germany)

EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)

EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS
Carrie Lynn Kitko, Stefania Gaspari (United States)

MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS
Hooi Ching Lim, Shamit Soneji, Robert Palmason, Stig Lenhoff, Thomas Laurell, Stefan Scheding (Sweden)

COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS

CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS
Avichai Shimoni, Noga Shem-Tov, Ivetta Danylesko, Ronit Yerushalmi, Arnon Nagler (Israel)
COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING

SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION

TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS
Suze A. Jansen, Wouter Nijhuis, Helen Leavis, Annelies Riezebos-Brilman, Caroline A. Lindemans, Rob Schuurman (Netherlands)

EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE
Charlotte Burton, Nick C. Mattthews, Arun Alfred (United Kingdom)

IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS

PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD
Carolina Secreto, Martina Tonelli, Alessandro Busca, Matilde Scaldaferr, Chiara Della Casa, Luisa Giaccone, Lucia Brunello, Sara Butera, Giorgia Iovino, Francesco Cattel, Benedetto Bruno (Italy)

RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
Rong Xie, Qin Liu, Dan Han, Wenlan Chen, Han Yan, Fanjun Cheng, Yong You, Ping Zou, Zhaodong Zhong (China)

CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS
Chiara Montagna, Maria Teresa Lupo Stanghelli, Ilaria Scortechini, Magda Marcatti, Raffaella Greco, Fabio Giglio, Andrea Assaneli, Consuelo Corti, Monica Poiani, Federica Monaco, Giuseppina Urbano, Giorgia Mancini, Irene Federici, Jacopo Peccatori, Fabio Ciceri, Attilio Olivieri, Simona Piemontese (Italy)

IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETTE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
Sarah Lindner, Tobias Berg, Christian Seidl, Franziska Kalensee, Michael Rieger, Hubert Serve, Gesine Bug, Joachim Schwaebele, Evelyn Ullrich (Germany)

ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Antonela Lelas, Lana Desnica, Ivan Sabol, Zlatko Giljevic, Tina Dusek, Dina Ljubas Kelecic, Irena Karas, Nadira Durakovic, Zinaida Peric, Ranka Serventi Seiwerth, Radovan Vrhovac, Steven Z. Pavletic, Drazen Pulanic (Croatia)

CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION
Mohammad Sheikh, Shahrukh Hashmi (Pakistan)

ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER
Massimo Berger, Marta Barone, Francesco Saglio, Fabrizio Carnevale-Schianca, Marco De Gobbi, Luca Parruzzo, Paolo Nicoli, Manuela Spadea, Daniela Caravelli, Elena Ernestina Vassallo, Massimo Aglietta, Franca Fagioli (Italy)
PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS

THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS

Maria Gavrilaki, Ioanna Sakellari, Achilles Anagnostopoulos, Eleni Gavrilaki (Greece)

CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE

Michał Piątek, Izabela Zdolińska-Malinowska, Maciej Rojek, Monika Mielcarek-Siedziuk, Krzysztof Kałwak, Katarzyna Drabko, Agnieszka Zaucha-Prażmo, Dominik Grabowski, Janina Marta Choma, Miroslaw Markiewicz, Monika Dzierżak Mietla, Jolanta Goździk, Zsuzsanna Kiss, Krzysztof Cyżewski, Robert Dębski, Anna Krenska, Jan Styczyński, Mariusz Wysocki, Dariusz Boruczkowski (Poland)

PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: 'A POSTERIORI' ANALYSIS IN A SINGLE CENTER

THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

Shinpei Harada, Koichiro Minauchi, Hajime Senjo, Naoki Miyashita, Tomohiro Yamakawa, Junko Iwasaki, Shojiro Takahashi, Kohei Okada, Akio Shigematsu, Masahiro Imamura, Naoki Kobayashi, Shuichi Ota (Japan)

THYMoglobulin AND GRAFALON EFFECT ON ALLOGENEIC STEM CELL TRANSPLANT - POOLED DATA FROM WROCLAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL CENTER LJUBLJANA, SLOVENIA

THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

Daihong Liu, Liping Dou, Lu Wang, Fei Li, Lijun Wang (China)

NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

Stalin Ramprakash, Rajat Kumar Agarwal, C P Raghuram, Pallavi Mehta, Paula Tacia, S Sandeep, Rakesh Dhanya, Lawrence Faulknner (India)

IN VIVO DYNAMICS OF REGULATORY T-CELLS AND B-CELLS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DETECTION OF PREDICTIVE MARKERS FOR ACUTE GRAFT-VERSUS-HOST DISEASE

Masahiro Yoshida, Hayato Maruoka, Yoshimitsu Shimomura, Satoshi Yoshioka, Akiko Matsushita, Hisako Hashimoto, Takayuki Ishikawa (Japan)

PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN

Hideaki Yoshimura, Atsushi Satake, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Shinya Fujita, Tomoki Ito, Kazuyoshi Ishiii, Shosaku Nomura (Japan)
Scientific Programme

RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE
Melissa Torres Ochando, Paula Fernández-Caldas González, Haridian de la Nuez Melián, Cynthia Acosta Fleitas, Santiago Jiménez Bravo de Laguna, María Perera Álvarez, Leslie González Pinedo, Luisa Guerra Domínguez, Alexia Suárez Cabrera, Luz María González del Castillo, Leonor Pérez Ortiz, Teresa Molero Labarta (Spain)

OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION

RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE
Yanping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Zimin Sun (China)

SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE
Gaurav Kharya, Archana Rauthan, Manju Joseph, Himshikha Yadav, Bharti Sharma, Atish Bakane (India)

POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE-GLOBULIN IN HLA-MATCHED UNRELATED TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES: SINGLE-CENTER EXPERIENCE

DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY
Ivan Pasic, Ashley Di Meo, Ioannis Prassas, Ihor Batruch, Leeann Wilson, Eleftherios Diamandis, Fotios Michelis (Canada)

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE
Xabier Gutiérrez López de Ocariz, Elena Vera-Guerrero, María Calbacho, Jose María Sánchez-Pina, Ana Jiménez-Ubieto, Antonia Rodríguez, Sara Redondo, Marta Hidalgo-Soto, Rodrigo De Nicolás, Nieves López-Muñoz, Buenaventura Buendia-Ureña, Joaquín Martínez-López (Spain)

CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL

CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Matthias Alexander Fante, Tobias Wertheimer, Anna-Sophia Kattner, Daniela Weber, Barbara Holler, Ernst Holler, Matthias Edinger, Wolfgang Herr, Daniel Wolff (Germany)

THE EXTRACELLULAR CTLA-4 DOMAIN FUSION PROTEIN ABATACEPT AS SALVAGE THERAPY IN THE TREATMENT OF CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS

A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)

EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER
THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN

ANALYSIS OF HISTOLOGY’S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Elena María Gámez Jiménez, Pedro Antonio González Sierra, Elisa López Fernández, Lucía Moratalla López, Zoraida Mesa Morales, Antonio Romero Aguilar, Manuel Jurado Chacón (Spain)

RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE

FEcal MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY
Won-Hyoung Seo, Ik-Chan Song, Myung-Won Lee, Sang-Hoon Yeon, Yoon-Seok Choi, Bu-Yeon Heo, Jaeyul Kwon, Deog-Yeon Jo (Korea, Republic of)

EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD
Masato Yanagi, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Koya Kodama, Daisuke Suzuki, Kunihiro Kobayashi (Japan)

FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE
Matías Sanchez, Marcela Vargas, Javiera Donoso, Natalia Aranguiz, Alejandro Berkowits, Sebastian Ewoldt, Veronica Bustamante, Laura Paredes, Teresa Dibarrart, Patricia Lobos, Leonardo Cabrera (Chile)

COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD
Francesca Compagno, Antonia Avanzini, Elena Bergami, Stella Boghen, Tommaso Mina, Santina Recupero, Elisa Lenta, Stefania Croce, Laura Catenacci, Alessandra Tolva, Federico Bonetti, Giovanna Giorgiani, Patrizia Comoli, Marco Zecca (Italy)

MULtIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT

A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD

INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION
Sami Brake (United States)

AUTOIMMUNE MYOSITIS AS PARANEoplastIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE

UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT

Poster Sessions
09:00 - 18:00

Graft-versus-host disease – preclinical and animal models
ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION  
Antonella Mancusi, Samanta Bonato, Rachele Del Sordo, Sara Piccinelli, Eni Hoxta, Tiziana Zel, Roberta Iacucci Ostini, Franca Falzetti, Alessandra Carotti, Loredana Ruggeri, Michele Giansanti, Robert S. Negrin, Massimo F. Martelli, Andrea Velardi, Antonio Pierini (Italy)

LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKewing CD4+ T CELL POLARIZATION TOWARDS TREG CELLS  
Huihui Liu, Zhengyu Yu, Bo Tang, Shengchao Miao, Chenchen Qin, Miao Yan, Zhengyang Song, Hanyun Ren, Yujun Dong (China)

ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN  
Kang Sun, Ping Chen, Mengran Lee, Jun Ruan, Yuxue Xia, Mei Hong, Jun Fang, Hao Tang (China)

NLRP6 IN DONOR T CELLS REGULATES GRAFT-VERSUS-HOST DISEASE IN EXPERIMENTAL MURINE BMT  
Tomomi Toubai, Masahiro Suto, Eri Matsuki, Erika Sekiguchi, Hiroyo Tamaki, Isao Tawara, Grace Chen, Kenichi Ishizawa, Reddy Pavan (Japan)

CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS  
Suze A. Jansen, Marliek van Hoesel, Michal Mokry, Leire Saiz Sierra, Shuichiro Takashima, Edward E.S. Nieuwenhuis, Alan M. Hanash, Caroline A. Lindemans (Netherlands)

INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS  
Emmanuelle Moraes Ribeiro, Hannes Schmid, Ruoyun Dong, Kathy-Ann Secker, Hildegard Keppeler, Corina Schneidawind, Dominik Schneidawind (Germany)

ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION  
A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE  
MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS  
Merav Bar, Mohammed Toufiq, Darawan Rinchai, Mohammed Elanbari, Sabri Boughorbel, Valentina Mattei, Rebecca Mathew, Irene Cavattoni, Sabine Forer, Clarisa Brown, Marco Zecca, Patrizia Comoli, Giovanni Grillo, Catherine Cole, Chiara Cugno, Sara Tomei, Damien Chaussabel, Sara Deola (Qatar)

CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE  
Anna Kroeze, Anne Cornelissen, Fernanda Pascutti, Sjoerd Klarenbeek, Achia Ait Soussan, Tom van der Poll, Mette Hazenberg, Erfan Nur, Ellen van der Schoot, Carlijn Voermans, Sacha Zeerleder (Switzerland)

DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECtor T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION  
Masatsugu Oh-Hora, Anri Aki, Hiroaki Maeda, Kiyoshi Morimoto (Japan)

ENDOThelial MICROPARTICLES DELIVERING LncRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT  
B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE  
Dhanya Kizhakayil, Abhirami Sathappan, Zoltan Pos, Nikolett Lupsa, Christophe M Raynaud, Giusy Gentilcore, Mohammad A Al-Aghbar, Cristina Maccalli, Jean-Charles Grivel, Nicholas van Panhuys, Sara Deola (Qatar)
Scientific Programme

IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS
Dhinoth K Bangarusamy, Arun P Lakshmanan, Sara Deola, Dhanya Kizhakayil, Zoltan Pos, Nikolett Lupsa, Annalisa Terranegra (Qatar)

Granulocyte and osteoclast disorders

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS
Ehud Even-Or, Irina Zaidman, Polina Stepensky (Israel)

Haemoglobinopathy and inborn errors

HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT
Stalin Ramprakash, C P Raghuram, Pallavi Mehta, Paula Tacia, Priya Mawah, Rajpreet Soni, Deepa Trivedi, Vaibhav Shah, Rakesh Dhanya, Rajat Kumar Agarwal, Lawrence Faulkner (India)

CTLA4Ig-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD
Sarita Rani Jaiswal, Prakash Bhakuni, Hema Malini Aiyer, Aditi Chakrabarti, Satish Bansil, Suparno Chakrabarti (India)

LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA
Mattia Algeri, Richard A. Colvin, Weijian Liu, Ge Tao, Franco Locatelli (Italy)

BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE

OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSES TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY
Maria Escolar, Nicholas Bascou, Bridget Kiely, Aleksandra Safonova, Maria Beltran, Michele Poe, Paul Szabolcs (United States)

HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMIA PATIENTS
PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSONAL STORAGE DISEASE IN CHILDREN
Hemalatha Doss, Denise Bonney, Helen Campbell, David Deambrosis, Simon James, Kay Poulton, Wendy Ogden, Wynn Robert F (United Kingdom)

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE

LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD
Oruc Ali Quliyev, Gulcihan Ozek, Savas Kansoy, Serap Aksoylar (Turkey)

HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR
Christina Oikonomopoulou, Anna Paisiou, Eleni-Dikaia Ioannidou, Aikaterini Kaisari, Anna Komitopoulou, Maria Theodosaki, Eftichia Petrakou, Ioulia Peristeri, George Vessalas, Evgenios Goussetis, Vassiliki Kitra-Roussou (Greece)

ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS
Erfan Nur, Sacha Sergio Zeerleder, Aafke Gaartman, Caroline Rutten, Liesbeth Suijk, Charlotte van Tuijn, Judith Wentholst, Mette Hazenberg, Bart Biemond (Netherlands)

A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR
Jürgen Föll, Katharina Kleinschmidt, Anja Tröger, Petra Turowski, Rainer Spachtholz, Norbert Ahrens, Andreas-Michael Brosig, Matthias Evert, René Schmidt, Daniel Wolff, Matthias Edinger, Matthias Eyrich, Rupert Handgretinger, Susanne Ellinger, Selim Corbacioglu (Germany)

COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA MAJOR

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY

UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA
Xiaowen Zhai, Xiaowen Qian, Ping Wang, Hongsheng Wang, Wenjin Jiang (China)

PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA

CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS
Gaurav Kharya, Archana Rauthan, Manju Joseph, Himshikha Yadav, Bharti Sharma, Atish Bakane (India)

HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE
Eman Khattab, Rula Najjar, Abdelghani Tbaksi, Rawad Rihani, Mayada Abu Shanap, Hasan Hashem, Aram Ahmod, Nilly Hussein, Iyad Sultan (Jordan)
Scientific Programme

Multiple myeloma

PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE

Zübeyde Nur Özkurt, Ayşe Asena Dikyar, Zeynep Arzu Yeğin, Lale Aydin Kaynar, Özlem Karacaoglu, Emin Ateş (Turkey)

UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS

CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN≤PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT

RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS

IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMBAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION

ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Scientific Programme

RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY
Aya Nakaya, Takae Kohara, Hirohiko Shibayama, Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Toru Kida, Satoru Kosugi, Jun Ishikawa, Ryouuke Yamamura, Yutaka Shimazu, Hirokazu Tanaka, Shin-ichi Fuchida, Yuji Shimura, Miki Kiyota, Katsuya Wada, Tomoki Ito, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Ken-suke Ohtta, Chihiro Shimazaki, Masayuki Hino, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura (Japan)

MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Nobuhiro Tsukada, Junichiro Bashimoto, Yui Uto, Kota Sato, Kanji Miyazaki, Mizu Ogura, Yumiko Yoshoki, Yu Abe, Kiyoshi Okazuka, Tadao Ishida, Kensi Suzuki (Japan)

AUTOLOGOUS STEM CELL TRASPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOsis

NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES ‘ZERO’ CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)
Emilian Snarski, Agnieszka Tomaszewska, Martyna Maciejewska, Michał Góra, Anna BROdziak, Sara Zawadzka-Leska, Anna Waszczyuk-Gajda, Jaroslaw Biliński, Marcin Jasieński, Karol Lis, Kamila Skwierawska, Hubert Heleniak, Mateusz Ziarlakiewicz, Dorota Zduńczyk, Wojciech Sachs, Elżbieta Urbanowska, Magdalena Feliński-brot - Bratosiewicz, Małgorzata Król, Maria Król, Wiesław Wiktor-Jędrzejczak, Grzegorz Basak (Poland)

OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPANTATION IN MULTIPLE MYELOMA
Pokpong Piriyakhunthorn, Adisak Tantiworawit, Thanawat Rattanathammeethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattaritamrong, Lalita Norasetthada (Thailand)

DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES
Yeung-Chul Mun, Jee-Young Ahn, Eun Sun Yoo, Kyoung Eun Lee, Eun Nam, Soon Nam Lee, Hyun Ae Woo, Sue Goo Rhee, Chu Myong Seong (Korea, Republic of)

THE CAPACITY BUILDING APPROACH FOR START-UP OF FIRST BMT CENTER IN IRAQI KURDISTAN. EVIDENCE OF SUCCESS BY PRELIMINARY ANALYSIS OF AUTOLOGOUS TRANSPLANTATION RESULTS IN MM

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE
Ayse Tulun Tugluğlar, Tayfun Elbil, Arda Bayar, Belgin Aidag, Ozen Oruc, Tarik Ercan, Yildiz Ipek, Fatma Arikan, Asu Fergün Yilmaz, Işık Atağındüz, Tayfur Toptas (Turkey)

FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT
Hee Jeong Cho, Dong Won Baek, Ju Hyung Kim, Sung Hoon Jung, Sang Kyun Sohn, Joon Ho Moon (Korea, Republic of)

LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS
Ozren Iaksic, Zeljko Prka, Mario Pirsic, Zdravko Mitrovic, Ena Soric, David Cicic, Tamara Vasilj, Zeljko Jonjic, Marko Lucijanic, Ivana Maricic, Gorana Dzepina, Rajko Kusec, Vlatko Pejza (Croatia)

MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRASPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS
N Amer, MT Villalobos, R Del Campo, Jb Borras, A Porcel, Jm Guerra, A Jaramillo, A Cladera, M Mascarró, J Perales-Amengual, M Canet, P Velez, J Perales, A Muntañola, Ja Soler, M López, M Diaz, F Valls-Ilovera, Jm Marti, J Bargay (Spain)
ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE

RESULTS OF TREATMENT MULTIPLE MYELOMA IN COMBINATION WITH BONE AND/OR EXTRAMEDULLARY PLASMACYTOMAS
Valentina Porunova, Olga Pirogova, Olga Kudjasheva, Elena Darskaya, Ilya Nikolaev, Boris Afanasyev (Russian Federation)

USE OF NETUPITRAN/PAISONSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA
İlknur Demir, Sacide Pehlivan, Vahap Okan, Handan Sahin, Sertac Durusoy, Yasemin Oyaci, Mustafa Pehlivan (Turkey)

SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE

PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY
Xiuyan Tao, Wenwen Ma, Limei Gao, Jiajia Yue, Yuehui Lin (China)

Poster Sessions
09:00 - 18:00

Myelodysplastic syndromes

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
Marie Robin, Junfeng Wang, Linda Koster, Dietrich Beelen, Martin Bornhaeuser, Nikolaus Kroeger, Uwe Platzbecker, Jurgen Finke, Arnold Ganser, Dietrich Beelen, Marie Robin, Nicolaus Kroeger, Hélène Labussière, Patrice Chevallier, Jakob Passweg, Jan J Cornelissen, Carmen Botella, Amandine Charbonnier, Francesca Bonifazi, Katya Mauff, Liesbeth de Wreede, Patrick Hayden, Christoph Scheid, Ibrahim Yakoub-Agha (France)

HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES FOR PATIENTS WITH REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA: A COMPARISON OF CHILDREN WITH ADOLESCENTS AND YOUNG ADULTS
Asahito Hama, Daisuke Hasegawa, Motohiro Kato, Kenichiro Watanabe, Daiichiro Hasegawa, Yukiyasu Ozawa, Noriko Doki, Maho Sato, Yasushi Onishi, Yoshiyuki Kosaka, Yasuhiro Okamoto, Yoshiko Hashii, Koji Kato, Tatsuo Ichinohe, Yoshiho Atsuta, Jun Aoki, Nao Yoshiida (Japan)

IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, Friedrich Stölzel, Christina Rautenberg, Olivier Nibourel, Heiko Becker, Aleksandar Radajkovic, Peter Dreger, Maximilian Christopeit, Jürgen Finke, Uwe Platzbecker, Guido Kobbe, Michael Koldehoff, Markus Ditschkowski, Dietrich Beelen, Marie Robin, Nikolaus Kröger (Germany)

NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING
IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY


RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME


OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Nikolai Tcvetkov, Elena Morozova, Ildar Barkhatov, Ivan Moiseev, Maria Barabanshikova, Artem Tishkov, Dmitrij Bug, Ekaterina Izmailova, Sergey Bondarenko, Boris Afanasyev (Russian Federation)
Scientific Programme

‘KIT’-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS’ SUBTYPES
Selda Ugur, Lara Kristina Klauer, Christian Blasi, Fatemah Doraneh-Gard, Caroline Plett, Carina Gunsilius, Daniel Amberger, Melanie Weinmann, Olga Schutti, Zuzanna Stankova, Erdem Özkaya, Michael Atzler, Elena Pepeldjiyska, Antje Völker, Jörg Schmohl, Andreas Rank, Christoph Schmid, Doris Kraemer, Helga Maria Schmetzer (Germany)

ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS
Lin Li, Veronika Mussack, Elena Pepeldjiyska, Anne Hartz, Andreas Rank, Christoph Schmid, Erdem Özkaya, Selda Ugur, Michael Pfaffl, Helga Schmetzer (Germany)

HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCRαβ+/CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE

BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER
IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION
Christoph Kugler, Helga Schmetzer (Germany)

IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<SUB>LEU</SUB>) MEDIATED IMMUNE RESPONSES IN AML
Lara Kristina Klauer, Olga Schutti, Selda Ugur, Fatemeh Donareh-Gard, Nicole Rogers, Melanie Weinmann, Doris Krämer, Andreas Rank, Christoph Schmid, Britta Eiz-Vesper, Helga Maria Schmetzer (Germany)

TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)

Non-infectious early complications

BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS
Roni Shouval, Adi Eshel, Amir Kuperman, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, Shalev Fried, Mika Geva, Elizaveta Kouniavsky, Efrat Muller, Elhanan Borenstein, Yoram Louzoun, Omry Koren, Arnon Nagler (Israel)

DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP
IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT
Michal Gorka, Christophe Peczynski, Emmanuelle Polge, Karol Lis, Riitta Niittyvuopio, Hélène Labussière Wallet, Zinaida Peric, Helene Schoemans, Olaf Penack, Nina Worel, Christian Koenecke, Grzegorz Wladyslaw Basak (Poland)

HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION
Catherina Lueck, Gernot Beutel, Victoria Panagiota, Elke Dammann, Dominik Markel, Maleen Beck, Souheila Tayeb, Adrian Schwarzer, Daniel Kharazipour, Michael Stadler, Arnold Ganser, Matthias Eder (Germany)

TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME
IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Maria Schou Ebbesen, Christian Enevold, Anders Juul, Carsten Heilmann, Henrik Sengeløv, Klaus Müller (Denmark)

LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE
Irene García-Cadenas, Albert Esquivol, Rahinatu Awol, Silvana Saavedra, Silvana Novelli, Ana Garrido, Jordi López, Carol Moreno, Miquel Granell, Javier Briones, Salut Brunet, Jordi Sierra, Rodrigo Martino (Spain)

KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA
Najla El Jurdi, Christina Fair, John Rogosheske, Ryan Shanley, Daniel Weisdorf, Shernan Holtan, Mukta Arora, Veronika Bachanova, Claudia Brunstein (United States)

ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
Zeynep Tugba Guven, Serhat Celik, Leylagül Kaynar, Bulent Eser, Mustafa Cetin, Ali Ünal (Turkey)

SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING ACUTE GRAFT-VERSUS-HOST DISEASE
Anna Guo, LaQuisa Hill, Gabriela Rondon, Richard E. Champlin, Amin M. Alousi, Rima M. Saliba (United States)

COST-EFFECTIVENESS ANALYSIS OF DEFBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN
David Carcedo Rodriguez, Teresa Artola Urain, Anabelle Chinea Rodríguez, Estefanía García Torres, Marta González Vicent, Gonzalo Gutiérrez-García, Alexandra Regueiro García, Marcos Calvo Hidalgo, Alba Villacampa (Spain)

NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME
VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Esther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, Gesine Bug, Martina Crysandt, Sabine Dressler, Andreas Hausmann, Daniela Heidenreich, Klaus Hirschbühl, Matthias Hoepting, Edgar Jost, Jennifer Kaivers, Stefan Klein, Lambros Kordelas, Oliver Kriege, Lutz Müller, Christina Rautenberg, Judith Schaffrath, Christoph Schmid, Daniel Wolff, Rainer Haas, Martin Bornhäuser, Thomas Schroeder, Guido Kobbe (Germany)

EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS

Ana Carolina Amaral de Sao Jose Perrone, Clarissa Ferreira Cunha, Ana Paula da Silva Pinheiro, Italo Tuler Perrone, Leonardo Barbosa de Almeida, Kelli Borges dos Santos, Rodrigo Stephani, Henrique Couto Teixeira, Paula Alexandra da Graça Morais, Antonio Fernandes de Carvalho, Abrahao Elias Hallack Neto (Brazil)

TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Eileen van der Stoep, Dagmar Berghuis, Robbert Bredius, Emmeline Buddingh, Henk-Jan Guchelaar, Alex Mothseny, Irene Klaassen, Frans Smiers, Arjan Lankester, Juliette Zwaveling (Netherlands)

VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY

DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

Ignacio Gómez-Centurión, Cristina Muñoz, Arturo Alvárez Luque, Miguel Echenagusia Boyra, Diego Rincón, Nieves Dorado, Rebeca Bailén, Gillen Oarbeascoa, Javier Anguita, José Luis Diez-Martín, Mi Kwon (Spain)

DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE

NEUROLOGICAL COMPLICATEIS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY

ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS

Lenneke van Groningen, Doris Kalter, Wim Tissing, Walter van der Velden, Nicole Blijlevens (Netherlands)

DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS

Duncan Purtill, Ghassan Zammarr, Hutchison Andrew, Julian Cooney, Paul Cannell, Matthew Wright (Australia)
THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME
Vera Radici, Chiara Rosignoli, Rossella Stella, Maria Vittoria Dubbini, Alessandra Sperotto, Michela Cerno, Antonella Geromin, Marta Lisa Battista, Giorgio Soardo, Laura Scatà, Renato Fanin, Francesca Patriarca (Italy)

ENDOThelial CELL COMPLICATIONS AFTER ALLOGeneIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT

INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS
Volker Witt, Herbert Pichler (Austria)

EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS
Michiho Ebihara, Akihito Shinhara, Satoko Osanai, Michiko Ryuzaki, Yuki Izuka, Aya Watanabe, Norina Tanaka, Midori Ishiyama, Hiroshi Kazama, Shotaro Hagiwara, Kentaro Yoshinaga, Masayuki Shiseki, Junji Tanaka (Japan)

SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-Occlusive DISEase/Sinusoidal Obstruction SYndrome
Selim Corbacioglu, Saurabh Aggarwal, Ozlem Topaloglu, William Tappe (Germany)

VENO-Occlusive DISEase: Online, INTERprofessional, CASE-Based EDucation SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE Team
Lauren Willis, Mindy Tanzola, Tristin Abair, Pan Chen, Cathryn Jennissen, Alison Bemis, Angela R. Smith (United States)

HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME
José Luis Bueno, Azucena Losa, Clara González Santillana, Begona Perez de Camino, Guiomar Bautista, Irene Romero, Ana Alarcón, Daniel Naya, Cristina Teresa Fernández-Maqueda, Carlos de Miguel, María Esther Martínez-Muñoz, Almudena De la Valiesía, Laura Vicente, José Antonio García-Marco, Rafael Forés, José Rafael Cabrera, Rafael F Duarte (Spain)

EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN
Ramya Nataraj, Praveen Kurup, Alok Ekka, Gayathri Subramanian, Omendra Narayan, Denise Bonney, Helen Campbell, Hemalatha Doss, Robert Wynn (United Kingdom)

USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION

CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND
Rosa Toenges, Matthias Edinger, Gesine Bug, Anita Lawitschka, Hildegarde Greinix, Jörg Halter, Jann Arends, Franci Ayuk, Stefan Klein, Jan-Moritz Middeke, Eva Wagner-Drouet, Inken Hilgendorf, Annic Baumgartner, Daniel Wolff (Germany)
INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION
Frank Cirrone, Jamie Pavlonnis, Kelli Cole, Maher Abdul-Hay, Doyun Park, A Samer Al-Homsi (United States)

ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER
Dorra Belloumi, Rimel Kanoun, Rim Cherni, Rym El Fatmi, Lamia Torjemane, Nour Abdeljelil, Amel Lakhal, Saloua Ladeb, Tarek Ben Othman (Tunisia)

WERNICKE’S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT
Natalya Natrusova, Evgeny Burtsev, Bulat Kurmanov, Inna Schederkina, Gleb Bronin (Russian Federation)

ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE
IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-LIGHTNING IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)
ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Alexey Polushin, Oleg Goloshchapov, Tatiana Khutornaya, Olesya Paina, Tatiana Bykova, Asmik Gevorgian, Zhamal Rahmanova, Anastasia Frolova, Maria Vladovskaya, Ivan Moiseev, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Marcin Jasiński, Martyna Maciejewska, Michał Górka, Anna Brodziak, Kamila Skwierawska, Wiesław Wiktor-Jędrzejczak, Agnieszka Tomaszewska, Grzegorz Basak, Emilian Snarski (Poland)

REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PAISONESTRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANTATION PURE RED CELL APLASIA
Rahinatu Awol, Irene Garcia-Cadenas, Albert Esquirrol Santfeliu, Silvana Saavedra Gerosa, Jordi Sierra Gil, Rodrigo Martino Bufarull (Spain)

PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY
ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS
T-PA/UKRONASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA
Fei Zhou, Xuefeng He (China)
HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION
Luisa Sisinni, Yasmina Mozo, David Bueno, Raquel De Paz, Eduardo Lopez-Granados, Antonio Perez-Martinez (Spain)

IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY
Martina Crysandt, Eva Jennes, Klaus Strathmann, Uta Kunter, Stefan Wilop, Gerda Silling, Tim H Brümmendorf, Fabian Beier, Edgar Jost (Germany)

IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE
Prashant Mehta, Rahul Arora, Vikash Kumar, Siddharth Sood, Swati Pabbi, Jagsahib Kaur (India)

Non-infectious late effects, quality of life and fertility

POSTER SESSIONS
09:00 - 18:00

A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Egor Kulagin, Alisa Volkova, Ilya Nikolaev, Julia Rabik, Victoria Timchick, Anna Smirnova, Tatiana Bykova, Tatiana Rudakova, Elena Darshkaya, Alexander Alyanskiy, Ivan Moiseev, Sergey Bondarenko, Vasily Trofimov, Boris Afanasyev (Russian Federation)

CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN
Saiko Kurosawa, Ayako Mori, Mayumi Tsukagoshi, Yasushi Onishi, Chikako Ohwada, Takehiko Mori, Hideki Goto, Yuki Asano-Mori, Yuichiro Nawa, Masayuki Hino, Tomoko Fukuchi, Yasuo Mori, Reiko Yamahana, Yoshihiro Inamoto, Takahiro Fukuda (Japan)

SURVIVORSHIP CARE FOR ALLOGENEIC STEM CELL TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION
Fiona Dignan, Angela Hamblin, Amelia Chong, Julia Perry, Michelle Kenyon, Paul Miller, Maria Gilleece, Hannah Hunter, John Snowden (United Kingdom)

CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS’ PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE

MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)

GONADOTOXICITY AFTER TREATMENT WITH MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA
Irina Kostareva, Yulia Skvortsova, Elena Ilina, Nataliya Radlevich, Lyudmila Papusha, Dmitriy Balashov, Anna Livshits, Andrey Abrosimov, Larisa Sheliakhova, Darya Shasheleva, Kirill Voronin, Michael Maschan, Aleksey Maschan (Russian Federation)
REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE
Michal Karas, Katerina Steinerova, Marcela Hrabetova, Daniel Lysak, Alexandra Jungova, Lekaa Mohammad, Jiri Sramek, Pavel Jindra (Czech Republic)

FATHERHOOD AFTER A MYELOABLATIVE TRESULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS
Maria Teresa Lupo-Stanghellini, Andrea Assanelli, Fabio Giglio, Carlo Messina, Raffaella Greco, Daniela T. Clerici, Sara Mastaglio, Francesca Pavesi, Francesca Farina, Stefania Girlanda, Francesca Lorentino, Simona Plemontese, Sarah Marktel, Francesca Lunghi, Matteo G Carrabba, Magda Marcatti, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri (Italy)

COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM

PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN
Emilie Hofstetter, Dominik Kappeler, Noreen Roth Henig, Anne Bergeron (Germany)

NETUPITAN-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MIELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Vincenzo Apolito, Simone Ferrero, Mattia D'Agostino, Gisyet Cetani, Francesca Bonello, Federica Martella, Danilo Faraci, Sara Butera, Giuseppe Lanzarone, Alessandra Larocca, Stefania Oliva, Lucia Brunello, Luisa Giaccone, Mario Boccadoro, Dario Ferrero, Benedetto Bruno, Marco Cerrano (Italy)

MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS
Irati Ormazabal Velez, Marina Quesada Sánchez, Angela Figuera Álvarez (Spain)

INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP

EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN
Yoo Jin Lee, Jeong Sook Kim, Jae-Cheol Jo, Jaekyoung Cheon, Sukjin Koh, Young Joo Min, Kukju Kweon, Sang-Hyuk Park, Jun-Woo Ahn, Yunsuk Choi (Korea, Republic of)

MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Shafqat Inam, Shu Wong, Michelle Kenyon, Victoria Potter, Austin Kulasekhararaj (United Kingdom)

FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Yuta Katayama, Ryouta Imanaka, Koji Iwato, Tatsuya Terasaki, Takuya Nunomura, Fumiaki Jinnouchi, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsyoshiy Muta, Hideki Asaoku (Japan)

LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION
Scientific Programme

EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE
Melinda Tan, Jeffrey Quek, Yeh Ching Linn, William Hwang, Yvonne Loh, Yeow Tee Goh, Jing Jing Lee, Aloysius Ho (Singapore)

DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION

Posters

09:00 - 18:00
Poster Area (Exhibition Area)

Psychological issues

HOW PATIENTS’ VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE

CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES

ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT
Alex King, Julian Jacob, Lizzie Jones, Anna Bootle, Vijai Glackin, Angela Daniel, Clair LeBoutillier (United Kingdom)

FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR
Sandrine Letrecher (France)

1000 IN 10, 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE
Patrick Ben Soussan, Yolande Arnault, Laurence Caymaris, Didier Blaise (France)

IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA
Natalia Klipinina, Natalia Nikolskaya, Larisa Shelikhova, Zhanna Shekhovtsova, Maria Illushina, Rimma Khismatullina, Ekaterina Shutkova, Alina Khain (Russian Federation)

Nurses Posters - Adult

UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS
Xia Yan, Ting Wang, Wei Hu, Xiaodong Xu, Shujia Liu (China)

AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION

Page 69 / 203
EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?
C Eeltink, B Lissenberg, I Nauta, J Rood, L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY
Marco Cioce, Laura Orlando, Stefano Botti, Gianpaolo Gargiulo (Switzerland)

SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM

DEVELOPING A BESPOKE EDUCATION PACKAGE TO ENSURE THE SAFE DELIVERY OF IMMUNE EFFECTOR CELLS ON AN ONCOLOGY CLINICAL RESEARCH FACILITY

DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kader Caliskan, Gulbeyaz Can (Turkey)

THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kwan Suk Jo, Seung Nam Zang, Ga Yeon Kim, Hye Yun Cho, Yang Sook You (Korea, Republic of)

PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS’ PERSPECTIVE
Noemi Gianni, Tania Arthurs, Yvonne Patefield-Smith, Kirsten Rendall, Jo Wyatt, Rachel Miller (United Kingdom)

REDUCING ANTITHYMOCYTE GLOBULIN (ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA
Suha Alkhraisat, Moussab Damlaj, Maybelle Balili, Samer Ghazi, Innaam Shehab eddine, Isam Mahasneh, Bader Ahmari, Heba Alshobaki, Mohsen Alzahrani (Saudi Arabia)

NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE

NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS

NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS
Roberta Gironi, Marco Fabbrini, Daniela Clerici, Chiara Oltolini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Antonella Biella (Italy)

THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ting Wang, Xia Yan, Linnan Wang, Xinxin He, Boning Liu (China)

EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR

ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS
Llara Roca Gimeno, Elisabeth Lazaro Lora, Marta Yusta Arnal, Iria Gonzalez Alvarez (Spain)
PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY
C Eeltink, L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS
Jennefer Rose, Sophie Jones, Wendy Ingram (United Kingdom)

THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION
Lara Rowley, Amanda Ellis, Denise Wareham, Daja Barton, Emma Shaw, Olivia Hilsdon, Francesca Toselli, Shirley Hudson (United Kingdom)

VENO-OCLUSION DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY
Marie Waller, Christopher Heron, Hayley Dyos, Eleni Tholouli (United Kingdom)

RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION
Lian Schoonhoven-Bos (Netherlands)

PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE

THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY

PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Sinju Thomas, Adrien Quintela, Arthi Anand, Karen Bradley (United Kingdom)

INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA

SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING
Luke White, Kathryn Vowden (United Kingdom)

TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS

NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE
Annacarin Svanberg (Sweden)

THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER

NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS

RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL
Lorella Cappucciani, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubbelini, Andrea Contini (Italy)

GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION
Scientific Programme

IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY

ARE TYPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?
Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT
Lorella Cappucciati, Fabio Pollini, Vincenzo Matteo Quitadamo, Ramona Patras, Angelica Cravedi, Maria Teresa Borsotti, Ilaria Filati, Rosaria Scopelliti, Cinzia Merlini, Andrea Contini, Mirella Gubellini (Italy)

AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY
Lucilia Carreiro, Rosa Romão, Candida Damião (Portugal)

LEADERSHIP - LEADING THE TEAM
Klara Kabatova Maxova (Czech Republic)

PAIN ASSESSMENT IN ONCO HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)
Lorella Cappucciati, Giovanna Buonanno, Corrado Gozzo, Francesco Oleari, Raffaella Maestri, Noemi Paladini, Patrizio Imbriani, Lucrezia Maria Zagnoni, Sara Posla, Mirella Gubbelini, Andrea Contini (Italy)

TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME

COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS
Lucilia Carreiro, Carla Gonçalves, Fátima Pereira, Rosa Romão, Cândida Damião (Portugal)

IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!
Isabel Salcedo, Esther Ortiz, Juana María Acebes, Mari Luz Pascual, Beatriz Sanchez Sevilla, Almudena Laiglesia, Ana Alarcón, Rafael F Duarte (Spain)

INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY
Poonam Thorat, Meera Sharad Achrekar, Deepti Ghonge (India)

COMPLETION TIME TO HLA TYPING

GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION

Poster Sessions
09:00 - 18:00

Nurses Posters - Paediatric

EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA
Kim van der Niet, Lisa Rozendaal, Dagmar Berghuis, Eileen van der Stoep-Yap, Erik von Asmuth, María de Taeye-Veldhuizen, Arjan Lankester, Hilda Mekelenkamp (Netherlands)
Scientific Programme

CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE
Ida Bremer Ophorst, Tineke Terlouw (Netherlands)

SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEPIENTS: A SINGLE CENTER EXPERIENCE
Rosanna Ceresoli, Stefano Benvenuti, Patrizia Bevilacqua, Mirella Savoldi, Fulvio Porta (Italy)

PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES
Rosanna Ceresoli, Stefano Benvenuti, Emilio Ferrari, Fulvio Porta (Italy)

TOTTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT
Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS
Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

CARING FOR MINOR SIBLING DONORS
Eugenia Trigoso Arjona, Estrella Larios Reyes, Maria Sol Abert Velert (Spain)

EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTherapy AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME
Anna Tailby, Julia Nixon, Alison Bridgman, Angela Burns, Abigail Cotton, Hannah Ezard, Josephine Nicholls, Melani Rooney, Elisabeth Thomas, Ilan Uri, Marita Macken, Sarah Lawson, Martin English (United Kingdom)

EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES
Bart Maertzdorf, Anouk Jongekrijg (Netherlands)

RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT

Poster Sessions
09:00 - 18:00

Nurses Posters - Research

NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE
Carmen Conde, Ariadna Domenech, Iria Gonzalez, Verónica Linde Blazquez, Eugenia Trigoso Arjona, Julia Ruiz Pato (Spain)

CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH
Yun Fang, Minjie Liu, Chen Xie (China)

ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT

MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP
Yaya Song, Xiaoming Zhu, Yin Lu, Yongqin Ge, Qin Li, Fang Tang, Ying Chen, Yaohong Li (China)
VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT
Isabel Salcedo, Angela Salas, Laura Vicente, Lucia Paola Cuéllar, Virginia Infante, Carmen de la Puente, Jose Luis Bueno (Spain)

A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL
Shreya Ludbe, Meera Sharad Achrekar, Rynel Quadras (India)

DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?
ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE
Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, María Cabezas López de Sosoaga, Montserrat Pilar Barrilero Lopez (Spain)

SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS
Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, María Cabezas López de Sosoaga, Montserrat Pilar Barrilero Lopez (Spain)

A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA
Bhushan Shelar (India)

ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT
Cristina Alberquilla Ramos, Salvadora Aleza Estera, Josefa Navarrete Ruiz, Beatriz Alonso González, Rocio Rico Muñoz, Ana Isabel Torre Polo, Pilar Herreros López, Julia Ruiz Pato (Spain)

SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY
Yaohong Li, Xiaming Zhu, Yin Lu, Fang Tang, Yongqin Ge, Qin Li, Ying Chen, Yaya Song (China)

**Industrial Theatre**
10:30 - 11:00

**IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session**

**Chairs:**
Pau Montesinos (Spain)

**Plenary Session**
11:00 - 12:30

**P1, Gene Therapy for Inherited Disorders in 2020**

**Chairs:**
Cristina Díaz de Heredia (Spain)
Arjan Lankester (Netherlands)

Gene therapy in Fanconi Anaemia
Juan Bueren (Spain)
Scientific Programme

**Gene therapy in leucodystrophies and other metabolic disorders**
Maria Ester Bernardo (Italy)

11:22 - 11:44

**Haemoglobinopathies**
Selim Corbacioglu (Germany)

11:44 - 12:06

**The future of gene therapy for primary immunodeficiencies**
Claire Booth (United Kingdom)

12:06 - 12:28

---

**Educational**

11:00 - 12:30

Hall A (Exhibition Area)

**E2, Waldenström Macroglobulinaemia**

**Chairs:**
Silvia Montoto (United Kingdom)
Maria José Terol Castera (Spain)

**How biology in Waldenström Macroglobulinaemia may affect treatment strategy?**
Véronique Leblond (France)

11:00 - 11:30

**Conventional and new drugs**
Ramón García-Sanz (Spain)

11:30 - 12:00

**Haematopoietic stem cell transplantation in Waldenström Macroglobulinaemia**
Charalampia Kyriakou (United Kingdom)

12:00 - 12:30

---

**Workshop**

11:00 - 12:30

Hall B (Exhibition Area)

**W3, Steroid-refractory chronic GVHD**

**Chairs:**
Hildegard Greinix (Austria)
Carlos Solano Vercet (Spain)

**Pulmonary steroid-refractory chronic GVHD**
Hildegard Greinix (Austria)

11:00 - 11:30

**Ocular cGVHD diagnostics - How to properly diagnose ocular cGVHD?**
Igor Petricek (Croatia)

11:30 - 12:00

**Gastrointestinal manifestations of chronic GVHD**
Daniel Wolff (Germany)

12:00 - 12:30
Scientific Programme

E3, Emerging and personalized approaches in MDS

Chairs:
Juan Carlos Hernández-Boluda (Spain)
Christoph Scheid (Germany)

- **Microtransplantation**
  Micha Srour (France)
  11:00 - 11:30

- **Emerging and personalized cellular therapy approaches for myeloid diseases**
  Marco Davila (United States)
  11:30 - 12:00

- **Risk assessment of patients with CMML**
  Francesco Onida (Italy)
  12:00 - 12:30

Cell therapy

- **Evolving technologies for gene modification / gene editing of haematopoietic stem cells and immune effector cells**
  Chiara Bonini (Italy)
  11:00 - 11:30

- **Where are we with mesenchymal stem cells in 2020?**
  Francesco Dazzi (United Kingdom)
  11:30 - 12:00

- **Haematopoietic stem cell expansion: Latest preclinical and clinical results**
  Elizabeth Shpall (United States)
  12:00 - 12:30

OS3, Oral session 3 - Acute Leukaemia 1

Chairs:
Josep M. Ribera (Spain)
Michael Loschi (France)

**ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION**

Rafael F. Duarte, María E. Martínez-Muñoz, Myriam Labopin, Manuela Badoglio, Anja van Biezen, Stephanie Nguyen, José L. Diez, Jakob Passweg, Lucrecia Yáñez, Andy Peniket, Jean Y. Cahn, Tsila Zuckerman, Jenny L. Byrne, Gerard Socié, Noel Milpied, Jan J. Cornelissen, Arnon Nagler, Selim Corbacioglu, Silvia Montoto, Jan Styczynski, Nicolaus Kroger, Mohamad Mohty (Spain)

11:00 - 11:11
COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTETA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS

TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS

ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES
Pier Edoardo Rovatti, Laura Zito, Eleonora Draghi, Monika Herrmann, Anetta Marcinek, Bettina Brauchle, Cesare Covino, Mattia Di Bono, Matteo Giovanni Carrabba, Massimo Bernardi, Karl-Peter Hopfner, Cristina Toffalori, Fabio Ciceri, Marion Subklewe, Luca Vago (Italy)

POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE
Valentina Gambacorta, Daniela Gnani, Laura Zito, Stefano Beretta, Lucia Zanotti, Giacomo Oliveire, Davide Cittaro, Ivan Merelli, Fabio Ciceri, Raffaella Di Micco, Luca Vago (Italy)

CYTOGENETIC RISK SCORE MAINTAINS ITS PROGNOSTIC SIGNIFICANCE IN AML PATIENTS WITH DETECTABLE MEASURABLE RESIDUAL DISEASE UNDERGOING TRANSPLANTATION IN REMISSION: ON BEHALF OF THE ALWP EBMT

ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE Lymphoblastic Leukemia harboring <i>IKZF1</i> GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES
Scientific Programme

Working Party Session
11:00 - 12:30
Sala Colón

TCWP, Transplant Complications Working Party Session

Chairs:
Grzegorz Basak (Poland)
Zinaida Peric (Croatia)

- **Introduction**
  Grzegorz Basak (Poland)
  11:00 - 11:05

- **Fecal microbiota transplantation for GVHD**
  Jaroslaw Bilinski (Poland)
  11:05 - 11:17

- **Evaluation of VOD scoring**
  Tapani Ruutu (Finland)
  11:17 - 11:29

- **EASIX index as a prognostic tool**
  Olaf Penack (Germany)
  11:29 - 11:41

- **Male-specific late effects: An update on a joint EBMT/CIBMTR systematic review**
  Rachel Phelan (United States)
  11:41 - 11:53

- **Importance of patient-reported outcomes - Survey**
  Hélène Schoemans (Belgium)
  11:53 - 12:05

- **Steroid-refractory GVHD - Survey**
  Zinaida Peric (Croatia)
  12:05 - 12:17

- **EBMT GVHD recommendations**
  Olaf Penack (Germany)
  12:17 - 12:29

Meetings
11:00 - 11:40
N107

NG Business Meeting, Nurses Group Annual Business Meeting

Chairs:
Daphna Hutt (Israel)

Transplant Coordinator Day
11:00 - 12:30
Sala Neptuno

TCD2, EBMT-WMDA Transplant Coordinators Day: Donor attrition and backup strategies

Chairs:
Annette Rasche (Germany)
Maria Teresa Solano Moliner (Spain)

- **Ethics of donation and donor attrition at the search stage**
  11:00 - 11:30
Scientific Programme

Donor-related cancellations at the final (work-up) stage
Katalin Balassa (United Kingdom)

11:30 - 12:00

Back-up strategy along graft request
Irina Evseeva (United Kingdom)

12:00 - 12:30

Psy Day
Psy Day

11:00 - 12:30

Psy2, Workshop II: Donors, caregivers and the transplant team

Chairs:
Alice Polomeni (France)
Soledad de Linares Fernández (Spain)

The dynamics of donor commitment
Suzanna M. van Walraven (Netherlands)

11:00 - 11:30

Supporting transplant caregivers
Maria Die Trill (Spain)

11:30 - 12:00

Supporting the transplant team
Alice Polomeni (France)

12:00 - 12:30

Data Management

11:00 - 11:40

DM2, Education session 2

Chairs:
Helen Baldomero (Switzerland)

Registry upgrade and other data collection news in the EBMT
Per Ljungman (Sweden)

11:00 - 11:40

Data Management

11:00 - 12:30

DM14, Training session 1 (continued) (pre-registration required)

Chairs:
Asterios Kasmiris (United Kingdom)

MACRO data entry
Asterios Kasmiris (United Kingdom)

11:00 - 12:30
Joint Session
11:00 - 12:30

JS2, Joint session EHA: Moving CAR T-Cell Therapy in Europe

Chairs:
John Gribben (United Kingdom)
Nicolaus Kröger (Germany)

- **Academic CAR T-cell development in Europe**
  Álvaro Urbano-Ispizua (Spain)
  11:00 - 11:30

- **Center Qualification Process in Europe**
  Jorge Sierra (Spain)
  11:30 - 12:00

- **Sharing CAR T-cell data: Governance structure of EBMT Cellular Therapy registry**
  Jürgen Kuball (Netherlands)
  12:00 - 12:30

How do I ... ?
11:00 - 12:30

HDI1, How Do I... mobilize autologous stem cells - Supported through an unrestricted educational grant by Sanofi Genzyme

Chairs:
Carmen Martínez Chamorro (Spain)
Adrián Alegre (Spain)

- **After antibody and ImIDS based induction in MM patients**
  Francesca Gay (Italy)
  11:00 - 11:30

- **If tandem transplant is planned in myeloma**
  Patrick Wuchter (Germany)
  11:30 - 12:00

- **By optimizing apheresis centre time**
  José Luis Bueno (Spain)
  12:00 - 12:30

Special Session
11:15 - 12:30

SS2, Social media session - Do's and don'ts of the interaction in the social media for the HSCT and cell therapy community

Chairs:
Pere Barba (Spain)
Miguel-Angel Perales (United States)

- **Social media beyond Twitter for the HSCT and Cell Therapy community**
  Navneet Majhail (United States)
  11:15 - 11:35

- **Do's and don'ts of interaction in social media: Nurse's perspective**
  11:35 - 11:55

- **Do's and don'ts of interaction in social media: Patient's perspective**
  Gillian Adams (United Kingdom)
  11:55 - 12:15
Scientific Programme

Panel discussion 12:15 - 12:30

Nurses Group
11:40 - 12:30  N107

NG05, Cellular Therapy update

Chairs:
Esperanza Santos (Spain)
Letizia Galgano (Italy)

What's new?
11:40 - 12:05
Orla Stewart (United Kingdom)

Guidelines
12:05 - 12:30
Rose Ellard (United Kingdom)

Nurses Group
11:40 - 12:30  N109

NG06, How do I manage... Protective isolation?

Chairs:
Yolanda Guijarro Herraiz (Spain)

The case for
11:40 - 12:05
Iris Agreiter (Ireland)

The case against
12:05 - 12:30
Cristina Gallego (Spain)

Nurses Group
11:40 - 12:30  N111

NG07, Patients and donors preparation

Chairs:
Mairead Ni Chonghaile (Ireland)
Rodrigo Serrano (Spain)

Patient work-up
11:40 - 12:05
Manuela Salinero (Spain)

Donor work-up
12:05 - 12:30
Annika Kisch (Sweden)
Scientific Programme

Data Management
11:50 - 12:30

DM3, Education session 3
Chairs:
Julia Lee (United Kingdom)

Molecular diagnostic markers: Interpreting the results of molecular diagnostics for Med-A/B forms
April Sellors (United Kingdom)

Industry Symposium
13:00 - 14:15

IS24, Your decisions in action: The reality of severe hepatic VOD management - Jazz Pharmaceuticals Industry Symposium

Industry Symposium
13:00 - 14:00
Hall A (Exhibition Area)

IS25, An update on induction and front-line therapy for transplantation-eligible patients with MM - Janssen Industry Symposium
Chairs:
María-Victoria Mateos Manteca (Spain)

Introduction
María-Victoria Mateos Manteca (Spain)

Latest data on treatment approaches for transplant eligible patients in frontline MM
Philippe Moreau (France)

Panel discussion
María-Victoria Mateos Manteca (Spain)
Philippe Moreau (France)
Niels van de Donk (Netherlands)

How will recent data change your clinical practice? - Clinical case studies focusing on patients with 'standard' and 'high' risk MM
María-Victoria Mateos Manteca (Spain)
Niels van de Donk (Netherlands)

CME Symposium
13:00 - 14:00
Hall B (Exhibition Area)

IS26, Gene Therapy for β-Thalassemia: The future is now - CME Symposium
Chairs:
Evangelia Yannaki (Greece)
Scientific Programme

Test your knowledge  13:00 - 13:10
Evangelia Yannaki (Greece)

Christof von Kalle (Germany)

Franco Locatelli (Italy)

Evangelia Yannaki (Greece)
Franco Locatelli (Italy)

Audience Q&A  13:50 - 14:00

Industry Symposium
13:00 - 14:00  N105

IS27, Nurse Symposium: Therakos ECP Immunomodulation - How and why - Therakos Industry Symposium

Chairs:
John Murray (United Kingdom)

Welcome and introduction  13:00 - 13:05
John Murray (United Kingdom)

The role of nurses in delivering ECP - Special patient conditions  13:05 - 13:20
Britt Storm Tråsdahl (Denmark)

Nina Worel (Austria)

Wilfred Emmanuel-Jones (United Kingdom)

Q&A  13:55 - 14:00

Statistics
13:00 - 14:30  N115

Stat4, Statistics symposium

Chairs:
Liesbeth de Wreede (Netherlands)
Hein Putter (Netherlands)

Sensitivity Analysis: E-value based on directly adjusted survival probabilities  13:00 - 13:30
Mei-Jie Zhang (United States)

Methods for missing data in competing risks  13:30 - 14:00
É. F. Bonneville, M Resche-Rigon, L. C. de Wreede, H. Putter (Netherlands)
Scientific Programme

14:00 - 14:30
Bayesian methods for early detection of treatment effects in phase 3 trials with survival endpoints
Lucie Biard (France)

Industrial Theatre
13:00 - 13:30
Industry Theatre

IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session

Chairs:
Krzysztof Kalwak (Poland)

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

IS28, Celgene Industry Meet the Expert Lunch - Room A10.05

Management of cellular therapies in RRMM
Albert Oriol (Spain)

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

IS29, Takeda Industry Meet the Expert Lunch - Room A10.06

Treatment paradigm in higher-risk MDS
Guillermo Sanz Santillana (Spain)

Industrial Theatre
13:45 - 14:15
Industry Theatre

IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session

Chairs:
Dick Sundh (Sweden)

General
14:30 - 16:00

GS2, Presidential Symposium

Chairs:
Nicolaus Kröger (Germany)
Rafael Duarte (Spain)
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
30 August - 2 September 2020,
Madrid, Spain

Scientific Programme

Van Bekkum Award - Introduction
Nicolaus Kröger (Germany) 14:30 - 14:33

RESULTS OF THE EBMT SAAWP PHASE III PROSPECTIVE RANDOMIZED MULTICENTER RACE STUDY OF HORSE ATG AND CICLOSPORIN WITH OR WITHOUT ELTROMBOPAG IN NAÏVE SAA PATIENTS

Basic Science Award - Introduction
Rafael Duarte (Spain) 14:44 - 14:47

JUN ACTIVATION IN DERMAL FIBROBLASTS PROMOTES FIBROSIS AND INFLAMMATION IN SCLERODERMATOUS GRAFT-VS-HOST DISEASE IN MICE AND HUMANS
Antonia Müller, Lu Cui, Tristan Lerbs, Megan King, Claire Muscat, Tyler Shibata, Jessica Chen Lee, Ryanne Brown, Sebastian Fernandez-Pol, Sally Arai, Judith Shizuru, Gerlinde Wernig (Switzerland) 14:47 - 14:58

SUPERIOR EVENT-FREE SURVIVAL WITH BLINATUMOMAB VERSUS CHEMOTHERAPY IN CHILDREN WITH HIGH-RISK FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A RANDOMIZED, CONTROLLED PHASE 3 TRIAL

RESULTS OF BMT CTN PROTOCOL 1101 A MULTICENTER PHASE III RANDOMIZED TRIAL OF TRANSPLANTATION OF DOUBLE UMBILICAL CORD BLOOD VS. HLA-HAPLOIDENTICAL-RELATED BONE MARROW
Eileen van der Stoep, Alice Bertaina, Dirk Jan Moes, Mattia Algeri, Robbert Bredius, Frans Smiers, Henk-Jan Guchelaar, Franco Locatelli, Juliette Zwaveling, Arjan Lankester (Netherlands) 15:08 - 15:18

TREOSULFAN EXPOSURE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH EARLY TOXICITY BUT NOT WITH EVENT-FREE SURVIVAL
Robert Zeiser, Nikolaos von Bubnoff, Jason Butler, Mohammad Mohty, Dietger Niederwieser, Reuven Or, Jeff Szer, Eva Maria Wagner, Tsiila Zuckerman, Bruryère Mahuzier, Judith Xu, Kunal K. Gandhi, Gérard Socie (Germany) 15:18 - 15:28

RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT VS HOST DISEASE (AGVHD)
Robert Zeiser, Nikolaos von Bubnoff, Jason Butler, Mohammad Mohty, Dietger Niederwieser, Reuven Or, Jeff Szer, Eva Maria Wagner, Tsiila Zuckerman, Bruryère Mahuzier, Judith Xu, Kunal K. Gandhi, Gérard Socie (Germany) 15:28 - 15:38

HOST T CELLS IN SKIN AND GUT SURVIVE STEM CELL TRANSPLANTATION AND CONTRIBUTE TO ACUTE GVHD
Eileen van der Stoep, Alice Bertaina, Dirk Jan Moes, Mattia Algeri, Robbert Bredius, Frans Smiers, Henk-Jan Guchelaar, Franco Locatelli, Juliette Zwaveling, Arjan Lankester (Netherlands) 15:38 - 15:48
Scientific Programme

PRE-TRANSPLANT MRD NEGATIVITY PREDICTS FAVORABLE OUTCOMES OF CAR-T THERAPY FOLLOWED BY HAPLOIDENTICAL HSCT FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER RETROSPECTIVE STUDY 15:48 - 15:58

Cell therapy
14:30 - 16:00

CTD3, Cell Therapy Day: Conditions for implementation of innovative haematopoietic cellular therapies

Chairs:
Jürgen Kuball (Netherlands)
Éliane Gluckman (France)

Ethics beyond gene editing 14:30 - 15:00
Aurélie Mahalatchimy (France)

Access to Gene Therapies in Tanzania 15:00 - 15:30
Julie Makani (Tanzania, United Republic of)

Integration of care and research leading to individualized treatment 15:30 - 16:00
Miriam Koopman (Netherlands)

Nurses Group
14:30 - 16:00

NG08, Oral Session 1: Best paediatric abstracts

Chairs:
Hilda Mekelenkamp (Netherlands)
Carmen Conde (Spain)

TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP 14:30 - 14:48
Julia Ruiz Pato, Marta Ausín Fernández, Ana Aida Casado Pardo, Rebeca García Heras, Laura Lozano Ferreiro, Pilar Herreros López, Miguel Angel Diaz Perez (Spain)

CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER 14:48 - 15:06
Giuseppe Marco Deiana, Evelina Olcese, Simona Calza, Paolo Petralia, Silvia Scelsi (Italy)

EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION 15:06 - 15:24
Lu Huang, Chengzhen Jia, Yun Wu (China)

SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION 15:24 - 15:42
Lisa Burnett, Kayleigh Douglas (United Kingdom)
Scientific Programme

NURSES´ VIEW ON COMBINING TWO DIFFERENT SPECIALTIES; HEMATOLOGY-ONCOLOGY, HSCT AND ORGAN TRANSPLANTS
Maija Kuusisto, Lotta Tornberg (Finland)

15:42 - 16:00

NG09, How do I... Understand blood counts?

Chairs:
Carina Paixao (Portugal)
Montserrat Barrilero López (Spain)

Liver counts
Ignacio Alberto Gómez Centurión (Spain)
14:30 - 14:50

Renal counts
Iván López-Torija (Spain)
14:50 - 15:10

Full blood counts
Maria Esther Martínez Muñoz (Spain)
15:10 - 15:35

Cross matching
Josune Zubizaray Saégui (Spain)
15:35 - 16:00

NG10, Supportive and palliative care

Chairs:
Sandra Schoenfeld (Switzerland)

Meaning centered care
Katharina Scheffold (Germany)
14:30 - 15:00

Challenges in decision-making: End of life
Jakob Passweg (Switzerland)
15:00 - 15:30

Early integration and parallel planning
Richard Towers (United Kingdom)
15:30 - 16:00

Transplant Coordinator Day
14:30 - 16:00

TCD3, EBMT-WMDA Transplant Coordinators Day: Training for Transplant Coordinators - A Workshop to find out your needs (at the Meet the Expert rooms)
Scientific Programme

Round table: Interactive discussions and exchange - Rooms A10.12, A10.13, A10.15
Irina Evseeva (United Kingdom)
Annette Rasche (Germany)
Suzanna M. van Walraven (Netherlands)

Psy Day
14:30 - 16:00

Psy3, How do I...?

Chairs:
Karen Syrjala (United States)
Maria Die Trill (Spain)

How do I... Evaluate psychosocial factors and complexities that may influence the HSCT process and outcomes? 14:30 - 15:00
Alex King (United Kingdom)

How do I... Address the psycho-oncologists' well-being? 15:00 - 15:30
Frank Schulz-Kindermann (Germany)

How do I... Identify unmet needs and plan research? 15:30 - 16:00
Corinna Bergelt (Germany)

Data Management
14:30 - 15:10

DM4, Education session 4

Chairs:
Linda Koster (Netherlands)

Response in Multiple Myeloma 14:30 - 15:10
Meral Bekscar (Turkey)

Data Management
14:30 - 16:00

DM15, Training session 2 (pre-registration required)

Chairs:
Silvia Zaccagnino (United Kingdom)

MACRO Reports 14:30 - 16:00
Silvia Zaccagnino (United Kingdom)
Scientific Programme

How do I … ?
14:30 - 16:00

**HD12, How Do I... consider patients' needs in induction and front line therapy for transplant (eligible patients with Multiple Myeloma) - Nurses' Session - Supported through an unrestricted educational grant by Janssen**

**Chairs:**
Maaike de Ruijter (Netherlands)

- **Treatment approaches for transplant eligible patients in front line Multiple Myeloma**
  - Laure Vincent (France)
  - 14:30 - 15:00

- **How do new therapy combinations offer newly diagnosed Multiple Myeloma patients' benefits, case studies**
  - Sarah Henshaw (United Kingdom)
  - 15:00 - 15:30

- **How do I.....consider patients' needs from a psycho-social perspective?**
  - Surabhi Chaturvedi (United Kingdom)
  - 15:30 - 16:00

Data Management
15:20 - 16:00

**DM5, Education Session 5**

**Chairs:**
Beate Lindner (Austria)

- **Follow up forms - How to get a chronological overview of the patient history and follow up**
  - Elena Ferrer Martínez (Spain)
  - 15:20 - 16:00

Industrial Theatre
16:00 - 16:30

**IT4, KYMRIAH in the Real World - Novartis Industry Theatre Session**

**Chairs:**
Catherine Thieblemont (France)

Industry Symposium
16:30 - 18:00

**IS30, Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction with HSCT - PVI Industry Symposium**

**Chairs:**
David I. Marks (United Kingdom)

- **Welcome and introduction**
  - David I. Marks (United Kingdom)
  - 16:30 - 16:35
Scientific Programme

**MasterClass 1: Understanding the transplant context in AML and considerations with antibody therapy**
Farhad Ravandi (United States)  
16:35 - 17:00

**MasterClass 2: Insights on the integration of novel antibodies as options for transplant-eligible patients with ALL**
David I. Marks (United Kingdom)  
17:00 - 17:25

**Practicum: A case-based exploration of antibody therapy in AML/ALL transplant recipients**
David I. Marks (United Kingdom)  
Farhad Ravandi (United States)  
Matthias Stelljes (Germany)  
17:25 - 17:50

**Symposium summary, reflection, and audience Q&A**
David I. Marks (United Kingdom)  
17:50 - 18:00

**Industry Symposium**
16:30 - 18:00  
Hall A (Exhibition Area)

**IS31, HSCT-TMA - Omeros Industry Symposium**
Chairs:
Rafael Duarte (Spain)

**Welcome and introduction**
Rafael Duarte (Spain)  
16:30 - 16:35

**Complement activation in Endothelial Injury Syndromes**
Eleni Gavriilaki (Greece)  
16:35 - 17:00

**Diagnostic challenges in HSCT-TMA**
Sonata Jodele (United States)  
17:00 - 17:20

**MASP-2 inhibition with the investigational agent narsoplimab for the treatment of HSCT-TMA: Overview of data and case discussion**
Rafael Duarte (Spain)  
17:20 - 17:50

**Question-and-Answer session**
17:50 - 18:00

**Oral Session**
16:30 - 18:00  
Hall B (Exhibition Area)

**OS4, Oral session 4 - Multiple Myeloma**
Chairs:
Isabel Krsnik Castello (Spain)  
Patrick Hayden (Ireland)

**DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA**
16:30 - 16:41
EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS

16:41 - 16:52

CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA

Hervé Avet-Loiseau, Marie Béné, Soraya Wuilleme, Jill Corre, Michel Attal, Bertrand Arnulf, Laurent Gardere, Margaret Macro, Anne-Marie Stoppa, Michel Delforge, Annemiek Brojl, Sonja Zweegman, Kon-Siong Jie, Niels WCJ van de Donk, Lixia Pei, Carla de Boer, Christopher Chiu, Veronique Vanquickelberghe, Tobias Kampfenkel, Jessica Vermeulen, Philippe Moreau, Pieter Sonneveld (Netherlands)

16:52 - 17:03

LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)

17:03 - 17:14

DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE

17:14 - 17:25

HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL

17:25 - 17:36

OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS

Nico Gagelmann, Francis Ayuk, Djordje Atanackovic, Nicolaus Kröger (Germany)

17:36 - 17:47

25 YEARS OF AUTOLOGOUS TRANSPANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS


17:47 - 17:58

E4, What’s new in the pathophysiology and treatment of patient complications?

Chairs:
Eolia Brissot (France)
Gustavo Kusminsky (Argentina)

CAR T toxicity
Julio Delgado (Spain)

Early transplant complications
Christian Koenecke (Germany)

Acute GVHD
Olaf Penack (Germany)
Scientific Programme

Pathophysiology and treatment of chronic GVHD  
José Antonio Pérez-Simón (Spain)

Cell therapy  
16:30 - 18:00

CTD4, Cell Therapy Day: Modern developments in immunogenetics and immunology in the context of HSCT

Chairs:  
Luca Vago (Italy)  
Katharina Fleischhauer (Germany)

Immunogenetics in the era of NGS and haplo-mismatched transplantations  
Valérie Dubois (France)

Immunogenetics of haematopoietic stem cell transplantation  
Effie Petersdorf (United States)

Immune monitoring of patients treated with immune effector cells  
Raffaella Greco (Italy)

Workshop  
16:30 - 18:00

W4, When modern haematology and antiinfective drugs meet at CYP450

Chairs:  
Oliver Cornely (Germany)  
Juan Diego Vélez (Colombia)

Is it time TDM our recent haematologic advances?  
Roger Brüggemann (Netherlands)

Crossroads of life-saving drugs - A clinical perspective in modern haematology?  
Jannik Stemler (Germany)

A regulatory perspective on evaluating TDM and DDI with current antiinfective standards in haematology drug development  
Arantxa Sancho (Spain)

Discussion

Industry Symposium  
16:30 - 18:00

HDI3, How do I... Expect, predict and improve survival of severe hepatic VOD? - Supported by Jazz Pharmaceuticals
NG11, Oral Session 2: Abstract finalists

Chairs:
Caroline Bompoint (France)
Janet Baker (United Kingdom)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)</td>
<td>Annika M Kisch, Karin Bergkvist, Anette Alvariza, Jeanette Winterling (Sweden)</td>
<td>16:30 - 16:48</td>
</tr>
<tr>
<td></td>
<td>PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG</td>
<td>Gianpaolo Gargiulo, Laura Orlando, Marco Cioce, Valentina De Cecco, Cristina Mentone, Annarita Pesce, Emanuela Samaran, Sonia Soave, Francesca Bonifazi, Fabio Ciceri, Stefano Botti (Italy)</td>
<td>16:48 - 17:06</td>
</tr>
<tr>
<td></td>
<td>ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS</td>
<td>Anna Carmagnola, Alessia Arioli, Giulia Righi, Francesca Vergara, Massimo Bernardi, Consuelo Corti, Fabio Giglio, Daniela Clerici, Jacopo Peccatori, Raffaella Greco, Fabio Ciceri, Antonella Biella (Italy)</td>
<td>17:06 - 17:24</td>
</tr>
<tr>
<td></td>
<td>&lt;i&gt;BOLUS:&lt;/i&gt; TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION</td>
<td></td>
<td>17:24 - 17:42</td>
</tr>
<tr>
<td></td>
<td>A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AH SCT) FOLLOW UP PILOT FOR LYMPHOMA</td>
<td>Helen Gillespie, Victoria Potter, Shireen Kassam, Andrea Kuhnl, Emma Kane, Michelle Kenyon (United Kingdom)</td>
<td>17:42 - 18:00</td>
</tr>
</tbody>
</table>

NG12, Nurse Care

Chairs:
Marie Waller (United Kingdom)
Cristina Canaleta Ros (Spain)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mindfulness</td>
<td>Troy Chase (United Kingdom)</td>
<td>16:30 - 17:00</td>
</tr>
<tr>
<td></td>
<td>Leadership</td>
<td>Klara Kabatova Maxova (Czech Republic)</td>
<td>17:00 - 17:30</td>
</tr>
<tr>
<td></td>
<td>Tips and tricks for self care</td>
<td>Jane Keep (United Kingdom)</td>
<td>17:30 - 18:00</td>
</tr>
</tbody>
</table>
Scientific Programme

Nurses Group
16:30 - 18:00

NG13, Non-malignant diseases update

Chairs:
Seckin Erdal (Turkey)
Ariadna Domènech (Spain)

Aplastic anaemia 16:30 - 16:55
Simon Slade (United Kingdom)

Sickle cell disease 16:55 - 17:15
Jean-Hugues Dalle (France)

Multiple sclerosis 17:15 - 17:35
Helen Jessop (United Kingdom)

ITP 17:35 - 18:00
Elena Sebastián (Spain)

Transplant Coordinator Day
16:30 - 18:00 Sala Neptuno

TCD4, EBMT-WMDA Transplant Coordinators Day: Family donations

Chairs:
Suzanna M. van Walraven (Netherlands)
Nina Worel (Austria)

Children as donors - Psychological aspects 16:30 - 17:00
Galen Switzer (United States)

International Family Donation - How Registries can help 17:00 - 17:30
Ann O'Leary (United Kingdom)

Follow up on related donors - The Swiss solution 17:30 - 18:00
Grazia Nicoloso (Switzerland)

Psy Day
16:30 - 18:00

Psy4, Abstract session

Chairs:
Angela Scherwath (Germany)
Anna Barata (United States)

INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD 16:30 - 16:52
Mari Campbell, Titman Penny, Emma Morris, Austen Worth, Ronjon Chakraverty, Ben Carpenter, Bethany Nicholson, Rupert Goodman, James Day, Steve Morris, Deborah Ridout, Kit Sandford, Siobhan Burns (United Kingdom)
Scientific Programme

THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES 16:52 - 17:14
Alisa Volkova, Maria Zinoveva, Svetlana Oleshko, Tatyana Kozlova, Olga Chernenko, Yuliya Sviridova, Asmik Gevorgian, Olesya Paina, Tatyana Bykova, Anna Osipova, Inna Markova, Elena Semenova, Alla Potapchuk, Tatyana Ionova, Tatyana Nikitina, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT 17:14 - 17:36
Zinaida Peric, Christophe Peczynski, Emmanuelle Polge, Nicolaus Kroger, Gerard Socie, Jurgen Finke, Ernst Holler, Didier Blaise, Grzegorz Helbig, Riitta Niittyvuopio, Victoria Potter, Donald Bunjes, Istvan Benedek, Olaf Penack, Helene Schoemans, Christian Koenecce, Grzegorz Bask (Croatia)

ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT 17:36 - 17:58
Alina Khain (Russian Federation)

Data Management
16:30 - 17:10

DM6, Education session 6

Chairs:
Emmanuelle Polge (France)

Treatment of relapse after transplant (DLI, CAR T, second allograft) 16:30 - 17:10
Christoph Schmid (Germany)

Data Management
16:30 - 17:30

DM16, Training session 2 (continued) (pre-registration required)

Chairs:
Silvia Zaccagnino (United Kingdom)

MACRO Reports 16:30 - 17:30
Silvia Zaccagnino (United Kingdom)

Oral Session
16:30 - 18:00

OS5, Oral session 5 - Autoimmune Diseases

Chairs:
Montserrat Rovira (Spain)
Riccardo Saccardi (Italy)
**Scientific Programme**

**AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME**
**16:30 - 16:41**
Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaoqiang Han (United States)

**CD39 GENETIC POLYMORPHISM IS A MAJOR DETERMINANT OF T REGULATORY CELL RECONSTITUTION AND SUPPRESSIVE FUNCTION IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS**
**16:41 - 16:52**
Kevin Hendrawan, Malini Visweswaran, Carole Ford, Melissa Kho, John Zaunders, Tim Molloy, Laura Cook, Jennifer Massey, David Ma, John Moore (Australia)

**BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY**
**16:52 - 17:03**
Riccardo Saccardi, Manuela Badoglio, Joachim Burman, Grzegorz Helbig, Chiara Innocenti, Majid Kazmi, Giovanni Luigi Mancardi, John Moore, Paolo Muraro, Basil Sharrack, Marek Smilowski, Maria Pia Sormani, John A Snowden (Italy)

**A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT**
**17:03 - 17:14**
Geoffrey Gillard, Jennifer Proctor, Melissa Brooks, Tahirih Lamothe, Sharon Hyzy, Sean McDonough, Nicholas Clark, Rahul Palchauhdhuri, Anjali Bhat, Ganapathy Sarma, Prashant Bhattacharai, Pranoti Sawant, Bradley Pearse, Charlotte McDonagh, Anthony Boitano, Michael Cooke (United States)

**LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)**
**17:14 - 17:25**
Nassim Ait Abdallah, Mianbo Wang, Zora Marjanovic, Pauline Lansiaux, Catney Charles, Fanny, Urbain, Mary Hudson, Dominique Farge (France)

**ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**
**17:25 - 17:36**
Denis Fedorenko, Vladimir Melnichenko, Gorgut Zeinalov, Tatiana Nikitina, Natalia Porfirieva, Tatiana Ionova (Russian Federation)

**CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION**
**17:36 - 17:47**
Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaoqiang Han (United States)

**POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS**
**17:47 - 17:58**
Kaja Kasarełło, Martyna Seta, Tomasz Ciesielski, Dorota Sulejczak, Robert Wrzesień, Agnieszka Cudnoch-Jędrzejewska, Emilian Snarski (Poland)

**Joint Session**
**16:30 - 18:00**

**JS3, Joint session WBMT: International access to HCT drugs: Impact on transplant practice and patients**

**Chairs:**
Daniel Weisdorf (United States)
Carlos Solano Vercet (Spain)
Scientific Programme

**Causes of drug shortages and finding enduring solutions**
16:30 - 17:00

**How can pharmacists help the HCT team in drug shortages and cost of medications**
17:00 - 17:30
Gunar Stermer (Austria)

**Successful models of cooperation to offer essential drugs in the care of HCT patients: Role of WBMT**
17:30 - 18:00
Hildegard Greinix (Austria)
Scientific Programme

Tuesday, 01 September 2020

Meetings
07:00 - 09:00

Paediatric Diseases Working Party Business Meeting

Chairs:
Selim Corbacioglu (Germany)

Meetings
07:00 - 09:00

Autoimmune Diseases Working Party Business Meeting

Chairs:
John Snowden (United Kingdom)

Meetings
07:00 - 09:00

Infectious Diseases Working Party Business Meeting

Chairs:
Jan Styczynski (Poland)

Meetings
07:00 - 09:00

Transplant Complications Working Party Business Meeting

Chairs:
Grzegorz Basak (Poland)

Quality Management
08:00 - 09:00

QM1, Introduction to JACIE

Chairs:
Esther Zafra (Spain)

Accreditation process
Eva Controle (Spain) 08:00 - 08:15

Basic quality management concepts
Ivana Ferrero (Italy) 08:15 - 08:30
Scientific Programme

Lessons learned from first-time inspections and re-accreditation inspections
Carole Charley (United Kingdom) 08:30 - 08:45

Questions & Answers 08:45 - 09:00

Meet the Expert 08:00 - 09:00

MTE8, Meet the Expert Session 8 - Room A10.01

HSCT in high-risk MDS
David Valcárcel Ferreiras (Spain) 08:00 - 09:00

Meet the Expert 08:00 - 09:00

MTE9, Meet the Expert Session 9 - Room A10.05

Prophylaxis of acute graft versus host disease: ATG or not ATG?
Francesca Bonifazi (Italy) 08:00 - 09:00

Meet the Expert 08:00 - 09:00

MTE10, Meet the Expert Session 10 - Room A10.06

Clinical hurdles for academic development of clinical Advanced Therapies: The perspective from the GMP Lab
Fermín Sánchez-Guijo (Spain) 08:00 - 09:00

Meet the Expert 08:00 - 09:00

MTE11, Meet the Expert Session 11 - Room A10.07

The fast changing paradigm of myeloma treatment: What’s best in 2020?
Sergio Giralt (United States) 08:00 - 09:00

Meet the Expert 08:00 - 09:00

MTE12, Meet the Expert Session 12 - Room A10.12

How I manage double hit lymphomas
Andrew Davies (United Kingdom) 08:00 - 09:00
Meet the Expert
08:00 - 09:00
Meet the Expert Rooms

**MTE13, Meet the Expert Session 13 - Room A10.13**

The role of HSCT in mantle cell lymphoma in 2020
Olivier Hermine (France)

Meet the Expert
08:00 - 09:00
Meet the Expert Rooms

**MTE14, Meet the Expert Session 14 - Room A10.15**

Maintenance strategies after allogeneic HSCT in patients with AML
Ali Bazarbachi (Lebanon)

Multi-stakeholder Forum on Innovative Cellular Therapies
08:30 - 09:30 Sala Retiro

**MF1, 1st Multi-stakeholder Forum on Innovative Cellular Therapies: Introduction and welcome**

**Chairs:**
Christian Chabannon (France)
Harry Dolstra (Netherlands)

**Introduction and welcome**
Christian Chabannon (France) 08:30 - 08:45

**Keynote Lecture: EMA’s Regulatory Science to 2025 in the area HSCT and gene/cellular therapies**
Jordi Llinares (Netherlands) 08:45 - 09:30

Statistics
08:30 - 10:30 EBMT 1 - Meeting Room

**Stat5, Statistical consulting**

Plenary Session
09:00 - 10:30 N103

**P2, Artificial Intelligence approach to haemato-oncology and HSCT**

**Chairs:**
Rafael Duarte (Spain)
Nicolaus Kröger (Germany)

**Basic concepts, applications, and limitations of Machine Learning: A primer for haematologists**
Roni Shouval (Israel) 09:00 - 09:22
### Scientific Programme

#### Artificial Intelligence in haematology
Grzegorz Basak (Poland)  
09:22 - 09:44

#### Artificial Intelligence to support clinical decision making on infections in haematology
Carolina García-Vidal (Spain)  
09:44 - 10:06

#### The role of technology and Artificial Intelligence in GVHD
Shahrukh Hashmi (United States)  
10:06 - 10:28

### Educational

**09:00 - 10:30**  
Hall A (Exhibition Area)

#### E5, Long-term management of alloHSCT recipients

**Chairs:**  
María del Mar Perera Álvarez (Spain)  
Patrice Chevallier (France)

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Survivorship care plans</strong></td>
<td>09:00 - 09:22</td>
</tr>
<tr>
<td>Navneet Majhail (United States)</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary malignancies</strong></td>
<td>09:22 - 09:44</td>
</tr>
<tr>
<td>Christian Koenecke (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>Endocrine complications</strong></td>
<td>09:44 - 10:06</td>
</tr>
<tr>
<td>Mutlu Arat (Turkey)</td>
<td></td>
</tr>
<tr>
<td><strong>Practical management of long-term organ complications</strong></td>
<td>10:06 - 10:28</td>
</tr>
<tr>
<td>Mutlu Arat (Turkey)</td>
<td></td>
</tr>
</tbody>
</table>

### Oral Session

**09:00 - 10:30**  
Hall B (Exhibition Area)

#### OS6, Oral session 6 - Cellular Therapies other than CARs

**Chairs:**  
Miguel Blanquer (Spain)  
Stephan Mielke (Sweden)

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES</strong></td>
<td>09:00 - 09:11</td>
</tr>
<tr>
<td>Sarita Rani Jaiswal, Hema Malini Aiyer, Gitali Bhagwati, Anupama Mehta, Aditi Chakrabarti, Satish Bansil, Suparno Chakrabarti (India)</td>
<td></td>
</tr>
<tr>
<td><strong>HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES</strong></td>
<td>09:11 - 09:22</td>
</tr>
<tr>
<td>María Esther Martínez-Muñoz, Rafael Forés, Carmen Regidor, Jose Luis Bueno, Yolanda Gutiérrez, Miguel García, Guiomar Bautista, Almudena de Laiglesia, Carlos Vilches, Cristina Fernández-Maqueda, Jose Antonio García-Marco, Emilio Ojeda, José Rafael Cabrera, Rafael Francisco Duarte (Spain)</td>
<td></td>
</tr>
</tbody>
</table>
DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT
Nicole Santoro, Katya Mauff, Raynier Devillier, Luca Castagna, Zafer Gülbas, José Diez-Martín, Arancha Bermúdez, Concepcion Herrera Arroyo, Eric Deconinck, Jorge Sierra, Manuel Abeoasis, Hakan Ozdogu, Maria Caterina Micò, Vandorocha, Denis Guyotat, Yves Chalandon, Edouard Forcade, Hans Martin, Riccardo Saccardi, Sebastian Giebel, Mauro Di Ianni, Jorinde Hoogenboom, Liesbeth C de Wreede, Annalisa Ruggeri, Christian Chabannon (Italy)

SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION
Sergey Blagov, Ivan Zvyagin, Larisa Shelikhova, Mariia Ishushina, Julia Starichkova, Dmitriy Balashov, Dmitriy Pershin, Elena Osipova, Natalia Khripkova, Mariia Efimenko, Viktoria Fomchenkova, Ekaterina Komech, Jakov Muzalevskii, Alexei Kazachenok, Elena Kurnikova, Galina Novichkova, Alexei Maschan, Michael Maschan (Russian Federation)

PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLET ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA

BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLS FOR REFRACTORY CMV
Vanessa Fabrizio, Irene Rodriguez-Sanchez, Audrey Mauguen, Parastoo Dahi, Ekatarina Doubrovina, Richard J. O'Reilly, Susan Prockop (United States)

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPAÑOL TRASPLANTE HEMATOPOYÉTICO)

PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS
Lucia Silla, Vanessa Valim, Cristiane Weber, Alini Vargas, Dayane Catelli, Bruna Correa, Maria da Silva, Bruna Amorin, Bruna Zambonato, Juliana Nobrega, Fernanda Scherer, Claudia Astigarraga, Lisandra Rigoni, Liane Daudt, Rosane Bittencourt, Mariana Michalowski, Fernando Duarte, Nelson Hammerschlag, Vicente Odone, Mariana Jobim, Joice Merzoni, Samantha Michele, Laura Fogliatto, Juliano Perez, Raul Rodrigues, Nicole Kilian, Jeniffer dos Anjos, Leo Sekine, Alessandra Paz, Dean A Lee (Brazil)

E6, Infectious complications: New therapies and prevention

Chairs:
Jan Styczynski (Poland)
Rafael de la Cámara (Spain)

Multiresistant bacteria in children and adults: Insight on new antibiotics
Dina Averbuch (Israel)

Management strategies in the new adenovirus landscape
Per Ljungman (Sweden)
How to structure an effective HSCT vaccine programme  
Catherine Cordonnier (France)

Paediatric Day  
09:00 - 10:30  
N101

Paediatrics1, Paediatric Diseases Working Party Session

Chairs:  
Selim Corbacioglu (Germany)  
Persis Amrolia (United Kingdom)

Memorial to Dietrich Niethammer  
Rupert Handgretinger (Germany)

Dietrich Niethammer Award - Introduction  
Selim Corbacioglu (Germany)

Christina Peters, Jean-Hugues Dalle, Franco Locatelli, Ulrike Poetschger, Herbert Pichler, Petr Sedlacak, Jochen Büchner, Peter Shaw, Raquel Staculuk, Marianne Ifversen, Kim Vettenranta, Peter Svec, Olga Aleinikova, Jerry Stein, Tayfun Gungor, Jacek Toporski, Tony Truong, Cristina Diaz De Heredia, Marc Bierings, Hany Ariffin, Mohammed Essa, Arjan Lankester, Marc Ansari, Martin Schrappe, Arend von Stackelberg, Adriana Balduzzi, Selim Corbacioglu, Peter Bader (Austria)

PDWP update on prospective activities

PDWP activities and next events  
Selim Corbacioglu (Germany)

Cell based therapies in children

Overview of novel developments in CAR T  
Patrick Schlegel (Germany)

CD5- and CD7-directed CAR T Cells for T-cell malignancies  
Maksim Mamonkin (United States)

Adoptive transfer of multivirus-specific T-cells  
Tobias Feuchtinger (Germany)

Real world Data: Relapse after CAR T  
Susana Rives (Spain)

"Real World Data" on CAR T: HSCT vs. CAR T in leukaemia  
Peter Bader (Germany)

Beyond Europe

Brazil  
Carmem Bonfim (Brazil)

Mexico  
Alberto Olaya-Vargas (Mexico)
Scientific Programme

Quality Management
09:00 - 10:30
Sala Colón

QM2, Draft 8th Edition of the STD
Chairs:
Eugenia Trigoso Arjona (Spain)

- **Clinical standards**
  Kim Orchard (United Kingdom) 09:00 - 09:15

- **Collections standards**
  Nina Worel (Austria) 09:15 - 09:30

- **Processing standards**
  Ivan van Riet (Belgium) 09:30 - 09:45

- **Quality Management standards**
  Simon Hack (United Kingdom) 09:45 - 10:00

- **Immune effector cells standards**
  Riccardo Saccardi (Italy) 10:00 - 10:15

- **Questions & Answers** 10:15 - 10:30

Nurses Group
09:00 - 10:30
N107

NG14, Joint session: Teamwork in the CAR T-cells setting
Chairs:
Maaike de Ruijter (Netherlands)
Sara Marcos Corrales (Spain)

- **Indications and patient selection**
  Reuben Benjamin (United Kingdom) 09:00 - 09:30

- **Training the UK workforce** 09:30 - 10:00

- **Quality of life in caregivers and patients undergoing CAR T therapy**
  Anna Barata (United States) 10:00 - 10:30

Special Session
09:00 - 10:30
N109

SS3, Young Ambassadors session
Chairs:
Razan Mohty (France)
Abdul Hamid Bazarbachi (United States)

- **How to build up a career in:**
  **Academia** 09:00 - 09:10
  Didier Blaise (France)
Scientific Programme

**Pharmaceutical Industry**
Suzanne Janssen (France) 09:10 - 09:20

**Public domains**
Eva Hilgenfeld (Germany) 09:20 - 09:30

**What to avoid when writing a paper**
Jakob Passweg (Switzerland) 09:30 - 09:45

**How to write a successful grant**
Robert Zeiser (Germany) 09:45 - 10:00

**Introduction to medical statistics**
Simona Iacobelli (Italy) 10:00 - 10:15

**Social media in stem cell transplantation and cellular therapy**
Navneet Majhail (United States) 10:15 - 10:30

---

**Workshop**
09:00 - 10:30 N111

**W5, Bone marrow failure: From diagnosis to treatment in 2020**

**Chairs:**
Carlos Vallejo (Spain)
Andrea Bacigalupo (Italy)

**Constitutional BMF diagnosis work-up in the era of NGS and gene panels**
Carlo Dufour (Italy) 09:00 - 09:30

**Guidelines for the use of eltrombopag in aplastic anaemia in Europe**
Régis Peffault de Latour (France) 09:30 - 10:00

**New complement inhibitors: Time for the show**
Antonio Risitano (Italy) 10:00 - 10:30

---

**Workshop**
09:00 - 10:30 Sala Neptuno

**W6, Donor HLA assessment and matching for allogeneic HSCT**

**Chairs:**
Katharina Fleischhauer (Germany)
Alejandro Madrigal (United Kingdom)

**HLA laboratory perspective and recommendations**
Steven Marsh (United Kingdom) 09:00 - 09:30

**Clinical perspective and recommendations**
Francesca Lorentino (Italy) 09:30 - 10:00

**Selection of unrelated donors and cord blood units for haematopoietic cell transplantation: Guidelines from NMDP/CIBMTR**
Stephen Spellman (United States) 10:00 - 10:30
Pharmacists Day
09:00 - 10:30

**Pharm1, Pharmacotherapy in HSCT**

**Chairs:**
Rick Admiraal (Netherlands)
Maria Estela Moreno Martínez (Spain)

**General introduction: Local Pharmacy Committee and EBMT Pharmacists Committee**
Tiene Bauters (Belgium)
Maria Estela Moreno Martínez (Spain)

09:00 - 09:10

**Current evidence for TDM in HSCT: An overview**
Vera Domingos (Portugal)

09:10 - 09:30

**GFR estimation in HSCT patients: Is creatinine enough?**
Claudia Langebrake (Germany)

09:30 - 09:50

**Drug-Drug Interactions between antifungals and immunosuppressive agents: An EBMT guidance**
Erik van Maarseveen (Netherlands)

09:50 - 10:10

**ATG vs. post-cyclophosphamide**
Eolia Brissot (France)

10:10 - 10:30

---

**Data Management**
09:00 - 10:30

**DM7, Education session 7**

**Chairs:**
Helen Baldomero (Switzerland)

**Discussion forum - Med A**
Helen Baldomero (Switzerland)
Hildegard Greinix (Austria)
Lidia Gil (Poland)
Johannes Schetelig (Germany)
Sebastian Giebel (Poland)

09:00 - 10:30

---

**Data Management**
09:00 - 10:30

**DM17, Training session 1 (pre-registration required)**

**Chairs:**
Asterios Kasmiris (United Kingdom)

**MACRO Data Entry**
Asterios Kasmiris (United Kingdom)

09:00 - 10:30
SS4, Gender Equality forum

Chairs:
Silvia Montoto (United Kingdom)
Anna Sureda (Spain)
John Murray (United Kingdom)

Physician's (female) perspective  09:00 - 09:22
Jane Apperley (United Kingdom)

Physician's (male) perspective  09:22 - 09:44
John Snowden (United Kingdom)

Nurse's perspective  09:44 - 10:06
John Murray (United Kingdom)

The role of gender in doctor-patient interaction and outcomes  10:06 - 10:28
Natacha Bolaños (Spain)

HDI4, How Do I... manufacture T-cells for cellular therapies - Supported through an unrestricted educational grant by Miltenyi Biotec

Chairs:
João Lacerda (Portugal)

Home-brew CAR T-Cells  09:00 - 09:30
Michael Schmitt (Germany)

Generating antiviral T-cells for clinical application  09:30 - 10:00
Britta Eiz-Vesper (Germany)

Generation of T regulatory cells  10:00 - 10:30
Mauro Di Ianni (Italy)

SSS5, How to get published

BMT: Official journal of the EBMT  09:00 - 09:20
Hillard Lazarus (United States)

How to get published  09:20 - 09:40
Mohamad Mohty (France)

Questions & Answers  09:40 - 10:00
Scientific Programme

Poster Sessions
09:00 - 18:00

Experimental stem cell transplantation

AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY

2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT

ESTABLISHING A TRANSPLANT SHARING PROGRAM

Experimental transplantation

IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Florent Malard, Aonghus Lavelle, Giorgia Battipaglia, Béatrice Gaugler, Rémy Dulery, Eolia Brissot, Tounes Ledraa, Razan Mohty, Harry Sokol, Mohamad Mohty (France)

MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS

EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA
Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Raya Chaghnej Lorestani (Iran, Islamic Republic of)

PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN
Mehrdad Payandeh, Sakineh Ghorbani, Farzaneh Chahardoli, Fouzieh Rahimzadeh (Iran, Islamic Republic of)

Haematopoietic stem cells

CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENIC TRANSPLANTATION RECIPIENTS
Flavia Peci, Markus J. van Roosmalen, Rurika Oka, Marc Bierings, Ruben Boxtel, Mirjam Belderbos (Netherlands)

ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS

TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY
Thomas Longval, Jacques-Emmanuel Galimard, Anne-Claire Leprêtre, Felipe Suarez, Denise Amiranoff, Marine Cazaux, David Michonneau, Terezca Coman, Jean-Henri Bourhis, Stéphanie Nguyen Quoc, Eleonore Kaphan, Gérard Socié, Régis Peffault de Latour, Matthieu Resche-Rigon, Flore Sicre de Fontbrune (France)
FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT
Andreas Rank, Christophe Peczynski, Myriam Labopin, Matthias Stelljes, Celestine Simand, Grzegorz Helbig, Jürgen Finke, Stella Santaroni, Johanna Tischer, Andrzej Lange, Martin Mistrik, Mohamed Houhou, Arnon Nagler, Christoph Schmid, Mohamad Mothy (Germany)

CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION
Lisa O'Connor, Nicola Gardiner, Ashique Khan, Valerie Broderick, Paul Browne, Patrick J. Hayden (Ireland)

HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY
Kristin Skaarud, Johannes R. Hov, Simen H. Hansen, Martin Kummeren, Tobias Gedde-Dahl, Asta Bye, Vemund Paulsen, Knut E. A. Lundin, Marius Trøseid, Geir E. Tjønnfjord, Per O. Iversen (Norway)

UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS
Zohreh Nademi, Kanchan Rao, Su Han Lum, Stephen Jolles, Colin Steward, Stephen Hughes, Robert Wynn, Winnie Ip, Austen Worth, Paul Veys, Arjan Lankester, Maria Elena Maccari, Terry Flood, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION
Michael Spencer Chapman, C. Matthias Wilk, Steffen Boettcher, Markus G. Manz, Peter Campbell (United Kingdom)

SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Tangia Muquith, Michele Lm Poon, Tan Lip Kun, Koh Liang piu (Singapore)

ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY

INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)

IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS
Paula Arruda Tacla, Rajat Kumar Agarwal, Rakesh Dhanya, C P Raghuram, Pallavi Mehta, Deepa Deepa Trivedi, VaibHAV Shah, Priya Marwah, Rajpreeet Soni, SadaF Khalid, S Sandeep, Sarah Sarah Khan Gilani, Aliya Batoool, Lallindra Gooneratne, Ruwangi Dissanayake, Fatima Itra, Tatheer Zahra, Lawrence Faulkner, Stalin Ramprakash (Brazil)

COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS
Maria Barabanshikova, Elena Morozova, Ivan Moiseev, Julia Vlasova, Vadim Baykov, Inna Ushal, Gennadij Rodionov, Sergey Moiseev, Ildar Barkhatov, Ksenija Afanasyeva, Sergey Bondarenko, Boris Afanasyev (Russian Federation)

THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kübra Haşimoğlu, Ferda Can, Oktay Tertemiz, Asena Dikyar, Didem Akçalı, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin (Turkey)

HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT

IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW
Seyed Asadollah Mousavi, Maryam Barkhordar, Tanaz Bahri, Sahar Tavakoli, Leila Mirzakhani, Leyla Sharifi Aliabadi (Iran, Islamic Republic of)

EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES

SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE
Ludovic Jondreville, Laetitia Souchet, Françoise Norol, Madalina Uzunov, Stéphanie Nguyen (France)

SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY

INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Carlos Solano, Lourdes Vázquez, Estela Giménez, Eliseo Albert, Montserrat Rovira, Ildelfonso Espigado, Carmen Martín, Anabelle Chinea, Albert Esquirol, Ariadna Pérez, Arazazu Bermúdez, Rafael De la Câmara, Raquel Saldaña, Inmaculada Heras, Ana Julia González-Huerta, Tamara Torrado, Monserrat Batlle, Santiago Jiménez, Carlos Vallejo, Pere Barba, María Ángeles Cuesta, José Luis Piñana, David Navarro (Spain)

CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
Elifcan Aladag, Haluk Demiroglu, Yahya Buyukasik, Hakan Goker (Turkey)

USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA
Laura M. Pezzetti, Giambattista Bertani, Liliana Intropido, Tiziana Lamacchia, Francesca Bosè, Elisa Zucchetti, Giovanni Grillo, Mauro Turrini, Michela Anghileri, Roberto Cairoli (Italy)

OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA
RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA

PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE

USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN

TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG

Ekin Kircali, Guldan Cengiz Seval, DERYA Koyun, CemaalEDDin Ozturk, Atila Uslu, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topcuoglu, Onder Arslan, MuHIT Ozcan, Taner Demirer, Hamdi Akan, Osman ilhan, Gunhan Gurman, Meral BekSAC, Meltem Kurt Yuksel (Turkey)

EXCELLENT OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION USING A TARGETED BUSULFAN AND FLUDARABINE CONDITIONING IN PATIENTS WITH NONMALIGNE NT GENETIC DISEASES

Kyung Taek Hong, Bo Kyung Kim, Jung Yoon Choi, Sang Hoon Song, Kyung-Sang Yu, In-Jin Jang, Hee Young Shin, Hyo Jung Jin Kang (Korea, Republic of)

EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

Barbaros Sahin Karaqui, Bulent Antmen, Ilgen Sasmaz (Turkey)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAIVE T LYMPHOCYTES

Mª Del Pilar Sanz Martín, Yaiza Pérez García, Paula Díaz Fernandez, Víctor López Huete, Lorena Vega Piris, Ana Arteche López, Adrián Alegre Amor, Cecilia Muñoz Calleja (Spain)

DESENSITIZATION PROTOCOL IN ADULT ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE

ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

Claudia Sossa, Arilda-Baez Manuel, Wandurraga Edwin, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Jimenez Sara I, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017

Sandra Easdale, Chloe Anthias Anthias, Emma Nicholson, Joy Brennan, Maria Mulligan, Mike Potter, Mark Ethell (United Kingdom)

HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL

ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
Claudia Sossa, Manuel Ardila-Baez, Edwin Wandurraga, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Sara I Jimenez, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE
Sie Chong Doris Lau, Seong Lin Khaw, Chia Huan Ng, David Hughes, Jacqueline Fleming, Diane Hanna, Rachel Conyers, Francoise Mechinaud (Australia)

COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION
Miguel Angel Martinez Hernández, Dennis Lumpuy Obregón, Agnerys López Sacerio, Bárbaro Andrés Medina Rodriguez, Carlos Rodriguez Fadragaz, Jorge Félix Guerra Rodriguez (Cuba)

INFUSED TOTAL NUCLATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION
A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Haluk Demiroglu, Elifcan Aladag, Yahya Buyukasik, Sailih Aksu, Hakan Goker (Turkey)

THE CRYOPRESERVATION MEDIA USED FOR PRESERVING CD34+ STEM CELLS INFLUENCES THE CELL COUNT, SURVIVAL AND APOPTOSIS OF THESE CELLS POST-THAWING
Rebecca Axelsson-Robertson, Pablo Giusti, Jonas Axelson, Emma Watz, Lyda M Osorio (Sweden)

THE IMPACT OF CD34+ CELL AND IMMUNEFECTOR CELL DOSE ON TRANSPLANT OUTCOMES
TREOSULTAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY
Yolanda Gonzalez Romero, Lucrecia Yañez, Miguel Angel Cortes, Andres Insunza, Joan Manuel Mora, Miriam Sanchez-Escamilla, Sara Fernandez-Luis, David Gomez-Lamas, Jose Calvo-Sanchez, Sergio Fernandez-Garcia, Guillermo Martin-Sanchez, Mercedes Colorado, Enrique Ocio, Aranzazu Bermudez (Spain)

OUTOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Zofia Szmit, Anna Król, Krzysztof Kalwak, Marek Ussowicz, Małgorzata Salamonowicz-Bodziacho, Jowita Frączkiewicz, Monika Mielcarek-Siedziuk, Justyna Miśkiewicz-Bujna, Izabella Miśkiewicz-Migoń, Ewa Gorczyńska (Poland)

MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL
IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA
Silvia Pizzi, Mariana Roizen, Danila Labonia, Analia Julia, Carlos Figueroa Turienzo, Agustin Gonzalez Correas, Valeria Santidrian, German Carli, Ana Laura Naso, Raquel Staciuk (Argentina)

PHASE II STUDY OF PLERIXAFLOR AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSEDFRACTORY DIFFUSE LARGE B CELL,PET POSITIVE AFTER TWO R-DHAP
THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION
Elifcan Aladag, Haluk Demiroglu, Yahya Buyukasik, Salih Aksu, Hakan Goker (Turkey)

THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING
Asena Dikyar, Erhan Hocaoglu, Lale Aydin Kaynar, Zubeidey Nur Ozkurt, Zeynep Arzu Yejin (Turkey)

AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME
María Liz Paciello Coronel, Alejandra Leivas Aldea, Sara Redondo Velao, Encarnación Güemes Arce, Yolanda Paredes, Patricia Pérez Tomás, Mercedes Hernández, Borja Andrades Velazquez, Desire Sánchez Lozano, María Nieves Elvira Cortaberria, Consuelo Carralero, Joaquín Martínez López (Spain)

A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA
Zhijie Wei, Fei Pan, Rong Yang, Guanlan Yue, Kang Gao, Hui Li, Shuquan Ji, Peihua Lu (China)

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY
Aigul Tulebayeva, Ergaly Sarsekbaev, Riza Boranbayeva, Kulan Omarova (Kazakhstan)

THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE
Khalid Halahleh, Waleed Da’ana, Husam Abu-jazar, Mohamed Ma’koseh, Salwa Saadeh, Rozan Al Far, Abdelghani Tbakh (Jordan)

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER
Yolanda Gonzalez Romero, Joan Manuel Mora, Miguel Angel Cortes, Sara Fernandez-Luis, David Gomez-Lamas, Aranzazu Bermudez, Andres Insunza, Lucrecia Yañez, Cristina Amunarriz, Mercedes Colorado, Enrique Ocio, Guillermo Martin-Sanchez (Spain)

CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Claudia Sossa, Manuel Ardila-Baez, Edwin Wandurraga, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Sara I Jimenez, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Peripheral Blood Stem Cell Transplantation in Pediatric Recipients in Peru: Experience of a Referral Center
Essy Maradiegue, Sharon Chávez (Peru)

HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS
Nadia Tanya Giatt, Colwyn Poole, Bibi Rhode, Matlidi Moalosi, Khensani Mathye (South Africa)
Scientific Programme

TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Mireia Santos Gómez, Agueda Ancochea Serra, Eva Alonso Nogués, Joan Ramon Grífol Ronda, Mireia Morgades de la Fe, Mireia Franch Sarto, Georgina Gener Ricós, Christelle Ferrà Coll, Susana Vives Polo, Anna Torrent Catarineu, Miriam Moreno Velázquez, Montserrat Batlle Massana, Blanca Xicoy Cirici, Laura Abril Sabater, Gladys Ibarra Fernández, Alicia Senín Magán, Albert Oriol Rocafullger, Josep Maria Ribera Santusasana, Juan Manuel Sancho Cia (Spain)

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE
Sergio Murillo-Vizcarra, Karina Rojas-Fernandez, Carolina Benavides-Vallve, Karina Pinto-Gossin, Carlos Vidurriaga-De Amezaga (Peru)

COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019
Ieva Golubicikaitė, Birute Sabaniene, Inga Valanciute, Elena Juozaityte, Rolandas Gerbutavicius, Domas Vaitiekus, Aurija Kalasauskiene, Diana Remeikiene, Jonas Surkus, Ruta Leksiene, Milda Rudzianskiene, Martyna Beilneriene, Vilma Svetickiene, Ruta Dambrauskiene, Vaida Didziariekienė, Daiva Urboniene, Dietger Niederwieser (Lithuania)

EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHST): UNICENTRIC EXPERIENCE
MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION: A PILOT STUDY

REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
Marcia Silva, Natalia Laso, Maria Claudia Moreira, Simone Lermontov, Rita De cassia Barbosa, Simone Maradei, Marta Colares, Yung Gonzaga, Leonardo Arcuri, Renato Araujo, Decio Lerner (Brazil)

VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS

CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bosco Martin McNally Guillen, Brenda Lizeth Acosta Maldonado, Liliana Mey Rivera Fong, José Manuel Téllez Araujo, Oyuky Gissell Aguirre Reyes, José Luis Estrada Rico, Alejandra Mendoza Torres, Luis Manuel Valero Saldaña (Mexico)

Immunodeficiency diseases and macrophages

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS
Satoshi Miyamoto, Masakatsu Yanagimachi, Katsutsugu Umeda, Akihiro Iguchi, Yoji Sasahara, Hidetoshi Takada, Yoshiyuki Takahashi, Michiko Kajiwara, Masami Inoue, Koji Kato, Yoshiko Hashil, Yoshiko Atsuta, Hiromasa Yabe, Kohsuke Imai, Tomohiro Moro (Japan)

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA
Xiaowen Zhai, Xiaowen Qian, Hongsheng Wang, Wenjin Jiang, Ping Wang (China)
**IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
Dagmar Berghuis, Lisanne van Leeuwen, Jorinde Hoogenboom, Corry Weemaes, Mary Slatter, Reem Elfeky, Michael Albert, Roland Meisel, Alexandra Laberko, Akif Yesilipek, Lubna Mehyar, Andrew Gennery, Arjan Lankester (Netherlands)

**THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCRαβ/CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES**
Alexandra Laberko, Elvira Sultanova, Yulia Skvortsova, Irina Shipitsina, Svetlana Kozlovskaia, Svetlana Radygina, Anna Livshits, Aishat Kantulaeva, Elena Kurnikova, Anna Shcherbina, Alexei Maschan, Michael Maschan, Dmitry Balashov (Russian Federation)

**IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY**
Su Han Lum, Sahar Habibollah, Peter McNaughton, Zohreh Nademi, Terry Flood, Andrew Cant, Mario Abinun, Sophie Hambleton, Mary Slatter, Andrew Gennery (United Kingdom)

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN CHILDREN WITH FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE-CENTER REPORT**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE**

**OUTCOMES OF STEM CELL TRANSPLANT For RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE**
Peter McNaughton, Su Han Lum, Zohreh Nademi, Terry Flood, Eleri Williams, Andrew Cant, Mario Abinun, Andrew R Gennery, Sophie Hambleton, Mary Slatter, Stephen Owens (United Kingdom)

**IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT**

**SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR αβ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES**

**HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA**
Stalin Ramprakash, C P Raghuram, Chetan Ginigeri, Fulvio Porta, Sagar Bhattad (India)

**NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMENS FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA**
Xiaowen Qian, Xiaowen Zhai, Hongsheng Wang, Wenjin Jiang, Ping Wang (China)

**THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION**
Xiaowen Qian, Xiaowen Zhai, Chaofan Liu, Hongsheng Wang, Ping Wang, Wenjin Jiang (China)

**LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES**

HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY

DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
Emese Molnar, Nesrine Radwan, Gabor Kovacs, Siobhan Burns, Hajnalka Andrikovics, Matthew Buckland, Kimberly Gilmour (United Kingdom)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Infectious complications

RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY
Emilian Snarski, Jacqui Stringer, Małgorzata Mikulska, Lidia Gil, Gloria Tidello, Paul Bosman, Jennifer Hoek, Michał Karas, Samo Zver, Catherine Lueck, Nicole Blijlevens, Iria González, Małgorzata Ociepa-Wasilkowska, Michał Góra, Isabel Sánchez-Ortega, Inger Andersson, Lucrecia Yáñez, Mohamed Amine Bekadja, Jan Styczynski (Poland)

INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT
Moshe Yeshurun, Uri Rozovski, Liat Shargian, Oren Pasvolsky, Diana Averbuch, Steffie van der Werf, Nina Knelange, Małgorzata Mikulska, Jan Styczynski (Poland)

PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE

HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT
Małgorzata Mikulska, Olaf Penack, Lotus Wendel, Nina Knelange, J.J. Cornelissen, Nicole Blijlevens, Jakob Passweg, Nicolaus Kroger, Anke Bruns, Arnold Ganser, Marc Bierings, Helen Labussière-Wallet, Gilles Salles, Jan Styczynski (Italy)

THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN
Sung Han Kang, Jae Won Yoo, Jin Kyung Seo, Hyery Kim, Kyung-Nam Ko, Eun Seok Choi, Seongsoo Jang, Chan-Jeoung Park, Jong Jin Seo, Ho Joon Im (Korea, Republic of)

IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY

COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN-γ ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Eva Wagner, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärnter, Stephan Mielke, Martin Schreder, Guido Kobbé, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Grass, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rasche, Harald Guidan, Sascha Barabas, Ludwig Demi, Ralf Wagner, Daniel Wolff (Germany)
HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT

INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH
Jiaqi Fang, Phaedon D. Zavras, Yiqi Su, Amit Raval, Yuexin Tang, Anat Stern, Miguel-Angel Perales, Sergio Giralt, Genovefa A. Papanicolaou (United States)

POOR RECOVERY AND IMPAIRED FUNCTION OF Vδ1+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION

SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)

ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIF PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TIC
Ana Berceanu, Kevin Bounier, Etienne Daguindau, Anne Thiebaut-Bertrand, Regis Pefault de Latour, Felipe Suarez, Bruno Lioure, Helene Labussiere-Wallet, Marion Simonet, Sylvain Chanteple, Florence Beckerich, Marie-Therese Rubio, Stephanie Nguyen-Quoc (France)

SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE
Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis D. Kim, Jeffrey H. Lipton, Fotios V. Michalis (Canada)

COMPARISON OF RISK FACTORS AND MORTALITY OF DIFFERENT CYTOMEGALOVIRUS END-ORGAN DISEASES FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

INFECTION COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA AFTER NEW AGENTS’ THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION
Yuliya Ronacheva, Marina Popova, Kirill Lepik, Yuriy Zalyov, Lilia Stelmakh, Alisa Volkova, Iliya Nikolaev, Anastasia Beinarovich, Olga Pirogova, Evgeniya Borzenkova, Oleg Goloshchapov, Sergey Bondarenko, Ivan Moiseev, Vadim Baykov, Nataliya Mikhailova, Nikolay Klimko, Boris Afanasiev (Russian Federation)

SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION

CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION

Fecal microbiota transplantation in children to treat acute GVHD or multi-drug resistant bacteria colonization

VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION
Sigrun Einarsdottir, Malin Nicklasson, Malin Veje, Tomas Bergström, Per Ljungman, Berit Johansson, Mikael Olsson, Björn Andreasson, Marie Studahl, Benedicte Piauger, Anette Roth, Mats Brune (Sweden)

RIFAXMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT
Elisa Gabanti, Oscar Borsani, Daniela Caldera, Anna Amelia Colombo, Virginia Ferretti, Emilio Paolo Alessandrino, Paolo Bernasconi, Daniele Lilleri (Italy)

IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY
Chiara Camerini, Alessandra Carotti, Loredana Ruggeri, Adelmo Terenzi, Franca Falzetti, Silvia Bozza, Roberto Castronari, Samanta Bonato, Genni Casarola, Rita Felicini, Mario Griselli, Francesca Marzuttini, Matteo Paradiso, Sara Tricarico, Antonella Mencacci, Andrea Velardi, Antonio Plierini (Italy)

ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY

CLINICAL IMPACT OF COLONIZATION BY MULTI-DRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC
Alexis Genthon, Sylvain Chantepie, Amandine Le Bourgeois, Jacques Olivier Bay, Marie-Thérèse Rubio, Ali Bazarbachi, Stephanie Nguyen, Yves Beguin, Xavier Poiré, Amandine Charbonnier, Nathalie Fegueux, Michaël Loschi, Micha Sour, Eolia Brissot (France)

RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN

EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS
Yasuo Mori, Goichi Yoshimoto, Tetsuya Eto, Koji Nagafuji, Hiromi Iwasaki, Yoshikyo Ito, Yuju Ohno, Tomohiko Kamimura, Ryosuke Ogawa, Akihiko Numata, Koji Katu, Katsuto Takenaka, Toshihiro Miyamoto, Koichi Akashi (Japan)

RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Eva Wagner, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärtnert, Stephan Mielke, Martin Schreder, Guido Kobbe, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Grass, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rascle, Harald Guldan, Sascha Barabas, Ludwe Deml, Ralf Wagner, Daniel Wolf (Germany)

IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT
ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS

Ioannis Tsonis, Ioannis Baltadakis, Maria Stamouli, Konstantinos Gkirkas, Christina Economopoulou, Dimitra Gardeli, Thomas Thomopoulos, Anna Paisiou, Dimitra Oikonomopoulou, Tiatiana Tzenou, Nikolaos Siafakas, Spyridon Pournaras, Anastasia Antoniadou, Aggeliki Karagiannidi, Eirini Grispou, Joseph Meletiadis, Dimitra Kavatha, Stavros Gigantes, Evgenios Goussetis, Dimitrios Karakasis, Panagiotis Tsirigotis (Greece)

TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

Christine Camacho-Bydume, Irene Rodriguez-Sanchez, Audrey Mauguen, Genovefa Papanicolaou, Susan Prockop, Elizabeth Klein, Nancy Kernan, Jaap-Jan Boelen, Maria Cancio (United States)

OUTCOME OF BRINCIDOFOVIR (CMX-001) TREATMENT FOR VIRAL INFECTIONS AFTER STEM CELL TRANSPLANTATION

Karoline Ehlert, Peter Lang, Johannes H. Schulte, Sebastian Voigt (Germany)

PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS

Charlotte de Mooij, Walter van der Velden, Antonius de Haan, Lenneke van Groningen, Nicole Blijlevens (Netherlands)

PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT


COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT

Louis-Pierre Girard, Yin Jie Koh, Xin Liu, Davanaliz Gonzales Ramos, Teck Guan Soh, Lip Kun Tan, Michelle LM Poon, Lionel Lum, Liang Piu Koh (United Kingdom)

THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION

NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

Atsushi Satake, Jun Ichikawa, Ryo Saito, Akiko Konishi, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Shinya Fujita, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura (Japan)

AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL

EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPHENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

EFFICACY AND SAFETY IN MICAFUNGIN SODIUM FOR PROPHYLAXIS AGAINST INVASIVE FUNGAL DISEASE DURING NEUTROPENIA IN PEDIATRIC & ADOLESCENT PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hong Yul An, Hee Young Shin, Hyo Young Jin Kang (Korea, Republic of)

THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Mateja Kraljevic, Nina Khanna, Michael Medinger, Jakob Passweg, Yves Chalandon, Stavroula Masouridi-Levrat, Nicolas Mueller, Urs Schanz, Christian Van Delden, Dionysios Neofytos (Switzerland)

IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY
Muhammet Erdem, Vildan Ozkocaman, Ismail Anaç, Fahir Özkalın (Turkey)

PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES
José Miguel Mateos Pérez, José Ramon Álamo Moreno, Carlos De Miguel Jiménez, Clara González Santillana, Alonso Trillo Rosalia, Sara Garrido Paniagua, Ángela Benéitez Fernández, Lucía Núñez Martín-Buitrago, Ana Bocanegra Pérez-Vicaino, Marta Liébana Villela, Ana Alarcón Tomás, María Esther Martínez, Ana Fernandez-Cruz, Guiliom Bautista Carrascosa, José Rafael Cabrera Marín, Antonio Ramos Marín, Rafael F. Duarte (Spain)

REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT
Dafydd Stonehewer, Joanne Ellis, Tasneem Khalid, Stephen Hughes, Robert Wynn (United Kingdom)

LETERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE
Patrick Derigs, Maria-Luisa Schubert, Paul Schnitzler, Tilman Schöning, Carsten Müller-Tidow, Thomas Luft, Peter Dreger, Michael Schmitt (Germany)

ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Incidence and Impact of Epstein-Barr Virus Events in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation
Samuel Macy, Nina Khanna, Hans Hirsch, Dominik Heim, Claudia Lengerke, Dimitrios Tsakiris, Jakob Passweg, Michael Medinger (Switzerland)

ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY
INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECII PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY
Nieves López Muñoz, Elena Vera Guerrero, Marta Hidalgo Soto, María Calbacho, Jose María Sánchez Pina, Joaquín Martínez-López (Spain)

INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE: COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS
Amado Karduss, Angela Trujillo, Angelica Cardona, Rosendo Perez, Giovanni Ruiz, Gloria Suarez (Colombia)
LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY

Rachael Biggart, Sarah Bird, Chloe Anthias, Sandra Easdale, Michael Potter, Joy Brennan, Maria Mulligan, Emma Thistlethwaite, Kim Davis, Mark Ethell, Unell Riley, Emma Nicholson (United Kingdom)

HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Genevieve Douglas, Michelle Yong, Shioyen Tio, Maggie Chau, Joe Sasadeusz, Monica Slavin, David Ritchie, Lynette Chee (Australia)

EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS

Elizabeth de Kort, Walter van der Velden, Paul Verweij, Nicole Blijlevens (Netherlands)

EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)

Nour Ben Abdeljelil, Rihab Ouerghi, Dorra Belloumi, Amel Lakhal, Lamia Torjemane, Rym El Fatmi, Wafa Achour, Saloua Ladeb, Tarek Ben Othman (Tunisia)

DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS

A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBSAG-POSITIVE DONORS TO RECIPIENTS

BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE

Ismail Anac, Vildan Ozkocaman, Muhammet Erdem, Fahır Ozkalemkas (Turkey)

VERSATILE EFFECTS OF LETERMUVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS

Fumiaki Jinnouchi, Yuta Katayama, Ryota Imanaka, Tatsuya Terasaki, Takuya Nunomura, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Hideki Asaoku, Koji Iwato (Japan)

IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER

INTRAVESICAL INSTILLATION OF CIDOVIRFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION

MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE
RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Chiara Rosignoli, Vera Radici, Rossella Stella, Alessandra Sperotto, Antonella Geronin, Marta Lisa Battista, Michela Cerno, Renato Fanin (Italy)

RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bernd Gruhn, Pania Mokthari (Germany)

IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT
Magdalena Dutka, Agata Szymańska, Patryk Sobieralski, Maria Bieniaszewska (Poland)

BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS
RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Rebecca E. Schultze-Florey, Sabine Tischer-Zimmermann, Hans-Gert Heuft, Christoph Priesner, Britta Lamottke, Albert Heim, Martin Bauer, Karl-Walter Sykora, Rainer Blasczyk, Britta Eiz-Vesper, Britta Maeck-Kolhoff (Germany)

RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS
ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE
TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT
PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)
INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY
CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE
UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS
Ana Lerma Verdejo, Clara Cuéllar Pérez-Ávila, Begonia Pérez de Camino Gaisse, Javier Cornago Navascués (Spain)

EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS
USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPETIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS
TOXOPLASMOsis DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?
Laura Escobar Fernandez, Marina García Morín, Eduardo Bardón Cancho, Jorge Huerta Aragonés, Cristina Beléndez Bieler, Elena Rincón López, María Slocker Barrio, Elena Cela de Julián (Spain)
Scientific Programme

**TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT**
Haridian de la Nuez Melián, Melissa Torres Ochando, Leslie González Pinedo, Santiago Jiménez Bravo de Laguna, María Del Mar Perera Álvarez, Paula Fernández-Calderón González, Leonor Pérez Ortiz, Joan González Fernández, Asunción Borroto Borrego, Juan Francisco López Rodríguez, Luisa Guerra Domínguez, Teresa Molero Labarta (Spain)

**POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS**

**LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT**
Gloria Elena Mora, María Jose Lopez Mora, Enrique Pedraza, Herman Esguerra, Javier Figueroa, Oscar Peña, Sergio Ardila, Angie Guarin, Diego Orlando Diaz, Licet Villamizar, Cesar Lamadrid, Gustavo Adolfo Lopez (Colombia)

**LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**INFECTION COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFECT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE GVHD PROPHYLAXIS ON THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION IN NON-HODGKIN LYMPHOMA**
Gonzalo Gutiérrez-García, Marcela Ortiz-Mosovich, Carmen Martínez, Alexandra Pedraza, María Teresa Solano, Carla Ramos, Noemí de Llobet, Nuria Borrás, Anna Serrahima, María Suárez-Lledó, Pedro Marín, Miquel Lozano, Joan Cid, Laura Rosiñol, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Monserrat Rovira (Spain)

**Efficacy and Safety of Donor Lymphocyte Infusions for Patients Affected by Advanced Lymphoid Malignancies After Allogeneic Stem Cell Transplantation: A Retrospective Study**
Elisa Direl, Raynier Devillier, Sabine Furst, Angela Granata, Stefania Bramanti, Samia Harbi, Jacopo Mariotti, Chiara De Philippis, Barbara Sarina, Thomas Pagliardini, Valerio Maisano, Rocco Piazza, Reda Bouabdallah, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise, Luca Castagna (France)

**BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY**

**Poster Sessions**

**Lymphoma**

**EFFECT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE GVHD PROPHYLAXIS ON THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION IN NON-HODGKIN LYMPHOMA**
Gonzalo Gutiérrez-García, Marcela Ortiz-Mosovich, Carmen Martínez, Alexandra Pedraza, María Teresa Solano, Carla Ramos, Noemí de Llobet, Nuria Borrás, Anna Serrahima, María Suárez-Lledó, Pedro Marín, Miquel Lozano, Joan Cid, Laura Rosiñol, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Monserrat Rovira (Spain)

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY**
Elisa Direl, Raynier Devillier, Sabine Furst, Angela Granata, Stefania Bramanti, Samia Harbi, Jacopo Mariotti, Chiara De Philippis, Barbara Sarina, Thomas Pagliardini, Valerio Maisano, Rocco Piazza, Reda Bouabdallah, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise, Luca Castagna (France)
NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA

IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC
Jean-Edouard Martin, Stéphane Morisset, Regis Peffault De La Tour, Nathalie Fegueux, Edouard Forcade, Sylvie François, Jean-Baptiste Mear, Patrice Chevallier, Eric Deconink, Hélène Labussière-Wallet, Claude-Eric Bulabois, Jacques-Olivier Bay, Mohamad Mohty, Marie-Thérèse Rubio, Didier Blaise, Stéphanie Nguyen (France)

THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN ‘OLDER’ PATIENTS WITH LYMPHOMA
David Davies, Keith Wilson, Sarah Doherty, Emma Kempshall, Hamdi Sati, Wendy Ingram (United Kingdom)

ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP
Masatoshi Sakurai, Takehiko Mori, Souichi Shiratori, Toshio Wakayama, Naoyuki Uchida, Hikaru Kobayashi, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo (Japan)

SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA
Dae Sik Kim, Sung-Hoon Jung, Deok-Hwan Yang, Youngil Koh, Junshik Hong, Ho-Young Yhim, Won Sik Lee, Yoo Jin Lee, Jeong-Ok Lee, Hye Jin Kang, Sung Yong Oh, Yun-Suk Choi, Ho Sup Lee, Jung-Hee Lee, Yong Park, Byung Baek Park, Young Rok Do, Ho-Jin Shin (Korea, Republic of)

HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY

AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTEL CELL LYMPHOMA

CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE
Gérard Socié, Arnaud Pigneux, Charles Herbaux, Paul Chauvet, Hairong Xu, Dhanalakshmi Thirumalai, Norma Guzman-Becerra, Arie Barlev, John Reitan, Mohamad Mohty (France)

THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS
Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, Thomas Luft, Ute Hegenbart, Andrea Bondong, Julia Meissner, Nora Liebers, Michael Schmitt, Carsten Müller-Tidow, Peter Dreger (Germany)
REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES
Eucario Leon Rodriguez, Monica Magdalena Rivera Franco (Mexico)

COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS
Ahmet Kursad Gunes, Ilknur Demir, Serpil Sarfakioğlu, Salih Sertac Durusoy, Dervis Murat Akkurt, Idris Ince, Gulkan Ozkan, Mustafa Pehlivan (Turkey)

NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?
Liudmila Fedorova, Kirill Lepik, Natalia Mikhailova, Elenia Kondakova, Yuri Zalyalov, Vadim Baykov, Elena Babenko, Evgeniya Borzenkova, Lilia Stelmakh, Boris Afanasyev (Russian Federation)

OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS
Pedro Chorão, Teresa Ribeiro, Maria Gomes Silva, Raquel Guilherme, Filipa Saraiva, Joana Vieira, Inês Carvalhais, Sérgio Chacim, José Mário Mariz, Daniela Coelho, Marília Gomes, Manuela Mafra, Mariana Leal Fernandes, Ana Mata, Daniela Alves, Fernando Príncipe (Portugal)

EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS
Reyad Dada, Ehab Abdelghany, Tarek Boubakr, Emily Lenore Goldman-Heaphy, Azhar Nawaz (Saudi Arabia)

EFFECTIC OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Anastasiya Beynarovich, Kirill Lepik, Natalia Mikhailova, Elena Kondakova, Yuri Zalyalov, Eugenia Borzenkova, Elena Babenko, Elena Darskaya, Alexander Aliynskiy, Ivan Moiseev, Boris Afanasyev (Russian Federation)

RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA

DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS

FIRST-LINE HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION RESULTS IN EXCELLENT LONG-TERM SURVIVAL FOLLOWING R-CHOP AND HIGH-DOSE CYTARABINE INDUCTION IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA

TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL
Andriyana Bankova, Urs Schanz, Eugenia Haralambieva, Ewerton Maggio, Corinne Widmer (United States)

OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)
TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP

Joanna Romejko-Jarosinska, Ewa Paszkiewicz-Kozik, Małgorzata Krawczyk-Kulis, Patrycja Mensah-Glanowska, Łukasz Targonski, Agnieszka Giza, Tomasz Czerw, Katarzyna Domanska-Czyz, Kseniya Kviatkouskaya, Paulina Magda, Włodzimierz Mentrek, Beata Ostrowska, Maria Sadus-Wojciechowska, Sebastian Giebel, Jan Walewski (Poland)

PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE

Elena Lepik, Andrey Kozlov, Evgenia Borzenkova, Yuri Zalyalov, Kirill Lepik, Elena Kondakova, Vadim Baykov, Aleksandr Alyanskiy, Ivan Moiseev, Tatiana Schneider, Natalia Mikhailova, Boris Afanasyev (Russian Federation)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY

Khouloud Touihri, Rym El Fatmi, Lamia Torjemane, Dorra Belloumi, Nour Ben Abdeljelil, Amel Lakhal, Saloua Ladeb, Tarek Ben Othman (Tunisia)

AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)

Natalia Kavardakova, Oleg Ryzhak, Julia Basaluk, Sofia Matsiboh, Olena Kreminska, Tatiana Ponomarenko, Tatiana Smolenska, Alexandra Sharamok, Olena Zinchuk, Olga Kohut, Svitlana Donska (Ukraine)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA

Dariusz Kata, Agata Wieczorkiewicz-Kabut, Grzegorz Helbig, Małgorzata Koperka, Aleksandra Zimnoch, Kamil Witosz (Poland)

NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS

Sakine Ghorbani, Mehrdad Payandeh, Nastaran Ahmadi, Mehrnoush Aeinfar (Iran, Islamic Republic of)

Poster Area (Exhibition Area)

Minimal residual disease, tolerance, chimerism and immune reconstitution

CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENIC HSCT

Katrine Kielsen, Dina Leth Møller, Anders Elm Pedersen, Marianne Ifversen, Claus H. Nielsen, Lars P. Ryder, Klaus Müller (Denmark)
IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR
Evgeny Klyuchnikov, Maximilian Christopeit, Anita Badbaran, Ute-Marie von Pein, Urike Fritzseh-Friedland, Christine Wolschke, Nikolaus Kröger (Germany)

FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY

IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS
Lia Minculescu, Anne Fischer-Nielsen, Eva Hastrup, Lars Peter Ryder, Niels Smedegaard Andersen, Ida Schjøedt, Lone Smidstrup Friis, Brian Thomas Kornblit, Søren Lykke Petersen, Hanne Vibeke Marquart, Henrik Sengelov (Denmark)

POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Zhihui Li, Tong Wu, Qinglong Zheng, Caiyan Zhang, Yongqiang Zhao, Yanzhi Song (China)

EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS
Susan Prockop, Ichelle van Roessel, Elizabeth Klein, Farid Boulad, Andromachi Scaradavou, Barbara Spitzer, Andrew Kung, Kevin Curran, Maria Cancio, Richard O'Reilly, Nancy Kernan, Jaap Jan Boelens (United States)

PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
Daniel Drozdov, Katrin Petermann, Leonhard Held, Tayfun Güngör, Mathias Hauri-Hohl (Switzerland)
A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION
Yang Zhou, Le-Qing Cao, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Qiao-Zhen Fan, Ying-Jun Chang, Xiao-Jun Huang (China)

OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERSIM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME
Mercedes Gasior Kabat, Luisa Sisinni, Raquel De Paz, David Bueno, Yasmina Mozo, Beatriz De La Cruz, Antonio Marcos, Ana Belen Romero, Victor Jimenez Yuste, Antonio Perez-Martinez (Spain)

MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Miquel Waterhouse, Sandra Patricia Pennisi, Dietmar Pfeifer, Justus Duyster, Hartmut Bertz, Jürgen Finke, Jesus Duque-Afonso (Germany)

TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Amandine Pradier, Stavroula Masouridi-Levrat, Carine Bosshard, Carole Dantin, Diem-Lan Vu, Marie-Céline Zanella, Elsa Boely, Caroline Tapparel, Laurent Kaiser, Yves Chalandon, Federico Simonetta, Eddy Roosnek (Switzerland)

PREEMPTIVE INTERFERON-α TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Si-Ning Liu, Xue-Yi Luo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo (China)

THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100
Manuela Spadea, Francesco Saglio, Massimo Berger, Francesca Carraro, Rosanna Pessolano, Emanuela Ricotti, Elena Ernestina Vassallo, Franca Fagioli (Italy)

ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME
Almudena Navarro-Bailon, Diego Carbonell, Julia Suárez-González, María Chicanos, Mi Kwon, Rebeca Bailén, Nieves Dorado, José Luis Díez-Martín, Carolina Martínez-Laperche, Ismael Buño (Spain)

EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS
COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPANTATION

FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD

Lars Klingen Gjærde, Sisse Rye Ostrowski, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Thomas Kornblit, Søren Lykke Petersen, Ida Schjødt, Henrik Sengeløv (Denmark)

MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT

Arnon Nagler, Myriam Labopin, Emmanuelle Poigie, Jordi Esteve, Ali Baazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciciri, Sebastian Giebel, Maria Gilleece, Norbert-Claude Gorin, Francesco Lanza, Zina Peric, Annalisa Ruggeri, Jaime Sanz, Bipin Savany, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Frederic Baron, Mohamad Mohty (Israel)

TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS

REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS

Chiara Mainardi, Giulia Reggiani, Manuela Tumino, Antonio Marzollo, Elisabetta Calore, Marta Pillon, Maria Vittoria Gazzola, Roberta Destro, Daniela Bovo, Piero Marson, Tiziana Tison, Anna Colpo, Alessandra Biffi (Italy)

THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES

PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS

Maryam Pourabdollah, Christine Cserti, Dennis Dong Hwan Kim, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerblitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michalis, Nayana Sondi, Jacob Pendergrast (Canada)

IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT

DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS

DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

Jose Ros Soto, John A Snowden, Richard Szydlo, Emma Nicholson, Alejandro Madrigal, Sandra Easdale, Mark Ethell, Mike Potter, Chloe Anthias (United Kingdom)

DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT

CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES
Scientific Programme

DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT
Alexandra Semchenkova, Vladimir Zhogov, Varvara Brilliantova, Olga Illarionova, Larisa Shelikhova, Michael Maschan, Alexander Popov (Russian Federation)

ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMERAISM AFTER HSCT

DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY
Rebecca Lloyd, Graham McIlroy, Nervana Abou-Zeid, Claire Horgan, Richard Lovell, Bhuvan Kishore, Julie Suhr, Charmaine Campbell, Kathleen Holder, Beena Salhan, Shankara Paneesha, Emmanouil Nikolousis, Alexandros Kanellopoulos (United Kingdom)

MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS

PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY
Etai Adam, Elad Jacoby, Bella Bielorai, Natalia Ilin, Daphna Hutt, Amos Toren (Israel)

Non-haematopoietic stem cells

THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED IN Variant T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Judith Schaffrath, Ole Vollstädt, Jana Lützkendorf, Christiane Katzerke, Josephine Schneider, Lisa Maria Siol, Mascha Binder, Lutz P. Müller (Germany)

ANALYSIS OF THE GENETIC STABILITY OF DONORS’ BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION

EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON’S JELLY MESENCHYMAL STEM CELLS

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS
Maciej Rojek, Michał Piątek, Izabela Zdolińska-Malinowska, Dariusz Boruczkowski (Poland)

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS

A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?
Seung Yun Yoon, Sung Kyu Park, Jong-Ho Won (Korea, Republic of)
Paediatric issues

HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?
Su Han Lum, Zohreh Nademi, Terry Flood, Andrew Cant, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

A 'RISK-ADJUSTED' CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TRESOSULFAN BASED CONDITIONING REGIMEN
Brigitte Strahm, Ayami Yoshimi, Miriam Erlacher, Michael Albert, Jochen Buechner, Birgit Burkhart, Barbara De Moerloose, Kristian Kallay, Peter Lang, Ricardo Masetti, Roland Meisel, Herbert Pichler, Ansgar Schulz, Karl-Walter Sykora, Dominik Turkiewitz, Franco Locatelli, Charlotte Niemeyer (Germany)

PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCRαβ/CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS
Lisa V.E. Oostenbrink, Alexandra Laberko, Elvira Sultanova, Els C.M. Jol-van der Zijde, Anja M. Jansen-Hooogendijk, Carly Vervat, Dmitry Pershin, Maria Fadeeva, Ivan Vladimirov, Robbert G.M. Bredius, Maarten J.D. van Tol, Michael Maschan, Marco W. Schilham, Dmitry Balashov, Arjan C. Lankester (Netherlands)

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA
Sunil Bhat, Revathi Raj, Arun Danewa, Gaurav Kharya, Biju George, Mehdi Intezar, Neha Rastogi, Vikram Mathews, Badiger Shobha, Atish Bakane, Ramya Uppuluri, Satya Prakash Yadav (India)

IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES
Claus-Philipp Majer, Friedhelm Schuster, Bernd Gruhn, Roland Meisel, Patrick Schlegel, Anne-Marie Lang, Wolfgang Schwinger, Tobias F. Feuchtinger, Holger Martinius, Rupert Handgretinger, Peter Lang (Germany)

OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR
Olesia Paina, Zhemal Rakhmanova, Polina Kozhokar, Anastasia Frolova, Lubov Tsvetkova, Kirill Ekushov, Inna Markova, Sergey Bondarenko, Elena Babenko, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE
Rajat Bhattacharyya, Ah Moy Tan, Michaela Su Fern Seng, Mya Nwe Soe, Prasad Iyer, Anh Thi Ngoc, Vijayakumari K, Wing Leung (Singapore)

GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT
Marc Ansari, Kateryna Petrykey, Mohammad Aziz Rezgui, Veronica Del Vecchio, Jacques Cortyl, Reginald-Olivier Ralph, Tiago Nava, Patrick Beaulieu, Pascal St-Onge, Simona Jurkovic Mikar, Patricia Huezo-Diaz Curtis, Chakrathara Rao S. Uppugunduri, Laurence Lesne, Yves Theoret, Yves Chalandon, Imke H. Bartelink, Jaap-Jan Boelens, Robbert G. M. Bredium, Jean-Hughes Dalle, Victor Lewis, Bill S. Kangarloo, Christina Peters, Daniel Sinnet, Henrique Bittencourt, Maja Krajinovic (Switzerland)
Scientific Programme

HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES
Francesco Saglio, Massimo Berger, Manuela Spadea, Francesca Carraro, Rosanna Pessolano, Paola Quarello, Elena Vassallo, Franca Fagioli (Italy)

THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY
Nicholas Gloude, Christopher Dandoy, Stella Davies, Kasiani Myers, Michael Jordan, Rebecca Marsh, Ashish Kumar, Jack Blessing, Ashley Teusink-Cross, Sonata Jodele (United States)

LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY
Blanca Molina Angulo, Marta Gonzalez Vicent, Ivan Lopez Torija, Ana Castillo, Manuel Ramirez, Miguel Angel Diaz Perez (Spain)

DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)
Marta Gonzalez Vicent, Cristina Diaz de Heredia, Jesus Gonzalez de Pablo, Blanca Molina, Alexandra Regueiro, Antonio Perez, Pilar Palomo, Laura Prieto, Estefania Garcia, José María Fernández, Ariadna Pérez, María José Jiménez, Manuel Regueiro, Carlos Vallejo, Ana Isabel Gallardo, Oriana López, Ana Benito, Julia Marsal, Mónica Lopez, Leyre Bento, Isabel Badell, Alexandra Pedraza, Ana Jimenez, Pedro Gonzalez, Mi Kwon, Lissette Costilla, Cristina Belendez, Albert Esquirol, Ildefonso Espigado, Esperanza Lavilla, Miguel Angel Diaz (Spain)

NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN’S LYMPHOMA

HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES
Fanette Bernard, Caroline de Pesters, Claire Galambrun, Mary Slatter, Charlotte Jubert, Nicolas Von der Weid, Eva De Berranger, Cecile Renard, Ben Carpenter, Benedictie Neven, Fanny Rialland, Jean-Hugues Dalle, Persis Amrolia, Marc Ansari, Catherine Paillard (Switzerland)

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)

IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES
Poh Lin Tan, Chintan Vyas, Mariflor Villegas, Frances Yeap, Teck Guan Soh (Singapore)

THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS

SINGLE-CENTER EXPERIENCE OF TCRβ/CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA
Svetlana Radygina, Larisa Shelikhova, Irina Shipitsina, Yulia Skvortsova, Anna Vasilieva, Svetlana Kozlovskaya, Rimma Khismatullina, Anna Livshits, Alexei Maschan, Michael Maschan, Dmitry Balashov (Russian Federation)
DETECTION OF RECIPIENT-SPECIFIC α/β-T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSC: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL
Ladislav Król, Dominik Turkiewicz, Stig Lenhoff, Annika Hult, Annika Kisch, Mari-Louise Römbo, Lisette Hollender, Ingrid Øra, Josefina Dykes (Sweden)

IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY
Marek Ussowicz, Aleksandra Wieczorek, Agnieszka Dłuźniewska, Anna Pieczonka, Katarzyna Drabko, Robert Dębski, Jolanta Goździk, Jacek Wachowiak, Walentyna Balwierz, Daria Handkiewicz-Junk (Poland)

THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS

USE OF RIC REGIMENS COMBINED WITH TCRαβ DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT
Peter Lang, Michaela Doering, Anne-Marie Lang, Patrick Schlegel, Christian Seitz, Robin Fischer, Marina Schmidt, Martin Ebinge, Ursula Holzer, Ines Brecht, Rupert Handgretinger (Germany)

THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES
Manuela Tumino, Giulia Reggiani, Chiara Mainardi, Elisabetta Calore, Antonio Marzollo, Elisa Carraro, Maria Vittoria Gazzola, Roberta Destro, Matteo Barioni, Aurora Strano, Marta Pillon, Alessandra Biffi (Italy)

CLINICAL IMPLICATION ON RECOVERY OF γδ T CELLS AFTER TCRαβ-DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE
Eun Seok Choi, Sung Han Kang, Jin Kyung Suh, Hyeri Kim, Kyung Nam Koh, Ho Joon Im (Korea, Republic of)

EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL
Angela María Trujillo Gaviria, Amado Jose Karduss U, Gloria Suarez, Angelica Cardona, Monica Ramirez, Jose Betancurt (Colombia)

FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
Katelynn Brodigan, Lindsay Frazier, Christine Duncan, Richard Yu, Marc Lauffer, Brent Weil, Elizabeth Ginsburg, Serena Srouji, Leslie Lehmann (United States)

VENO-OCLUSION DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE
Aharon Gefen, Shirley Pollack, Irina Zeidman, Neta Nevo, Israel Eisenstein, Daniella Magen, Myriam Weyl-Ben Arush (Israel)

OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW

THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL
Lubov Tsvetkova, Olesya Paina, Zhemal Rakhmanova, Polina Kozhokar, Anastasia Frolova, Kirill Ekushov, Inna Markova, Sergey Bondarenko, Elena Babenko, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)
Scientific Programme

T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION
Nobuhisa Takahashi, Shogo Kobayashi, Hideki Sano, Kazuhiro Mochizuki, Yoshihiro Ohara, Hitoshi Ohto, Kazuhiiko Ikeda, Atsushi Kikuta (Japan)

HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019
Rebecca Fisher, Jun Cai, Peter Shaw, Melissa Gabriel (Australia)

EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE
Ho Joon Im, Eun Seok Choi, Sung Han Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh (Korea, Republic of)

LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT
Erik von Asmuth, Marco Schilham, Hein Putter, Alexander Mohseny, Arjan Lankester (Netherlands)

BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS: A MULTICENTER STUDY
Massimo Berger, Francesco Saglio, Maura Faraci, Aracangelo Prete, Franca Fagioli (Italy)

NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION
Uwe Thiel, Sebastian Schober, Andreas Ranft, Susanne Jabar, Hendrik Gaßmann, Peter Bader, Ewa Koscielniak, Bernd Gruhn, Uta Dirkse, Jürgens Heribert, Stefan Burdach, Peter Lang (Germany)

ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE
Eman Khattab, Abdelghani Tbakhi, Rula Najjar, Mayada Abu Shanap, Rawad Rihani, Hasan Hashem, Wafa Hdeib, Rawan Abed Alrahman, Du‘A Darabseh, Nilly Hussein, iyad Sultan (Jordan)

STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY
Olga Moser, Arnaud Dalissier, Wilhelm Woessmann, Birgit Burkhardt, Karin Mellgren, Andre Manfred Willasch, Udo Kontny (Germany)

FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY
SUCCESSFUL HSCT IN IMMUNE DISREGOLATORY DISEASES

LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS
Davide Leardini, Daniele Zama, Edoardo Muratore, Andrea Tozzi, Teresa Papaleo, Francesco Bacelli, Tamara Belotti, Elena Legnani, Arcangelo Prete, Andrea Pession, Riccardo Masetti (Italy)

RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING’S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Zahra Hudda, Montserrat Cols Vidal, Susan Prockop, Richard O'Reilly, Nancy Kernan, Jayanta Chaudhuri (United States)

‘INCURABLE’ PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS
Mariflor Villegas, Yeap Frances, Doris Tan, Poh Lin Tan (Singapore)
EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE

SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES
Cristina Jercan, Ana Maria Bica, Letitia-Elena Radu, Alexandra Ionete, Ileana Constantinescu, Carmen Calugaroiu, Aurora Dragomiristeantu, Anca Colta (Romania)

IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?
Victoria Bordon, Patrick Verloo, Catharina Dhooge (Belgium)

TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS
Kenji Kishimoto, Daiichiro Hasegawa, Sayaka Nakamura, Akihiro Tamura, Aiko Kozaki, Asturo Saito, Toshiaki Ishida, Takeshi Mori, Yoshiyuki Kosaka (Japan)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE
Hila Rosenfeld Keidar, Amit Dotan, Sabina Edelman, Ronit Elhasid (Israel)

CONDITIONING FOR RETRANSLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED
Sarah Maria Bauer, Mehtap Sirin, Kerstin Felgentreff, Eva-Maria Jacobsen, Klaus-Michael Debatin, Ansgar Schulz, Manfred Hoenig (Germany)

TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS
Kinan Kafa, Claudia Bettoni da Cunha-Riehm, Tayfun Güngör, Jan-Henning Klusmann (Germany)

EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML
Zhemal Rakhmanova, Olesia Paina, Polina Kozhokar, Anastasias Frolova, Lubov Tsvetkov, Kirill Ekushov, Elena Babenko, Tatyana Gindina, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS
Johannes Raedler, Sita Heyde, Marie Kolokythis, Anna Eichinger, Vera Binder, Tobias Feuchttinger, Michael Albert (Germany)

HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS

USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHematological DISEASES
Nicoletta Abram, Valentina Baretta, Federico Mercolini, Gloria Tridello, Margherita Mauro, Simone Cesaro (Italy)

PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS
Scientific Programme

CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?
Victoria Bordon, Kathleen De Waele, Sophie Van Lancker, Catharina Dhooge (Belgium)

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES

NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT
Iván López Torija, Marta Gónzalez Vicent, Blanca Molina Angulo, Jesús González de Pablos, Miguel Ángel Díaz Pérez (Spain)

PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS
Johanna Schepp, Mehtap Sirin, Kerstin Felgentreff, Carolin Grimm, Klaus-Michael Debatin, Ansgar Schulz, Manfred Hoenig (Germany)

THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE
Poonam Lumb, Neil Tickner, Josu De La Fuente, Leena Karnik, Sandrine Bremathas (United Kingdom)

THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE

SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN

HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE

Regenerative medicine

WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER
Izabela Zdolina-Malinowska, Magdalena Chrościńska-Krawczyk, Michał Piątek, Maciej Rojek, Dariusz Boruczkowski (Poland)

MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS
Agata Borowik, Arkadiusz Janusz, Janusz Lange, Danuta Sosnowska, Emilia Jaskula, Andrzej Lange (Poland)

OSTEOGENIC DIFFERENTIATION CAPABILITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE
Hee-Hoon Yoon, In Keun Jang, O Kyu Noh, Jang Hoon Lee, Kwang Chul Lee, Jun Fun Park (Korea, Republic of)

Solid tumours
SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS
Sara Redondo Velan, María Calbacho Robles, Doris Elizabeth Cueva Arica, Maria Liz Paciello Coronel, Buenaventura Buendia Ureña, Ana Jimenez, José María Sanchez Pina, Daniel Castelliano, Guillermo De Velasco, Rosa Ayala Díaz, Joaquín Martínez López (Spain)

VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS
Wiebke Biehl, Akira Hattesohl, Rudolf Jörres, Thomas Duell, Ulrike Althöhn, Rembert Koczulla, Helga Schmetzer (Germany)

IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
Yanmin Zhao, Fei Gao, Yibo Wu, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Xiaoyu Lai, He Huang (China)

INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION

FAVORABLE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION FOR PATIENTS WITH HIGH-RISK HEMATOLOGICAL DISEASES: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS

HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY
Aurora Vassanelli, Denise Pavone, Simona Pollichieni, Nicoletta Sacchi (Italy)

ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSHAMIDE IN PATIENTS WITH INHERITED DISORDERS
Tatiana Bykova, Anna Osipova, Varvara Ovetchkina, Anna Dotcenko, Alexander Galimov, Alexander Alyanskiy, Ivan Molisev, Alexander Kulagin, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Min Kyoun Kim, Sung Hwa Bae, Je-Hwan Lee, Ho Sup Lee, Sung-Nam Lim, Won Sik Lee, Jung-Hee Lee, Eun-Ji Choi, Han-Seung Park, Sun-Hye Ko, Kyoo-Hyung Lee (Korea, Republic of)

THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION

IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER’S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL
Mutlu Arat, Nurcan Ozcelik, Deniz Goren Sahin, Tulay Ozcelik (Turkey)

YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY

DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS: A MONOCENTRIC EXPERIENCE OF 48 PATIENTS
Samia Harbi, Raynier Devillier, Sabine Furst, Angela Granata, Thomas Pagliardini, Luca Castagna, Faezeh Legrand, Christian Chabannon, Claude Lemarie, Boris Calmels, Maud Cecile, Cecile Braticevic, Pierre Jean Weiller, Didier Blaise (France)

COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS
Yolanda Gonzalez Romero, Joan Manuel Mora, Sara Fernandez-Luis, David Gomez-Lamas, Jose Calvo-Sanchez, Sergio Fernandez-Garcia, Jose Luis Arroyo, Aranzazu Bermudez, Enrique Ocio, Lucrecia Yañez (Spain)

HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES
Yongqiang Zhao, Yanzhi Song, Fan Yang, Zhihui Li, Min Jiang, Tong Wu (China)

EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS
Alena Hlaz, Ihar Iskrou, Olga Krasko, Anatoly Uss (Belarus)

IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY
HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRÍN

OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS
Jennifer Kaivers, Isabela Niculae, Elke Porbadnik, Christina Rautenberg, Esther Schulter, Jürgen Enczmann, Rüdiger Sorg, Johannes Fischer, Mustafa Kondakci, Rainer Haas, Ulrich Germing, Thomas Schroeder, Guido Kobbe (Germany)

THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES
Amir Ali Hamidieh, Alieh Safari-Sharari, Rashin Mohseni, Mahnaz Jamee, Zeynab Nifetrat, Leila Hejazipour, Hamideh Keykani, Fahimeh Jafari, Pouria Salajegheh, Maryam Behfar (Iran, Islamic Republic of)

DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA
CD8+γδ T CELLS DISPLAY ADAPTIVE-LIKE PHENOTYPE IN CMV SEROPOSITIVE BONE MARROW GRAFTS
Ahmed Gaballa, Lucas Arruda, Emelie Rådestad, Michael Uhlin (Sweden)

A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS
Eun Jung Ioo, Jongheon Jung (Korea, Republic of)

WITHDRAWN OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE
OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING
Seug Yun Yoon, Seong Kyu Park, Se Hyung Kim, Sung Hee Lim, Jong Ho Won, Dae Sik Hong (Korea, Republic of)

HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Seug Yun Yoon, Min-Young Lee, Namsu Lee, Sung Kyu Park, Jong-Ho Won (Korea, Republic of)

HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION
Ksenia Boriskina, Per Ljungman, Lyda Osorio Fernandez, Stephan Mielke (Sweden)

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE

Stem cell mobilization, collection and engineering

A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION

PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF

DEPLETION OF αβ T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES

ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS
Franziska Olm, Hooi Ching Lim, Katharina Schallmoser, Dirk Strunk, Thomas Laurell, Stefan Scheding (Sweden)

FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BEYOND STEM CELLS - DOES IT MATTER WHAT’S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?
Holly Emms, Dara Qadir, Rowayda Peters, Claire Wiggins, Oliver Gittner, Andy Drake, Matthias Klammer (United Kingdom)

EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS
Jeong-A Kim, Misuk Yang, Youngrok Park, Young Hoon Park, Jae-Yong Kwak (Korea, Republic of)
LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS
Anu Partanen, Antti Turunen, Jaaakkoo Valitola, Kaija Vasala, Lasse Ägren, Karri Penttilä, Marja Pyörälä, Taru Kuittinen, Pentti Mäntymaa, Jukka Peltonen, Esa Jantunen, Ville Varmavuo (Finland)

MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS
A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS
Evaluation of Via Freezetm Quad for Liquid Nitrogen-Free CGMP-Compatible Controlled-Rate Freezing of Hematopoietic Progenitor Cell Grafts
Bechara Mfarrej, Olivier Vicari, Sophie Thevenet, Kerjean Elodie, Claude Lemarie, Christian Chabannon, Boris Calmels (France)

CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS
PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY
Performance Qualification of Lovotm Medical Device for Washing and Concentrating 3 and More Hematopoietic Progenitor Cell Cryopreserved Bags
Bechara Mfarrej, Guillaume Bouchet, Jerome Couquiaux, Lionel Regimbaud, Sophie Thevenet, Elodie Kerjean, Claude Lemarie, Christian Chabannon, Boris Calmels (France)

FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS
Isaac Yaniv, Tsippi Kestenbom, Sigal Manor, Bracha Zisser (Israel)

LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS
Antonio José Palma Vallellano, Rocío Zapata Bautista, Carmen Beltrán, Margarita Bendala, Ana R. Carranco, Miguel A. Castilla, Blanca Díaz, Juan Francisco Domínguez, Francisco Fernández, Encarnación Gil, Karol Gómez, Susana Ramírez, Juan Nicolás Rodríguez, María Solé, Pilar Velarde (Spain)

FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS
The Impact of Plerixafor 'On Demand' on the Hematopoietic Stem Cell (HSC) Collection, Product's Quality and Engraftment
Simona Maria Muggianu, Maria Celentano, Paolo Palmieri, Cira Riccardi, Salvatore Palmieri, Mariangela Pedata, Daniela Graziano, Barbara Scarpati, Raffaella Casaburi, Claudio Falco, Mirella Alberti, Lidia Altomare, Mario Toreiello, Assunta Viola, Felicetto Ferrara, Alessandra Picardi, Michele Vacca (Italy)

ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN
Influence of the DMSO Wash Strategy on Adverse Reactions During Infusion of Hematopoietic Progenitors
Bone Marrow Donor Characteristics: Influence on Harvest Yield and Donor Recovery
Eva Zoubek, Jose Ros-Soto, Richard Szydlo, Adam Watson, Catherine Burtlon, Paul Johnson, Ann O'Leary, Chloe Anthias (United Kingdom)
Scientific Programme

PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED
Paul Miller, Janet Baker, Crischi Magsipoc, Joy Brennan, Maria Mulligan, Janet Wells, Helen McDonald, Kevin Boyd, Martin Kaiser, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Emma Nicholson (United Kingdom)

EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES
Izabela Zdolińska-Malinowska, Maciej Rojek, Michał Piątek, Dariusz Boruczkowski (Poland)

OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA

AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS

RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS
Limor Horev Azaria, Yakov Sverdlov, Michal Pearl-Yafe, Orad Shemesh, Alon Kalo, Dana Greenfeld, Jerry Stein (Israel)

CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES
Jacob Kalin, Anh Thy Nguyen, Benjamin Oshrine (United States)

MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD
Kathleen Deiteren, Jean-Philippe Defour, Kornelia Hummel, Holger Boysen, Hans Salwender, Jan-Dirk Studt, Antoine Mairesse, Katrien Vermeulen, Dominik Heim, Dimitrios A. Tsakiris (Switzerland)

IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE
Valarmathi Anandhan, Emma Searle, Jaya Sudhir, Alberto Rocci (United Kingdom)

TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE
Carmen Albo López, Concepción Andon, Dolores Villariño, Esperanza Lavilla, Julio Del Río, Cristina Fonte, Angeles Cobas (Spain)

AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION-PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA
Mona Najib, Ahmed Alsaeed, Ihab Hemaidi, Sameer Al Amoudi, Mohammed Mohammad (Saudi Arabia)

REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE
Eileen Butler, Noeleen Comey, Cormac Owens (Ireland)

UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT
Naziha Menasria, Javid Gaziev, Ruba Yasin Taha, Karama Makni, Halima El Omri, Afraa Mustafa Suleiman Fadul, Weam Zaid El Roz, Ayan Guled, Manal Yaghmour, Rola Sami Al Chahabi, Ajaeb Dakhilalla M H Al-Nabet (Qatar)

LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS
Zdenka Gasova, Zdenka Bhuiyan-Ludvikova, Martina Bohmova, Marketa Sloukova, Pavla Pecherkova, Jan Vydra (Czech Republic)
COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION
Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Raya Chagneh Lorestani (Iran, Islamic Republic of)

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Stem cell source

IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP
Itaru Kato, Hirotoshi Sakaguchi, Shunichi Kato, Maho Sato, Maiko Noguchi, Nao Yoshida, Masami Inoue, Yoshiko Hashii, Ken Tabuchi, Yoshiko Asutsu, Satoko Morishima, Junya Kanda (Japan)

CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION
Michiko Taniguchi, Dongyun Yang, Salman Otoke, Haris Ali, Shukaib Arsalan, Chattada Karanes, David Snyder, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura, Auayporn Nademanee, Ketevan Gendzekhadze, Monzr M. Al Malki (United States)

ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS
THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION

COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES
Yin Jie Koh, Ian Wu, Yeh Ching Linn, Lip Kun Tan, Michelle Poon, Liang Piu Koh (Singapore)

USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD
CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION
Nelli Bejanyan, Irina St Louis, Hesham Mohei, Qing Cao, Najla El Jurdi, Claudio Brunstein (United States)

REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT
Vipul Sheth, Fernanda Volt, Jaime Sanz, Laurence Clement, Jan Cornelissen, Didier Blaise, Jorge Sierra, Mauricette Michallet, Riccardo Saccardi, Eliane Gluckman, Christian Chabannon, Annalisa Ruggeri (United States)

COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE
Mizuki Watanabe, Shosuke Ohtera, Junya Kanda, Shusuke Hiragi, Tomohide Iwao, Tomohiro Kuroda, Akifumi Takaori-Kondo, Genta Kato (Japan)
ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES
Tomoe Ichiki, Tatsunori Goto, Yosuke Domon, Kohei Ishigiwa, Kenichiro Takeda, Motohito Okabe, Yuka Kawaguchi, Rena Matsumoto, Marie Ohbiki, Masahide Osaki, Takanobu Morishita, Yukiyasu Ozawa, Koichi Miyamura (Japan)

HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTITHYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL
Junya Kanda, Toshihiko Ando, Shun-Ichi Kimura, Shin-Ichiro Fujiwara, Kazunori Imada, Shin Fujisawa, Takayoshi Tachibana, Yoshide Atsuta, Yoshinobu Kanda (Japan)

INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES

ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOSOFAVIDE (PT-CY) SCHEDULE

MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON’S JELLY

EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Pharmacology

CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT

OPTIMAL DOSE CONVERSION RATIO DURING SWITCHOVER FROM INTRAVENOUS TO ORAL FORMULATION OF TACROLIMUS AMONG PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C Versus CREATININE

USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE

Page 143 / 203
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
30 August - 2 September 2020,
Madrid, Spain

Scientific Programme

ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN

DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY

OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACO-COST ANALYSIS

PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOYETIC PROGENITORS TRANSPLANTATION
Maria Saez-Garrido, Alberto Espuny-Miro, Agustina Ruiz-Gomez, Miguel Almanchel-Rivadeneyra, Andres Sanchez-Salinas, Maria Sacramento Diaz-Carrasco (Spain)

EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA
Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Nastaran Ahmadi Rad, Roya Chagneh Lorestani (Iran, Islamic Republic of)

Quality Management

IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE
Tina Cirman, Vesna Galvani, Primož Poženel, Marko Cukjati (Slovenia)

TIPS FOR GENERATING SUCCESSFUL 'TEAMWORKING' IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER
Simone Biagini, Mario D'Angelo, Giuseppina Li Pira, Elia Girolami, Valentina Cirillo, Maria Giuseppina Cefalo, Gianpiero Conflitti, Pietro Merli, Mattia Algeri, Federica Galaverna, Annalisa Ruggeri, Vincenzo Iaconianni, Franco Locatelli (Italy)

NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE
Ann-Mari Berthelsen, Jeanette Holder, Camilla Borch Jacobsen, Søren Lykke Petersen, Anne Fischer-Nielsen (Denmark)

FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT
Marie Dobrovolna, Jan Vydra (Czech Republic)
PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK

MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION

DIGITAL JACIE AT THE CHRISTIE

INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE

AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lea Brandt Kristensen, Stine Skriver Bregenov (Denmark)

QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN
Gracia Bravo, María Jesús Lorenzo, Emilio Ojeda, María Esther Martínez-Muñoz, Guiomar Bautista, Carlos de Miguel, Carlos Vilches, Rafael Cabrera, Rafael Duarte (Spain)

GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT
Beatriz Duran Jimenez, Jane Kinsella, Wendy Ogden, Simon Jones, Brian Bigger, Robert Wynn (United Kingdom)

UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HEMATOLOGICAL DISORDERS
Gülay Sezgin, Asiye Yaylaci, Ilker Ünal, Ibrahim Bayram (Turkey)

COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS

EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT
Wendy Ogden, Beatrix Duran (United Kingdom)

HAEMATOPOIETIC PROGENITOR CELL PROFICIENCY TESTING
Karieshma Kabani, Kon Zarkos, Craig Wright, Stephen Larsen (Australia)

VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)
Craig Wright, Julie Allerton, Karieshma Kabani, Kon Zarkos (Australia)

START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN
Malene Bokinge (Sweden)
ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY
James Pittson (United Kingdom)

INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION

CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA
Hyun Jung Lee, Myung Hee Chang, Hae Yong Pak (Korea, Republic of)

LEUKEMIA AND ITS TYPES

DATA MANAGEMENT

OPTIMIZING CYCLOSPORINE (CSA) DOSE POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC CANCER PATIENTS
Mennatallah Sh Elnaqgar, Hanafy Hafez, Amr Abdalla, Mahmoud M Hamza, Marwa M Khalaf, Alaa El-Haddad (Egypt)

SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?
Camilla Roepstorff, Heidi Petersen (Denmark)

ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT
Rachel Pearce, Julia Lee, Ruth Paul, Marie Wilson, Clementina Abamba, Kim Orchard (United Kingdom)

MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS
Xiu-Wen Liao, Jia-Hau Liu, Ming Yao, Bor-Sheng Ko, Cheng-Hong Tsai, Shang-Ju Wu, Shang-Yi Huang, Sheng-Chieh Chou, Hui-Hsuan Huang, Tai-Chung Huang, Hsin-An Ho, Wen-Chien Chou, Feng-Ming Tien, Jih-Luh Tang (Taiwan, Republic of China)

STATISTICS

USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Chloé Pasin, Ran Reshef, Andrew J Yates (United States)

THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW

GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS
Mark Barrios, Christopher Arthur, Keith Fay, Ian Kerridge, William Stevenson, Jad Othman, Julija Sipavicis, Cassandra Reid, Kelly Wong, Matthew Greenwood (Australia)
Scientific Programme

Poster Sessions
09:00 - 18:00
Poster Area (Exhibition Area)

Nurses Posters - Adult

UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS
Xia Yan, Ting Wang, Wei Hu, Xiaodong Xu, Shujia Liu (China)

AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION

EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?
C Eeltink, B Lissenberg, I Nauta, J Rood, L Incroci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY
Marco Cioce, Laura Orlando, Stefano Botti, Gianpaolo Gargiulo (Switzerland)

SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TUMORED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM

DEVELOPING A BESPOKE EDUCATION PACKAGE TO ENSURE THE SAFE DELIVERY OF IMMUNE EFFECTOR CELLS ON AN ONCOLOGY CLINICAL RESEARCH FACILITY

DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kader Caliskan, Gulbeyaz Can (Turkey)

THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kwan Suk Jo, Seung Nam Zang, Ga Yeon Kim, Hye Yun Cho, Yang Sook You (Korea, Republic of)

PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS’ PERSPECTIVE
Noemi Gianni, Tania Arthurs, Yvonne Patefield-Smith, Kirsten Rendall, Jo Wyatt, Rachel Miller (United Kingdom)

REDUCING ANTITHYMOCYTE GLOBULIN (ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA
Suha Alkhraisat, Moussab Dalmai, Maybelle Ballil, Samer Ghazi, Innaam Shehab eddine, Isam Mahasneh, Bader Ahmari, Heba Alshobaki, Mohsen Alzahrani (Saudi Arabia)

NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE

NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS

NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS
Roberta Gironi, Marco Fabbrini, Daniela Clerici, Chiara Oltolini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Antonella Biella (Italy)
THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION

Ting Wang, Xia Yan, Linnan Wang, Xinxin He, Boning Liu (China)

EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR

ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS

Llara Roca Gimeno, Elisabeth Lazaro Lora, Marta Yusta Arnal, Iria Gonzalez Alvarez (Spain)

PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY

C Eeltink, L Incrocci, I Verdonck-de Leeuw, S Zweegman (Netherlands)

CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS

Jennefer Rose, Sophie Jones, Wendy Ingram (United Kingdom)

THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION

Lara Rowley, Amanda Ellis, Denise Wareham, Daja Barton, Emma Shaw, Olivia Hilsdon, Francesca Toselli, Shirley Hudson (United Kingdom)

VENO-OCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY

Marie Waller, Christopher Heron, Hayley Dyos, Eleni Tholouli (United Kingdom)

RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION

Lian Schoonhoven-Bos (Netherlands)

PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE

THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY

PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION

Sinju Thomas, Adrien Quintela, Arthi Anand, Karen Bradley (United Kingdom)

INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA

SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING

Luke White, Kathryn Vowden (United Kingdom)

TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS

NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE

USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION

Anncarin Svanberg (Sweden)

THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER
Scientific Programme

NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS
Lorella Cappucciati, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubbelini, Andrea Contini (Italy)

RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL
Lorella Cappucciati, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubbelini, Andrea Contini (Italy)

GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION

IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY

RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

ARE TYPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?
Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME
Lucília Carreiro, Carla Gonçalves, Fátima Pereira, Rosa Romão, Cândida Damião (Portugal)

LEADERSHIP - LEADING THE TEAM
Klara Kabatova Maxova (Czech Republic)

PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT
Lorella Cappucciati, Fabio Pollini, Vincenzo Matteo Quitaldano, Ramona Patras, Angelica Cravedi, Maria Teresa Borsotti, Ilaria Filati, Rosaria Scopelliti, Cinzia Merlini, Andrea Contini, Mirella Gubbelini (Italy)

AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY
Lucília Carreiro, Rosa Romão, Candida Damião (Portugal)

PAIN ASSESSMENT IN ONCO.HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)
Lorella Cappucciati, Giovanna Buonanno, Corrado Gozzo, Francesco Oleari, Raffaella Maestri, Noemi Paladini, Patrizio Imbriani, Lucrezia Maria Zagnoni, Sara Posla, Mirella Gubbelini, Andrea Contini (Italy)

IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!
Isabel Salcedo, Esther Ortiz, Juana María Acebes, Mari Luz Pascual, Beatriz Sanchez Sevillano, Almudena Laiglesia, Ana Alarcón, Rafael F Duarte (Spain)

INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY
Poonam Thorat, Meera Sharad Achrekar, Deepti Ghonge (India)

COMPLETION TIME TO HLA TYPING

GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
Scientific Programme

Poster Sessions
09:00 - 18:00

Nurses Posters - Paediatric

EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA
Kim van der Niet, Lisa Rozendaal, Dagmar Berghuis, Eileen van der Stoep-Yap, Erik von Asmuth, Maria de Taeye-Veldhuizen, Arjan Lankester, Hilda Mekelenkamp (Netherlands)

CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE
Ida Bremer Ophorst, Tineke Terlouw (Netherlands)

SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEPIENTS: A SINGLE CENTER EXPERIENCE
Rosanna Ceresoli, Stefano Benvenuti, Patrizia Bevilacqua, Mirella Savoldi, Fulvio Porta (Italy)

PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES
Rosanna Ceresoli, Stefano Benvenuti, Emilio Ferrari, Fulvio Porta (Italy)

TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT
Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS
Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?
Almudena Pérez, Alba Martínez, Anna Negre, Laura Lahuerta (Spain)

CARING FOR MINOR SIBLING DONORS
Eugenia Trigoso Arjona, Estrella Larios Reyes, Maria Sol Abert Velert (Spain)

EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME
Anna Tailby, Julia Nixon, Alison Bridgman, Angela Burns, Abigail Cotton, Hannah Ezard, Josephine Nicholls, Melanie Rooney, Elisabeth Thomas, Ilian Uri, Marita Macken, Sarah Lawson, Martin English (United Kingdom)

EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES
Bart Maertzdorf, Anouk Jongekrijg (Netherlands)

RISK ASSESSING PAEDIATRIC PATIENTS’ NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT

Nurses Posters - Research

NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE
Carmen Conde, Ariadna Domenech, Iria González, Verónica Linde Blazquez, Eugenia Trigoso Arjona, Julia Ruiz Pato (Spain)
CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH
Yun Fang, Minjie Liu, Chen Xie (China)

ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT

MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP
Yaya Song, Xiaming Zhu, Yin Lu, Yongqin Ge, Qin Li, Fang Tang, Ying Chen, Yaohong Li (China)

VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APERESIS UNIT
Isabel Salcedo, Angela Salas, Laura Vicente, Lucia Paola Cuéllar, Virginia Infante, Carmen de la Puente, Jose Luis Bueno (Spain)

A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL
Shreya Ludbe, Meera Sharad Achrekar, Rynel Quadras (India)

DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?

ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE

SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS
Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, María Cabezas López de Sosoaga, Montserrat Pilar Barrilero Lopez (Spain)

A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA
Bhushan Shelar (India)

ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT
Cristina Alberquilla Ramos, Salvadora Aleza Estera, Josefa Navarrete Ruiz, Beatriz Alonso González, Rocío Rico Muñoz, Ana Isabel Torre Polo, Pilar Herreros López, Julia Ruiz Pato (Spain)

SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY
Yaohong Li, Xiaming Zhu, Yin Lu, Fang Tang, Yongqin Ge, Qin Li, Ying Chen, Yaya Song (China)

---

**Multi-stakeholder Forum on Innovative Cellular Therapies**
09:30 - 10:30
Sala Retiro

**MF2, Multi-stakeholder Forum on Innovative Cellular Therapies: The regulatory framework for new therapies for Dummies**

**Chairs:**
Mark Lowdell (United Kingdom)
Christian Chabannon (France)

The development of new ATMPs from an academic perspective: Hurdles and opportunities
Collin de Haar (Netherlands)
Scientific Programme

**National view**
Blanca García-Ochoa (Spain) 09:50 - 10:10

**Real-world regulatory issues in the implementation of Advanced Therapies**
Encarnación Cruz Martos (Spain) 10:10 - 10:30

---

**Plenary Session**
11:00 - 12:30  N103

**P3, Patient Reported Outcomes - A new paradigm in HSCT**

**Chairs:**
Rafael Duarte (Spain)
Hélène Schoemans (Belgium)
Guy Bouguet (France)

Do PRO predict HSCT outcome? 11:00 - 11:22
Bronwen Shaw (United States)

Optimizing the management of GVHD using patient reported outcome measures 11:22 - 11:44
Rubeta Matin (United Kingdom)

Patient-Reported Outcomes in CAR T-cell therapy 11:44 - 12:06
Anna Barata (United States)

Integrating the patient in HSCT research projects 12:06 - 12:28
Linda Burns (United States)

---

**Workshop**
11:00 - 12:30  Hall A (Exhibition Area)

**W7, CARs beyond T-cells: A focus on next generation CAR-NK cells**

**Chairs:**
Joaquín Martínez-López (Spain)
Katy Rezvani (United States)

CAR NK-cells as an “off the shelf” immunotherapy 11:00 - 11:30
Ulrike Köhl (Germany)

CAR-NK cells against haematological malignancies 11:30 - 12:00
Katy Rezvani (United States)

Atypical CAR-NKG2D cells - natural receptor/ligand to target tumors 12:00 - 12:30
Antonio Pérez-Martínez (Spain)
Scientific Programme

Workshop
11:00 - 12:30
Hall B (Exhibition Area)

W8, Controversies in patients with DLBCL

Chairs:
Anna Sureda (Spain)
Bertram Glass (Germany)

- Anything better than R-CHOP for first-line therapy?  
  Umberto Vitolo (Italy)  
  11:00 - 11:25

- Has HSCT come to an end in relapsed disease?  
  Bertram Glass (Germany)  
  11:25 - 11:50

- CAR T-cells in relapsed/refractory DLBCL and beyond  
  Alberto Mussetti (Spain)  
  11:50 - 12:15

- Round table discussion  
  12:15 - 12:30

Working Party Session
11:00 - 12:30

ALWP, Acute Leukaemia Working Party Session - Moving away from traditional immunosuppresion in acute leukaemia

Chairs:
Mohamad Mohty (France)
Sebastian Giebel (Poland)

- Welcome and introduction  
  Mohamad Mohty (France)  
  11:00 - 11:15

- Biological mechanisms of GVHD prevention with PTCy  
  Leo Luznik (United States)  
  11:15 - 11:40

- PT-Cy vs. ATG in 9/10 MUD transplant for acute myeloid leukaemia  
  Giorgia Battipaglia (France)  
  11:40 - 11:55

- PT-Cy vs. ATG in acute lymphoblastic leukaemia  
  Arnon Nagler (Israel)  
  11:55 - 12:10

- PT-Cy and ATG combination for high risk AML  
  Mohamad Mohty (France)  
  12:10 - 12:25

- Round table discussion  
  12:25 - 12:30

Paediatric Day
11:00 - 12:30

Paediatrics2, Inborn Errors Working Party Session

Chairs:
Arjan Lankester (Netherlands)
Michael Albert (Germany)
Scientific Programme

Landscape of GT and allogeneic therapy in IEM: The next years  11:00 - 11:15
Robert Wynn (United Kingdom)

Therapeutic standards for patients with SCID - Still a matter of discussion  11:15 - 11:30
Manfred Hoenig (Germany)

Antibody based conditioning  11:30 - 11:45
Agnieszka Czechowicz (United States)

Bridging to transplant in combined immunodeficiencies: Role of clinical scores and targeted treatments  11:45 - 11:55

Inflammation and autoimmunity in PID: Does it matter for HSCT?  11:55 - 12:10
Bénédicte Neven (France)

Discussion  12:10 - 12:25

Multi-stakeholder Forum on Innovative Cellular Therapies  11:00 - 12:00
Sala Retiro

MF3, Multi-stakeholder Forum on Innovative Cellular Therapies: Outcome data capture - Challenges and opportunities

Chairs:
Nicolaus Kröger (Germany)
Jorge Gayoso (Spain)

EMA’s Patient Registry initiative  11:00 - 11:20
Xavier Kurz (Netherlands)

EBMT Clinical Trials Office: Cell Therapy data capture  11:20 - 11:40
Marianne Mol (Netherlands)

Industry  11:40 - 12:00

Quality Management  11:00 - 12:00
Sala Colón

QM3, Inspectors Session

Chairs:
Carolina Herranz (Spain)

JACIE Activity Report & update  11:00 - 11:10
Raquel Espada (Spain)

Most frequent non-compliances from the 7th Edition of the STD  11:10 - 11:30
Louise McNamara (United Kingdom)

Inspection team: Roles  11:30 - 11:50
Mara Magri (Italy)
Nick van Sinderen (Netherlands)

Questions & Answers  11:50 - 12:00
Nurses Group  
11:00 - 12:30  

**NG15, Disease update**

**Chairs:**
Marijke Quaghebeur (Belgium)  
Patricia Moreno Galán (Spain)

- **Acute leukaemia**  
  Elisabeth Wallhult (Sweden)  
  11:00 - 11:20

- **Managing lymphoma: What nurses and healthcare professionals need to know**  
  Erik Aerts (Switzerland)  
  11:20 - 11:40

- **Multiple Myeloma**  
  Maaike de Ruijter (Netherlands)  
  11:40 - 12:05

- **Myeloproliferative disorders / CML (TKI management)**  
  Irene Caballes (United Kingdom)  
  12:05 - 12:30

Nurses Group  
11:00 - 12:30  

**NG16, Paediatric Session**

**Chairs:**
Teija Schröder (Finland)  
Jaana Matero (Finland)

- **Impact of a health information technology tool addressing information needs of caregivers of adult and paediatric haematopoietic stem cell transplantation patients**  
  Sung Won Choi (United States)  
  11:00 - 11:30

- **Music therapy supported quality of life and coping strategies for children during and after haematopoietic stem cell transplant**  
  Lena Uggla (Sweden)  
  11:30 - 12:00

- **Gamified mobile health intervention triumph to prevent psychological problems and support behavioural change: Learnings from a qualitative study of paediatric cancer patients**  
  Kadri Haljas (Estonia)  
  12:00 - 12:30

Nurses Group  
11:00 - 12:30  

**NG17, Research Committee Session: Oral Session 3 - Research Abstract finalists**

**Chairs:**
Sarah Liptrott (Italy)  
Isabel Sálcedo (Spain)
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
30 August - 2 September 2020,
Madrid, Spain

Scientific Programme

**SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**
Jessica Ward, Paula Murray, Kimberly Powers, Jilayne Smith, Melody Hellsten (United States)

**SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**
Kristina Nerskov, Jean C. Yi, Marie-Laure Crouch, Karen L. Syrjala (Denmark)

**STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**
Yun Fang, Xiaorong Zhang, Minjie Liu, Weiwei Zhang (China)

**SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY**
Linda Victoria Eriksson, Katarina Holmberg, Karin Bergkvist, Carina Lund Hagelin, Jeanette Winterling (Sweden)

**THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**
Esra Bayrak, Gulbeyaz Can (Turkey)

Workshop
11:00 - 12:30
Sala Neptuno

**W9, Autoimmune diseases**

**Chairs:**
Tobias Alexander (Germany)
Montserrat Rovira (Spain)

**HSCT in AD - Inducing tolerance through autologous and allogeneic HSCT**
Raffaella Greco (Italy)

**HSCT in AD - 20 years of evolution to evidence-based specialty guidelines**
John Snowden (United Kingdom)

**HSCT in AD - The Latin American perspective in 2020**
Maria Carolina Oliveira Rodrigues (Brazil)

Pharmacists Day
11:00 - 12:30
N113

**Pharm2, Management of adverse events**

**Chairs:**
Tiene Bauters (Belgium)
Vera Pires (Portugal)

**Management of adverse events of CAR T (tisagenlecleucel) in paediatrics**
Barbara de Moerloose (Belgium)
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
30 August - 2 September 2020,
Madrid, Spain

Scientific Programme

**CAR T and the clinical pharmacist - Standardisation of toxicity management across the UK**
11:20 - 11:40
Jackie Chappell (United Kingdom)

**Management of mucositis in HSCT**
11:40 - 12:00
Filipa Cosme Silva (Portugal)

**Chemotherapy Induced Nausea and Vomiting**
12:00 - 12:20

**Discussion**
12:20 - 12:30

Data Management
11:00 - 11:40

**DM8, Education session 8**

**Chairs:**
Mohamed Houhou (France)

**Minimal residual disease (MRD)**
11:00 - 11:40
Johannes Schetelig (Germany)

Data Management
11:00 - 12:30

**DM18, Training session 1 (continued) (pre-registration required)**

**Chairs:**
Asterios Kasmiris (United Kingdom)

**MACRO Data Entry**
11:00 - 12:30
Asterios Kasmiris (United Kingdom)

Oral Session
11:00 - 12:30

**OS7, Oral session 7 - Haematopoietic cell donors: Clinical results**

**Chairs:**
Ángela Figuera (Spain)
Amjad Hayat (Ireland)

**HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY**
11:00 - 11:11
Yingjun Chang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Han Yan, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Jun Huang (China)
### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:22</td>
<td>PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</td>
<td>Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michalis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)</td>
</tr>
<tr>
<td>11:33</td>
<td>SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018</td>
<td>Monique Jöris, Mirjam Fechter, Thilo Mengling, Lydia Foeken (Netherlands)</td>
</tr>
<tr>
<td>11:44</td>
<td>OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH</td>
<td></td>
</tr>
<tr>
<td>11:55</td>
<td>THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY</td>
<td>David Kliman, Steven Tran, David Gottlieb, Nada Hamad, Leonie Wilcox, John Moore (Australia)</td>
</tr>
<tr>
<td>12:17</td>
<td>ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES</td>
<td>Alberto Cardoso Martins Lima, Margaretta Kleina Feitosa, Luciana Nasser Dornelles, Geovana Borsato do Amaral, Gisele Loth, Samantha Nicole, Vanezua Araújo Moreira Funke, Samir Kanaan Nabhan, Noemi Farah Pereira, Carmem Bonfin, Ricardo Pasquini (Brazil)</td>
</tr>
</tbody>
</table>
How do I ... ?
11:00 - 12:30 A9.13

HDI5, How Do I... reduce therapeutic toxicity in GVHD therapy - Supported through an unrestricted educational grant by Therakos

Chairs:
Daniel Wolff (Germany)

- Strategies to avoid CNI as GVHD prophylaxis 11:00 - 11:45
  Olaf Penack (Germany)
- Cell based option to treat GVHD 11:45 - 12:30
  Hildegard Greinix (Austria)

Data Management
11:50 - 12:30 N117

DM9, Education session 9

Chairs:
Nina Knelange (Netherlands)

- Infectious complications 11:50 - 12:30
  Malgorzata Mikulska (Italy)

Multi-stakeholder Forum on Innovative Cellular Therapies
12:00 - 13:00 Sala Retiro

MF4, Multi-stakeholder Forum on Innovative Cellular Therapies: Health Technology Assessment

Chairs:
Eoin McGrath (Spain)
Beatriz Dominguez-Gil (Spain)

- The US view 12:00 - 12:20
  Miguel-Angel Perales (United States)
- An EU view 12:20 - 12:40
  Leonor Varela (Spain)
- A national view 12:40 - 13:00
  Amr Makady (Netherlands)

Quality Management
12:00 - 12:30 Sala Colón

QM4, Role of Quality Management Professionals in Stem Cell Transplant Programs

Chairs:
Julia Ruiz (Spain)
Scientific Programme

Results of the survey QM role
Renza Monteleone (Italy)  
12:00 - 12:20

Questions & Answers  
12:20 - 12:30

Industrial Theatre
12:45 - 13:30

IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session

Chairs:
Roy Chemaly (United States)

How I manage CMV in HSCT patients  
12:45 - 13:05

Closing remarks and audience Q&A  
13:05 - 13:30

Industry Symposium
13:00 - 14:15

IS32, Antineoplastic treatments and Invasive Mould Disease - Should we be worried and what can we do? - Pfizer Industry Symposium

Chairs:
Samir Agrawal (United Kingdom)

Introduction  
Samir Agrawal (United Kingdom)  
13:00 - 13:05

An introduction to IMD in the haematology unit and epidemiology  
Rafael de la Cámara (Spain)  
13:05 - 13:25

Novel therapies in haematology-oncology and the changing face of fungal disease  
Samir Agrawal (United Kingdom)  
13:25 - 13:45

PK/PD principles for choosing an invasive mould disease treatment in a complex environment  
Federico Pea (Italy)  
13:45 - 14:05

A case study illustrating how to treat IMD and ensure continued treatment of the underlying condition  
Amit Patel (United Kingdom)  
14:05 - 14:25

Discussion and closing  
14:25 - 14:30

Quality Management
13:00 - 14:00

QM5, QM Meet the Expert Sessions - located at the Meet the Expert rooms (topic pre-registration is required)
QM Meet the Expert Sessions 13:00 - 14:00

QM MTE 1: Risk & Change Management - Room A10.05
Dieter Klarmann (Germany)
Olga López Villar (Spain)

QM MTE 2: Audits & Document development and control - Room A10.06
Renza Monteleone (Italy)
Julie Dolva (Norway)

QM MTE 3: Adverse events & CAPA - Room A10.07
Anne Emmett (United Kingdom)

QM MTE 4: Maintaining the QM program and QM plan - Room A10.12
Nick van Sinderen (Netherlands)
Phuong Huynh (Belgium)

QM MTE 5: Outcome analysis and benchmarking & Validation and verification - Room A10.13
Mara Magri (Italy)
Kim Orchard (United Kingdom)

QM MTE 6: Personnel, Training and Competency - Room A10.15
Ilknur Kozanoglu (Turkey)
Songül Tepebasi (Turkey)

Statistics
13:00 - 13:45 Sala Neptuno

Stat6, Statistics Workshop

Chairs:
Myriam Labopin (France)
Xavier Poiré (Belgium)

Different method to analyse time-dependent covariates: The example of GVL 13:00 - 13:45
Ariane Boumendil (France)
Avichai Shimoni (Israel)

Industry Symposium
13:00 - 14:00 Meet the Expert Rooms

IS33, Therakos Industry Meet the Expert Lunch - Room A10.01

Calibrating the intensity of GVHD therapy to allow clinical tolerance - A role for ECP? 13:00 - 14:00
Daniel Wolff (Germany)
Scientific Programme

Industry Symposium
13:00 - 14:00

**IS34, Medac Industry Meet the Expert Lunch - Room EBMT 3**

Extending transplant indication for elderly patients by novel conditioning approaches  
Matthias Stelljes (Germany)

Pharmacists Day
13:30 - 14:00  

**Pharm3, Abstract Session**

**Chairs:**
Erik van Maarseveen (Netherlands)

- **EVALUATION OF THE ROBUSTNESS OF THERAPEUTIC DRUG MONITORING COUPLED WITH BAYESIAN FORECASTING OF BUSULFAN WITH REGARD TO INACCURATE DOCUMENTATION**  
  Adrin Dadkhah, Dzenefa Alihodzic, Astrid Broeker, Nicolaus Kroeger, Claudia Langebrake, Sebastian Wicha (Germany)

- **ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION**  
  Igor Novitzky Basso, Evangelia Vlachodimitropoulou, Ivanovs Andrejs, Emmanouil Nikolousi, John Porter (United Kingdom)

Industrial Theatre
13:45 - 14:15

**IT6, Treatment of HSCT-TMA with the investigational MASP-2 inhibitor narsoplimab - Omeros Industry Theatre Session**

Educational
14:30 - 16:00

**E7, CAR-T toxicity and management**

**Chairs:**
Joaquín Martínez-López (Spain)
Olaf Penack (Germany)

- **Cytokine release syndrome**  
  Susana Rives (Spain)

- **Neurotoxicity**  
  Miguel-Angel Perales (United States)

- **EBMT recommendations**  
  Ibrahim Yakoub-Agha (France)
Scientific Programme

Workshop
14:30 - 16:00
Hall A (Exhibition Area)

W10, Pretransplant risk management for allogeneic HSCT recipients and donors

Chairs:
Adrián Alegre (Spain)
Maria Gilleece (United Kingdom)

14:30 - 15:00
**Patient infectious risk factors**
Simone Cesaro (Italy)

15:00 - 15:30
**Patient comorbidity and organ issues**
Jaime Sanz Caballer (Spain)

15:30 - 16:00
**Donor issues that may pose a risk for themselves or for the patients**
Nina Worel (Austria)

Oral Session
14:30 - 16:00
Hall B (Exhibition Area)

OS8, Oral session 8 - GVHD: Clinical results

Chairs:
Rocío Parody Porras (Spain)
Maria Teresa Lupo-Stanghellini (Italy)

14:30 - 14:41
**KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)**
Aleksandr Lazaryan, Amandeep Salhotra, Carlos Bachier, Behyar Zoghi, Daniel Weisdorf, James Essell, Laurie Green, Olivier Schueller, Zhongming Yang, David Eiznhamer, Sanjay K Aggarwal, Bruce R Blazar, Stephanie J Lee, Madan Jagasia (United States)

14:41 - 14:52
**A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD**
Doris Ponce, Amin Alousi, Ryotaro Nakamura, Karamjeet Sandhu, Juliet Barker, Jinru Shia, Xiaojiang Yan, William Daley, Gillian Moore, Samira Fatmi, Cristina Soto, Antonio Gomes, John Slingerland, Paul Giardina, Jonathan Peled, Marcel van den Brink, Alan Hanash (United States)

14:52 - 15:03
**THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE**

15:03 - 15:14
**DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM**
Bingyu Yang, Shoubao Ma, Yan Yu, Xiaojin Wu, Depei Wu (China)
Scientific Programme

A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE
Zhonghui Katie Luo, Edgar Domenech-Estarellas, Amy Han, Robert Soiffer, Vincent Ho (United States)

EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION
Coco de Koning, Susan Prockop, Ichelle van Roessel, Elizabeth Klein, Farid Boulad, Nancy Kernan, Andromachi Scaradavou, Kevin Curran, Barbara Spitzer, Maria Cancio, Richard O’Reilly, Marc Bierings, Caroline Lindemans, Stefan Nierkens, Jaap Jan Boelens (United States)

INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)
Madan Jagasia, Stephanie J Lee, Zachariah DeFilipp, Amandeep Salhotra, Rohtesh Mehta, Trent Wang, Wanxing Chai-ho, Mukta Arora, Ayman Saad, Sunil Abhyankar, Carlos Bachier, John Galvin, Annie Im, Amelia Langston, Nirav Shah, Mark Juckett, Jane Liesveld, Aaron Logan, Levanto Schachter, Asif Alavi, Dianna Howard, Laurie Green, Olivier Schueller, Zhongming Yang, David Eiznhamer, Sanjay K Aggarwal, Bruce R Blazar, Steven Pavletic, Corey Cutler (United States)

EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY
Junya Kanda, Shigeki Hirabayashi, Hisayuki Yokoyama, Takakazu Kawase, Hidenori Tanaka, Naoyuki Uchida, Satoshi Takahashi, Makoto Onizuka, Masatsugu Tanaka, Yasuhiro Sugio, Tetsuya Eto, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta, Satoko Morishima (Japan)

Educational
14:30 - 16:00

E8, Allogeneic transplantation from family donors

Chinese experience on matched siblings vs. haploidential
Xiaojun Huang (China)

Matched siblings vs. haploidential in AML
Arnon Nagler (Israel)

Matched siblings vs. haploidential in lymphoma
Didier Blaise (France)
Paediatric Day
14:30 - 16:00

Paediatrics3, Paediatrics Diseases Oral Session

Chairs:
Miguel Ángel Díaz Pérez (Spain)
Adriana Balduzzi (Italy)

**TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: ASSESSING, CONTAINING, AND EXTINGUISHING THE FIRESTORM**
Sonata Jodele, Christopher E Dandoy, Adam Lane, Ashley Teusink-Cross, Kasiani C Myers, Gregory Wallace, Adam Nelson, Nicholas J Gloude, Stella M Davies (United States)

**ELEVATED MACROPHAGE ACTIVATION MARKERS SCD163 AND MANNOSE RECEPTOR ARE ASSOCIATED WITH OCCURRENCE OF AGVHD AND SOS AFTER PEDIATRIC ALLOGENEIC HSCT**
Laura Louise Fosgrau Hergel, Katrine Kielsen, Sarah Wegener Weischendorff, Marianne Segelcke Rosenkrantz Ifversen, Claus Nielsen, Henning Grønbæk, Klaus Gottlob Müller (Denmark)

**SURVEY OF TRANSPLANT ASSOCIATED MACROPHAGE ACTIVATION SYNDROME (TAMAS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND YOUNG ADULTS**
Petr Sedlacek, Cristina Diaz de Heredia, Akif Yesilipek, Pietro Merli, Priya Marwah, Stalin Ramprakash, Giorgio Ottaviano, Selim Corbacioglu (Czech Republic)

**THE EFFICACY AND TOXICITY OF UNMANIPULATED DLI AFTER HAPLOIDENTICAL EX-VIVO T-CELL DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN - A RETROSPECTIVE COHORT STUDY**

**IMPACT OF AB0 INCOMPATIBILITY, AGE AND STEM CELL SOURCE ON OUTCOME PARAMETERS IN MSD HSCT FOR HEMOGLOBINOPATHIES: A RETROSPECTIVE STUDY ON BEHALF OF THE PDWP**
Katharina Kleinschmidt, Josu de la Fuente, Jacques-Emmanuel Galimard, Arnaud Dalissier, Giorgio La Nasa, Jean-Hugues Dalle, Abdelghani Tbakhi, Yves Bertrand, Xavier Poiré, Gulsun Karasu, Gérard Michel, Despina Moshous, Hakan Ozdogu, Emel Ünal, Catherine Paillard, Akif Yesilipek, Selim Corbacioglu (Germany)

**THE ROLE OF HLA MATCHING IN UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE IN EUROPE**

**HAPLOIDENTICAL T-CELL DEPLETED HSCT REPRESENTS A SAFE THERAPEUTIC ALTERNATIVE TO MSD TRANSPLANTATION IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSEMAIA MAJOR**
Katharina Kleinschmidt, Juergen Foell, Beatrix Pfristinger, Anja Troeger, Agnes Mayer, Pauline Dibbern, Andreas Brosig, Norbert Ahrens, Selim Corbacioglu (Germany)

**ALPHABETA T AND B-CELL DEPLETED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (TBDEPL-HAPLOHSCT) IN CHILDREN WITH NON-MALIGNANT DISORDERS**
Scientific Programme

Multi-stakeholder Forum on Innovative Cellular Therapies
14:30 - 15:00 Sala Retiro

MF5, Multi-stakeholder Forum on Innovative Cellular Therapies: Keynote Lecture
Chairs:
Rafael Duarte (Spain)

The real-life experience on pricing and access to CAR T therapy in the USA
Inmaculada Hernández Delso (United States) 14:30 - 15:00

Quality Management
14:30 - 15:30 Sala Colón

QM6, Auditing more than JACIE
Chairs:
Sarah Holtby (United Kingdom)

Introduction
Olga López Villar (Spain) 14:30 - 14:45

Spain / UK
Olga López Villar (Spain)
Anne Emmett (United Kingdom) 14:45 - 15:00

The Netherlands / Turkey
Nick van Sinderen (Netherlands)
Ilknur Kozanoglu (Turkey) 15:00 - 15:15

Italy / Belgium
Renza Monteleone (Italy)
Phuong Huynh (Belgium) 15:15 - 15:30

Nurses Group
14:30 - 16:00 N107

NG18, Oral session 4
Chairs:
Klara Kabatova Maxova (Czech Republic)
Begoña de Andréis Gimeno (Spain)

Reducing accidental falls caused by orthostatic hypotension in bone marrow transplant recipients
Liya Katzir (Israel) 14:30 - 14:48

Prevalence, predictors and outcomes of CLABSI among HSCT patients
Jedidah L.M. Lieow, Pin Yan Tan, Yee Mei Lee, Mary Jeanette Jacinto Ignacio (Singapore) 14:48 - 15:06
AT-HOME MANAGEMENT IN AN ALLOGENEIC STEM CELL TRANSPLANTATION DURING IMMEDIATE POST-TRANSPLANTATION PHASE
Gloria Garcia, Cristina Gallego, Pilar Ayora, Montserrat Valverde, Lourdes Corominas, Gonzalo Gutierrez, Francesc Fernandez (Spain)

CREATION OF THE LABMT NURSES GROUP
Mariela Blanco, Eugenia Trigoso, Julia Ruiz, Ana Grace Barrantes, Sara Saez, Paola Viveros, Lidiane Soars, Lucia Vazquez, Tania Waisbeck, Cristina Vogel, Gregorio Jaimovich, Michelle Kenyon, Sebastian Galeano (Argentina)

THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY
Gunay Dikbiyik, Esra Koroglu Camdeviren (Turkey)

NG19, How do I become an expert?
Chairs:
Alberto Castagna (Italy)
Marta Irala Rivero (Spain)

Sexual function assessment in care
Jacqui Stringer (United Kingdom)

Late effects: Implementation of guidelines
Michelle Kenyon (United Kingdom)

How to conduct a comprehensive cGVHD assessment?
John Murray (United Kingdom)

NG20, Back to basics: How can I improve my skills?
Chairs:
Eugenia Trigoso Arjona (Spain)
Cristina Hernández García (Spain)

Oral care during inpatient haematopoietic cell transplantation
Nathaniel Simon Triester (United States)

Recognising sepsis
Jan Styczynski (Poland)

CVC management
Emilian Snarski (Poland)

Tumor lysis
Janet Baker (United Kingdom)
Scientific Programme

Special Session
14:30 - 16:00
Sala Neptuno

SS6, Global Committee Session - The impact of infections on HSCT performance worldwide

Chairs:
Norbert-Claude Gorin (France)
Nicolaus Kröger (Germany)

**Introduction**
Norbert-Claude Gorin (France)

14:30 - 14:33

**Impact (known or potential) of community respiratory virus infections on the outcome of recipients of an allogeneic HSCT or CAR T-cell therapy**
Rodrigo Martino (Spain)

14:33 - 14:50

**Tropical diseases and HSCT**
Francesca Norman (Spain)

14:50 - 15:07

**Parasitic infections in HSCT**
Gregorio Jaimovich (Argentina)

15:07 - 15:24

**Impact of infections in Asia**
Alok Srivastava (India)

15:24 - 15:41

**Particularities of infections in limited-resource countries**
Asma Quessar (Morocco)

15:41 - 15:58

**Conclusions**
Nicolaus Kröger (Germany)

15:58 - 16:00

Pharmacists Day
14:30 - 16:00
N113

Pharm4, Update infectious diseases in HSCT

Chairs:
Erik van Maarseveen (Netherlands)
Agnès Bonnin (France)

**What’s new in antivirals?**
Per Ljungman (Sweden)

14:30 - 14:50

**What is new in vaccines? The Dutch guidelines for HSCT patients**
Kim van der Elst (Netherlands)

14:50 - 15:10

**What’s new in Antifungals?**
Florent Malard (France)

15:10 - 15:30

**The effect of antibiotics on the microbiome in HSCT patients: Is it relevant?**

15:30 - 15:50

**Discussion**

15:50 - 16:00
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
30 August - 2 September 2020,
Madrid, Spain

Scientific Programme

Data Management
14:30 - 15:10

**DM10, Education session 10**

**Chairs:**
Marie Trnková (Czech Republic)

**Haematopoietic Cell Transplantation-Comorbidity Index "Sorror Score"**
Bronwen Shaw (United States) 14:30 - 15:10

Data Management
14:30 - 16:00

**DM19, Training session 2 (pre-registration required)**

**Chairs:**
Silvia Zaccagnino (United Kingdom)

**MACRO Reports**
Silvia Zaccagnino (United Kingdom) 14:30 - 16:00

Working Party Session
14:30 - 16:00

**LWP, Lymphoma Working Party Session**

**Chairs:**
Silvia Montoto (United Kingdom)
Peter Dreger (Germany)

**Welcome and introduction**
Silvia Montoto (United Kingdom) 14:30 - 14:35

**Highlights of the LWP activity: Allogeneic transplantation for DLBCL in the CART era: The EBMT-CIBMTR position**
Peter Dreger (Germany) 14:35 - 14:45

**LWP Educational Course 2019**
Anna Sureda (Spain) 14:45 - 14:50

**Presentation of Jian-Jian Luan Award winner**
Silvia Montoto (United Kingdom) 14:50 - 14:55

**OFATUMUMAB AS PART OF REDUCED INTENSITY CONDITIONING IN HIGH RISK B-CELL LYMPHOMA PATIENTS: RESULTS FROM A PROSPECTIVE MULTICENTER PHASE-II TRIAL**
Monica Cabrero, Estefania Perez-Lopez, Isidro Jarque, Fatima de la Cruz-Vicente, Ana Africa Martin-Lopez, David Valcarcel, Jaime Sanz, Alejandro Martin, Ildefonso Espigado, Guillermo Orti, Carmen Martin-Calvo, Carlos Grande, Lucia Lopez-Corrall, Dolores Caballero (Spain) 14:55 - 15:05

**LWP Keynote debate: Relapsed MCL - Should we transplant or continue on new drugs?**
Scientific Programme

Case presentation 15:05 - 15:15
Silvia Montoto (United Kingdom)

Transplant 15:15 - 15:30
Olivier Hermine (France)

New drugs 15:30 - 15:45
Marek Trneny (Czech Republic)

Patient's perspective and discussion 15:45 - 16:00
Natacha Bolaños (Spain)

Patient Advocacy Sessions
14:30 - 16:00

PA1, Patient Advocacy sessions: Different perspectives on CAR T

Chairs:
Guy Bouguet (France)
Bregje Verhoeven (Netherlands)

A dive into a patient's experience 14:30 - 14:40
Rose Ellard (United Kingdom)

Nurse's perspective - What are the changes needed in daily practice? 14:40 - 14:55

HTA view on reimbursement: A Dutch perspective - Patience for the patient 14:55 - 15:10
Amr Makady (Netherlands)

A payer's perspective 15:10 - 15:25

Patient advocate's perspective - Setting the right expectations 15:25 - 15:40
Natacha Bolaños (Spain)

Discussion 15:40 - 16:00

Special Session
14:30 - 15:45

SS7, Young Ambassadors: Jeopardy session

Chairs:
Alessandro di Gangi (Italy)
Eleni Gavrillaki (Greece)
Alexandra Gómez Arteaga (United States)

Introduction 14:30 - 14:40

Jeopardy 14:40 - 15:45
Multi-stakeholder Forum on Innovative Cellular Therapies
15:00 - 16:00 Sala Retiro

**MF6, Multi-stakeholder Forum on Innovative Cellular Therapies: How are new cellular therapies being rolled out?**

**Chairs:**
Mohamad Mohty (France)
Jorge Sierra (Spain)

- **France**
  - Ibrahim Yakoub-Agha (France) 15:00 - 15:15

- **England - JACIE and NHSE collaboration**
  - Kim Orchard (United Kingdom) 15:15 - 15:30

- **Netherlands - How are cellular therapies translated from academia to industrial partners. Pitfalls and opportunities**
  - Jürgen Kuball (Netherlands) 15:30 - 15:45

- **Switzerland**
  - Jörg Halter (Switzerland) 15:45 - 16:00

Data Management
15:20 - 16:00 N117

**DM11, Education session 11**

**Chairs:**
Jorinde Hoogenboom (Netherlands)

- **CAR T-cells - Moving into the mainstream**
  - Reuben Benjamin (United Kingdom) 15:20 - 16:00

Quality Management
15:30 - 16:00 Sala Colón

**QM7, Oral Abstracts 1**

**Chairs:**
Carlos Torrico (Spain)

- **COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS**
  - Louise McNamara, Tuula Rintala (United Kingdom) 15:30 - 15:40

- **DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT**
  - Christine Rosati, Jeffery Aulella, Catherine Desmond, David Hartley, John Huber, Hannah Ingraham, Anna Klunk, Mark Mueller, Rachel Phelan, Seth Rotz, Sarah Tarquin, Leslie Lehmann, Christopher Dandoy (United States) 15:40 - 15:50

Questions & Answers 15:50 - 16:00
Scientific Programme

**Industrial Theatre**
16:00 - 16:30

**IT7, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session**

- **Insights from clinical development**
  Franco Locatelli (Italy)
  16:00 - 16:10

- **Preparing for post-licensing clinical use**
  Ingo Müller (Germany)
  16:10 - 16:20

- **Panel discussion with Q&A and meeting conclusion**
  16:20 - 16:30

**Educational**
16:30 - 18:00

**E9, Landscape for CLL management in 2020**

**Chairs:**
Peter Dreger (Germany)
José A. García-Marco (Spain)

- **Dissecting CLL at a single-cell level - Implications for therapy and outcome**
  Catherine Wu (United States)
  16:30 - 17:00

- **The broadening landscape of targets and therapeutic options for CLL**
  Michael Hallek (Germany)
  17:00 - 17:30

- **HSCT and cellular therapy for CLL in 2020**
  John Gribben (United Kingdom)
  17:30 - 18:00

**Educational**
16:30 - 18:00

**E10, Therapies to bring resistant acute leukaemia into HSCT**

**Chairs:**
Arnon Nagler (Israel)
Jorge Sierra (Spain)

- **Novel targeted therapy before HSCT for AML/MDS**
  Guillermo García-Manero (United States)
  16:30 - 17:00

- **New conditioning regimen for relapsed acute leukaemia**
  Ali Bazarbachi (Lebanon)
  17:00 - 17:30

- **Sequential therapy for AML**
  Rémy Duléry (France)
  17:30 - 18:00
OS9, Oral session 9 - Early complications after transplantation 2

Chairs:
Virginia Abello Polo (Chile)
Christian Koenecke (Germany)

16:30 - 16:41
PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Mohamad Mehty, Marta Lisa Battista, Didier Blaise, Elisabetta Calore, Simone Cesaro, Natalia Maximova, Katia Perruccio, Cecile Renard, Marco Zecca, Myriam Labopin, Raj Hanvesakul, Robert J. Ryan, Fabio Ciciri, Sarah Lawson (France)

16:41 - 16:52
A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Mohamad Mehty, Marta Lisa Battista, Didier Blaise, Elisabetta Calore, Simone Cesaro, Natalia Maximova, Katia Perruccio, Robert Wynn, Marco Zecca, Myriam Labopin, Vian Amber, Robert J. Ryan, Sarah Lawson (France)

16:52 - 17:03
DEFIBROTIDE TREATMENT FOR VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY
Mohamad Mehty, Marta Lisa Battista, Didier Blaise, Elisabetta Calore, Simone Cesaro, Natalia Maximova, Katia Perruccio, Robert Wynn, Marco Zecca, Myriam Labopin, Vian Amber, Robert J. Ryan, Sarah Lawson (France)

17:03 - 17:14
INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD Diagnosis: IS IT LIFE-SAVING OR MONEY-WASTING?
Zofia Szmit, Ewa Gorczyńska, Anna Król, Marek Ussowicz, Monika Mielcarek-Siedziuk, Jowita Frączkiewicz, Krzysztof Kalwak (Poland)

17:14 - 17:25
PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

17:25 - 17:36
HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT-VERSUS-HOST DISEASE
Michelle Ehmann, Michael Medinger, Benjamin Bodenmann, Noemie Bollinger, Sarah Kraft, Dominik Heim, Dimitrios Tsakiris, Claudia Lengerke, Alexandar Tzankov, Jakob Passweg, Thomas Menter (Switzerland)

17:36 - 17:47
HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS

17:47 - 17:58
CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS
Lenneke van Groningen, Hannah Wardill, Stijn van der Aa, Rita Ferreira da Silva, Alex Kurilshikov, Walter van der Velden, Hermie Harmsen, Wim Tissing, Nicole Blijlevens (Netherlands)
CTIWP, Cellular Therapy and Immunobiology Working Party Session

Chairs:
Christian Chabannon (France)
Annalisa Ruggeri (France)

**Presentation of CTIWP activities**
Christian Chabannon (France)

16:30 - 16:40

**Presentation of the Jon J. van Rood Award**
Christian Chabannon (France)

16:40 - 16:50

**Jon J. van Rood award winning abstract presentation - “Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation”**
Cristina Toffalori (Italy)

16:50 - 17:10

**HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

17:10 - 17:22

**TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS**
Moniek A. de Witte, Anke Janssen, Clara A. Nijssen, Anna van Rhenen, Rick Admiraal, Lotte van der Wagen, Monique C. Minnema, Eefke Petersen, Reinier A.P. Raymakers, Kasper Westinga, Constantijn J.M. Halkes, Jaap Jan Boelens, Jurgen Kuball (Netherlands)

17:22 - 17:34

**In vivo reconstitution dynamics of human HSPC after HSC gene therapy**
Serena Scala (Italy)

17:34 - 17:59

Paediatric Day
16:30 - 18:00

Paediatrics4, Inborn Errors Oral Session

Chairs:
Luisa Sisinni (Spain)
Krzysztof Kalwak (Poland)

**HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCRαβ/CD19 GRAFT DEPLETION AMONG CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: HIGH SURVIVAL WITH LOW RATE OF GVHD**
Aishat Kantulaeva, Elena Gutovskaya, Alexandra Laberkov, Yulia Skvortsova, Larisa Shelikhova, Julia Starichkova, Dmitry Pershin, Elena Kurnikova, Yakov Muzalevskii, Aleksey Kazachenok, Galina Novichkova, Aleksey Maschan, Dmitriy Balashov, Michael Maschan (Russian Federation)

16:30 - 16:41

**NATIONAL HEALTH SERVICE ENGLAND (NHSE) PROGRAM FOR SELECTION OF ADULT PRIMARY IMMUNODEFICIENCY PATIENTS FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

16:41 - 16:52
Scientific Programme

OUTCOME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION IN ADOLESCENTS AND YOUNG ADULTS WITH PRIMARY IMMUNODEFICIENCY 16:52 - 17:03
Su Han Lum, Venetia Bigley, Daniel Drozdov, Zohreh Nademi, Terry Flood, Mario Abinun, Andrew Cant, Sophie Hambleton, Mary Slatter, Andrew Gennery (United Kingdom)

DONOR CHARACTERISTICS PREDICT THE SUCCESS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSAEMIA MAJOR: A SINGLE CENTRE ANALYSIS OF 250 PATIENTS 17:03 - 17:14
Revathi Raj, Ramya Uppuluri, Venkateswaran Vellaichamy, Nikila Ravichandran, Kesavan Iyer, David Dennison, Abdulhakim Alrawas (India)

LONG-TERM NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LATE-INFANTILE KRABBE DISEASE 17:14 - 17:25
Maria Escolar, Isabel Yoon, Nicholas Bascou, Michele Poe (United States)

LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY (GT): UPDATED RESULTS IN GROUP C PATIENTS FROM THE PHASE 1/2 HGB-206 STUDY 17:25 - 17:36
Markus Y. Mapara, John F. Tisdale, Julie Kanter, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Manfred Schmidt, Alexandra L. Miller, Francis J. Pierciey Jr., Melissa Bonner, Wenchai Huang, Jean-Antoine Ribeil, Alexis A. Thompson, Mark C Walters (United States)

VERY LONG-TERM FOLLOW UP OF 83 ADULTS WHO UNDERWENT ALLOGENEIC HSCT IN CHILDHOOD FOR PRIMARY IMMUNODEFICIENCY (PID): A SINGLE CENTRE EXPERIENCE 17:36 - 17:47
James Day, Rupert Goodman, Bethany Nicholson, Austen Worth, Paul Veys, Ronjon Chakraverty, Benjamin Carpenter, Rachael Hough, Mari Campbell, Penny Titman, Deborah Ridout, Kit Sandford, Siobhan O Burns, Emma Morris (United Kingdom)

LENTIVIRAL HAEMATOPOIETIC STEM CELL THERAPY IN PATIENTS WITH WISKOTT ALDRICH SYNDROME (WAS): LONDON EXPERIENCE 17:47 - 17:58
Reem Elfeky, Christine Rivat, Katie Snell, Jinhua Xu-Bayford, Kimberly Gilmour, Stuart Adams, Emma Morris, Gerialdine Honnet, Anne Galy, Claire Booth, Adrian J Thrasher (United Kingdom)

Multi-stakeholder Forum on Innovative Cellular Therapies
16:30 - 17:20 Sala Retiro

MF7, Multi-stakeholder Forum on Innovative Cellular Therapies: Managing expectations - Access to treatment

Chairs:
Bregje Verhoeven (Netherlands)
Anna Sureda (Spain)

Where's the access bottleneck: Centres, industry, authorities? 16:30 - 16:55
Joaquín Martínez-López (Spain)

Patients who missed their CAR - Failed intention to treat in real-life? 16:55 - 17:20
Antonio Pagliuca (United Kingdom)
Scientific Programme

Quality Management
16:30 - 17:30 Sala Colón

QM8, QM and future development in HSCT

Chairs:
Almudena de Laiglesia (Spain)

TRANSPOSE EU Project
Suzanna M. van Walraven (Netherlands) 16:30 - 16:45

EuroGTPPI: An interactive assessment tool for risk assessment of new processes
Aurora Vassanelli (Italy) 16:45 - 17:00

CAR T accreditation: What can you expect?
Mara Magri (Italy) 17:00 - 17:15

Questions & Answers 17:15 - 17:30

Nurses Group
16:30 - 18:00 N107

NG21, Care of the caregivers

Chairs:
Laura Vicente Izquierdo (Spain)

Empowering the caregivers: Social worker
Rebecca Parker (United Kingdom) 16:30 - 17:00

Implementation of a tool to support parents of your patients
Marijke Quaghebeur (Belgium) 17:00 - 17:30

Ambulatory transplants patients: Caregivers role
Audrey Casabona-Navarro (France) 17:30 - 18:00

Nurses Group
16:30 - 18:00 N109

NG22, Infections

Chairs:
Iris Agreiter (Ireland)
Francisco Xosé Román Losada (Spain)

How to find a fungal infection
Toine Mercier (Belgium) 16:30 - 16:50

CMV
Patrice Ceballos (France) 16:50 - 17:10

Polyoma virus
Marta Canesi (Italy) 17:10 - 17:35
Scientific Programme

Nursing leadership in antimicrobial stewardship interventions
Enrique Castro-Sánchez (United Kingdom) 17:35 - 18:00

Nurses Group
16:30 - 18:00

NG23, Quality processes in JACIE

Chairs:
Marjola Gjergji (Italy)
Alba Fernández-Arroyo (Spain)

Quality indicators for nurses
Louise McNamara (United Kingdom) 16:30 - 17:00

JACIE: What's new?
Eoin McGrath (Spain) 17:00 - 17:30

What is the nurse role as JACIE inspector?
Eugenia Trigoso Arjona (Spain) 17:30 - 18:00

General
16:30 - 17:30

GS3, General Assembly

Chairs:
Nicolaus Kröger (Germany)
Harry Dolstra (Netherlands)
Rafael Duarte (Spain)

President's Report
Nicolaus Kröger (Germany) 16:30 - 16:50

Treasurer's Financial Report
Harry Dolstra (Netherlands) 16:50 - 17:05

Secretary's Report
Rafael Duarte (Spain) 17:05 - 17:20

2020 Election Results
Rafael Duarte (Spain) 17:20 - 17:25

Outgoing Board Members
Nicolaus Kröger (Germany) 17:25 - 17:30
**Scientific Programme**

Pharmacists Day  
16:30 - 18:00  

Pharm5, Round table discussions (at the Meet the Expert rooms)  
Chairs:  
Claudia Langebrake (Germany)  

- **Round table discussions - Rooms A10.12, A10.13, A10.15**  
  16:30 - 17:30  
  JACIE for pharmacists in practice  
  Tiene Bauters (Belgium)  

- **The role of the aseptics pharmacist in gene therapy clinical trials**  
  17:30 - 18:00  
  Drug interactions with complementary and alternatives herbs and medicines  
  Tine van Nieuwenhuyse (Belgium)  

- **Summary of groups - Room N113**  

Data Management  
16:30 - 17:10  

**DM12, Education session 12**  
Chairs:  
Helen Baldomero (Switzerland)  

- **Discussion forum - Being a data manager: Practical issues**  
  16:30 - 17:10  
  Julia Lee (United Kingdom)  
  Juana Schwartz Mota (Spain)  
  Steffie van der Werf (Netherlands)  

Data Management  
16:30 - 17:30  

**DM20, Training session 2 (continued) (pre-registration required)**  
Chairs:  
Silvia Zaccagnino (United Kingdom)  

- **MACRO Reports**  
  16:30 - 17:30  
  Silvia Zaccagnino (United Kingdom)  

Working Party Session  
16:30 - 18:00  

**SAAWP, Severe Aplastic Anaemia Working Party Session**  
Chairs:  
Régis Peffault de Latour (France)  
Antonio Risitano (Italy)
Scientific Programme

**Introduction**
Régis Peffault de Latour (France)  
16:30 - 16:35

**Registry report**
Antonio Risitano (Italy)  
16:35 - 16:40

**Prospective randomised studies**

**RACE clinical trial**
Antonio Risitano (Italy)  
16:40 - 16:50

**The EMAA-Study: Evaluating the significance of Eltrombopag in moderate aplastic anaemia**
16:50 - 17:00

**Haplo-identical BMT and aplastic anemia: Past and future**
Andrea Bacigalupo (Italy)  
17:00 - 17:30

**Retrospective studies**

**Stem cell transplantation for Blackfan-Diamond Anaemia: A retrospective study of EBMT SAAWP**
Maurizio Miano (Italy)  
17:30 - 17:45

**Upfront MUD transplantation for patients with idiopathic aplastic anaemia**
Audrey Petit (France)  
17:45 - 18:00

Patient Advocacy Sessions
16:30 - 18:00  
A9.13

**PA2, Patient Advocacy sessions: Patient Reported Outcomes. A gap to fill**

**Chairs:**
Natacha Bolaños (Spain)  
Hélène Schoemans (Belgium)

**Clinical trials and PRO. Introduction to PRO, analysing the data and challenges**
Raúl Córdoba Mascuñano (Spain)  
16:30 - 16:45

**The use of real world data to support registers**
John New (United Kingdom)  
16:45 - 17:00

**The clinicians perspective: Why do we need PRO? Possibilities and challenges**
Hélène Schoemans (Belgium)  
17:00 - 17:15

**Introducing the patient's experience with PRO**
17:15 - 17:30

**Discussion**
17:30 - 18:00
Scientific Programme

Multi-stakeholder Forum on Innovative Cellular Therapies
17:20 - 17:30 Sala Retiro

MF8, Closing - 1st Multi-stakeholder Forum on Innovative Cellular Therapies

Chair: Jürgen Kuball (Netherlands)

Closing remarks
Jürgen Kuball (Netherlands) 17:20 - 17:30

Quality Management
17:30 - 18:00 Sala Colón

QM9, Oral Abstracts 2

Chair: Patricia Abichain (Argentina)

INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS 17:30 - 17:40
Kim Messelink, Shahira Fazel (Netherlands)

“TPFMEA”, AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM 17:40 - 17:50

Questions & Answers 17:50 - 18:00
Scientific Programme

Wednesday, 02 September 2020

Oral Session
08:00 - 08:50

OS10, Oral Session 10 - CAR T-cell therapy 1

Chairs:
María Liz Paciello Coronel (Spain)
Elad Jacoby (Israel)

08:00 - 08:10
A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)
Sattva Neelapu, Frederick Locke, Nancy Bartlett, Lazaros Lekakis, Patrick Reagan, David Miklos, Caron Jacobson, Ira Braunschweig, Olalekan Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita Depuy, Jenny Kim, Christian Gisselbrecht (France)

08:10 - 08:20
CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

08:20 - 08:30
INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS

08:30 - 08:40
THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

08:40 - 08:50
REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE
Gloria Iacoboni, Eva Catala, J.M. Sanchez Pina, Rebeca Bailen, Alberto Mussetti, J.M. Sancho, J.M. Ribera, Anna Sureda, Mi Kwon, Mari Liz Paciello Coronel, Francesc Bosch, Pere Barba (Spain)

Meet the Expert
08:00 - 09:00

MTE16, Meet the Expert session 16 - Room A10.05

HSCT and gene therapy in inherited metabolic diseases
Robert Wynn (United Kingdom)

Meet the Expert
08:00 - 09:00

MTE17, Meet the Expert session 17 - Room A10.06
Scientific Programme

Current challenges facing emerging donor registries in 2020
Mahmoud Aljurf (Saudi Arabia)

Meet the Expert Rooms
Meet the Expert
08:00 - 09:00

MTE18, Meet the Expert session 18 - Room A10.07
HSCT indications in paediatric MDS
Charlotte Niemeyer (Germany)

Meet the Expert Rooms
Meet the Expert
08:00 - 09:00

MTE19, Meet the Expert session 19 - Room A10.12
Ex vivo cellular manipulation and therapy as the platform of choice for allogeneic HSCT in 2020
Stephan Mielke (Sweden)

Meet the Expert Rooms
Meet the Expert
08:00 - 09:00

MTE20, Meet the Expert session 20 - Room A10.13
Current role of mesenchymal stromal cells in HSCT
Peter Bader (Germany)

Meet the Expert Rooms
Meet the Expert
08:00 - 09:00

MTE21, Meet the Expert session 21 - Room A10.15
HSCT in MS and immune-mediated neurological diseases: Patient selection and follow-up
Basil Sharrack (United Kingdom)

Meet the Expert Rooms
Meet the Expert
08:00 - 09:00

MTE15, Meet the Expert Session 15 - Room A10.01
Fungal infections in HSCT recipients - The challenges in 2020
Livio Pagano (Italy)
Scientific Programme

Plenary Session
09:00 - 10:30

N103

P4, New developments in the field of CAR T-cell therapy

Chairs:
Christian Chabannon (France)
Álvaro Urbano-Ispizua (Spain)

An independent evaluation of the economic value of the two approved CAR T-cells
John K. Lin (United States)

09:00 - 09:22

Safe and potent anti-CD19 CAR T-cell therapy - An experience from China
Zhitao Ying (China)

09:22 - 09:44

CAR T-cell technology and strategy for solid tumors
Hinrich Abken (Germany)

09:44 - 10:06

Future of CAR T-cell therapies
Stéphane Depil (France)

10:06 - 10:28

Educational
09:00 - 10:30

N105

E11, Management of early complications in an ambulatory/outpatient setting

Chairs:
Francesc Fernández-Avilés (Spain)
Tapani Ruutu (Finland)

Early infections
Jan Styczynski (Poland)

09:00 - 09:22

Organ toxicity
Gerhard Hildebrandt (United States)

09:22 - 09:44

Acute GVHD
Zinaida Peric (Croatia)

09:44 - 10:06

The Hospital Clínic experience
Gonzalo Gutiérrez-García (Spain)

10:06 - 10:28

Workshop
09:00 - 10:30

N101

W11, Battling acute leukaemia relapse after allogeneic HSCT

Chairs:
David Valcárcel Ferreiras (Spain)
Thomas Cluzeau (France)

CAR T-cells
Mohamad Mohty (France)

09:00 - 09:30
**Scientific Programme**

**Maintenance strategies after allogeneic HSCT**
Charles Craddock (United Kingdom)  
09:30 - 10:00

**Second allogeneic HSCT**
Bipin Savani (United States)  
10:00 - 10:30

**Workshop**  
09:00 - 10:30  
Sala Retiro  

**W12, HSCT for immune modulation of solid organ transplantation**

**Chairs:**  
Antonio Pérez-Martínez (Spain)  
Petr Sedlacek (Czech Republic)

**Basis and opportunities of HSCT as a tool to induce immunotolerance to SOT**
Megan Sykes (United States)  
09:00 - 09:30

**HSCT to induce immunotolerance to lung transplantation**
Paul Szabolcs (United States)  
09:30 - 10:00

**HSCT to induce immunotolerance to composite tissue transplantation**
Sebastian Giebel (Poland)  
10:00 - 10:30

**Special Session**  
09:00 - 10:30  
Sala Colón  

**SS8, EBMT benchmarking - A key quality improvement tool**

**Chairs:**  
Carlos Solano Vercet (Spain)  
Eoin McGrath (Spain)

**Project update**
John Snowden (United Kingdom)  
09:00 - 09:20

**Methodological aspects of EBMT benchmarking**
Hein Putter (Netherlands)  
09:20 - 09:40

**Results so far**
Riccardo Saccardi (Italy)  
09:40 - 10:00

**Next steps - Gaining confidence**
Kim Orchard (United Kingdom)  
10:00 - 10:20

**Round table discussion: Will benchmarking replace the need for accreditation?**  
10:20 - 10:30
OS11, Oral session 11 - Acute Leukaemia 2

Chairs:
Guiomar Bautista (Spain)
Maija Itälä-Remes (Finland)

09:00 - 09:11
THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT \(<i>ASXL</i>1-, \(<i>RUNX</i>1- AND \(<i>TP</i>53\) MUTATIONS
Katharina Heidrich, Jan Moritz Middeke, Kerstin Schäfer-Eckart, Walter E Aulitzky, Hermann Einsle, Carsten Müller-Tidow, Wolf Rösler, Mathias Hänel, Claudia D Baldus, Lars Fransecky, Friedrich Stölzel, Christoph Röllig, Franziska Tautbe, Michael Kramer, Sebastian Stasik, Andreas Neubauer, Andreas Burchert, Wolfgang E Berdel, Matthias Stelljes, Gesine Bug, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede, Johannes Schetelig (Germany)

09:11 - 09:22
ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

09:22 - 09:33
RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELPASE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA

09:33 - 09:44
OUTCOMES OF CHILDHOOD HIGH RISK B- AND T-CELL RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA - LONG TERM FOLLOW-UP OF THE \(<i>ALLR3</i>-AND \(<i>ALL-REZ BFM 2002</i>-CLINICAL TRIALS

09:44 - 09:55
LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER \(\alpha\beta\) T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL
Zhanna Shekhovtsova, Maria Dunaikina, Larisa Shelikhova, Elena Osipova, Dmitriy Pershin, Dmitriy Balashov, Elena Kurnikova, Alexei Kazachenok, Yakov Muzalevskii, Maria Ilushina, Rimma Khismatullina, Julia Starichkova, Galina Novichkova, Alexei Maschan, Michael Maschan (Russian Federation)

09:55 - 10:06
DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML
Maud Plantinga, Colin de Haar, Ester Dunnebach, Denise van den Beemt, Jaap Jan Boelens, Stefan Nierkens (Netherlands)

10:06 - 10:17
THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

10:17 - 10:28
BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT
OS12, Oral session 12 - Paediatric transplantation

Chairs: Alberto Olaya-Vargas (Mexico)  
       Marco Zecca (Italy)

PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL

Rick Admiraal, Stefan Nierkens, Robbert Bredius, Marc Bierings, Ineke van Vliet, Marta Lopez Yurda, Birgitta Versluijs, Caroline Lindemans, Michel Zwaan, Jaap Jan Boelens (Netherlands)

EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY

Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassiliios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)

EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY

Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edordo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasiev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP


TCRαβ+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION


THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION

Reem Elfekey, Natalia Bulles, Soumya Perinarajah, Joe Standing, Robert Chiesa, Giovanna Lucchini, Arina Lazareva, Maria Gabelli, Persis Amrolia, Paul Veys, Kanchan Rao (United Kingdom)
**IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?**

Fanette Bernard, Jacques-Emmanuel Galimard, Arnaud Dalissier, Amal El-Seraihy, Jean-Hugues Dalle, Chakradhara Rao S. Uppugunduri, Boris Afanasyev, Frederic Baleydier, Marco Zecca, Franco Locatelli, Chybicka Alicja, Franca Fagioli, Stephen Robinson, Adriana Balduzzi, Alessandra Biffi, Yves Chalandon, Peter Bader, Selim Corbacioglu, Marc Ansari (Switzerland)

**HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

Tina Gerbek, Ena Muhic, Camilla Von Jessen, Terkel Christiansen, Kaspar Sørensen, Sidsel Mathiesen, Marianne Ifversen, Henrik Sillesen, Klaus Müller (Denmark)

---

**NG24, Nurses Programme: Closing Session**

**Chairs:**
John Murray (United Kingdom)
Klara Kabatova Maxova (Czech Republic)

**GVHD practical tips**

- **Eye**
  - Sandra Schoenfeld (Switzerland)

- **Oral**
  - Caroline Bompoint (France)

- **Cutaneous**
  - John Murray (United Kingdom)

- **Supportive care and management of gastrointestinal complications in GVHD**
  - Lucija Jurisic (Croatia)

- **Genital**

---

**OS13, Oral session 13 - Infectious complications**

**Chairs:**
Rafael Rojas Contreras (Spain)
Lidia Gil (Poland)
PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT

Christine Robin, Catherine Cordonnier, Gloria Tridello, Nina Knelange, Aileen Xhaard, Sylvain Chantepie, Aline Tanguy-Schmidt, Harry Schouten, Moshe Yeshurun, Rocha Vanderstorm, Ibrahim Yakoub-Agha, Nicolas Kröger, Marie-Pierre Ledoux, Jakob Dalgaard, Anne Thiebaut, Stefano Giardino, Elisabetta Calore, Tsiila Zuckerman, Andreas Groll, Ludek Raida, Simona Avcin, Marta Gonzalez Vicente, Ain Kaare, Joanna Drozd-Sokolowska, Pascal Turlure, Stephane Bretagne, Malgorzata Mikulska, Simone Cesaro, Jan Styczynski (France)

UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPANTATION

SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY

Sabrina Basso, Enrico Marchioni, Luca Stoppini, Jessica Bagnarino, Francesca Campogno, Alessandra Maiello, Gloria Acquafredda, Arianna Panigari, Fausto Baldanti, Cesare Perotti, Maura Faracci, Mario Luppi, Marco Zecca, Patrizia Comoli (Italy)

EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY

Malgorzata Mikulska, Gloria Tridello, Nina Knelange, Stella Santarone, Paolo Di Bartolomeo, Rafael de la Camara, Clara Cuéllar, Andrea Velardi, Katia Perruccio, Per Ljungman, Stephan Mielke, Jan Zaucha, Agnieszka Piekarśka, Grzegorz Basak, Ewa Karakulska-Prystupiuk, Emanuele Angelucci, Fabio Ciceri, Maria Teresa Lupo Stanghellini, Loic Fouillard, Irene Garcia, Maria Cristina Menconì, Igor Wolfgang Blau, Luca Nasi, Laura Ambra Nicolini, Simone Cesaro *, Jan Styczynski * Equal contributors (Italy)

TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT


FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT

Andrew J Innes, Rohma Ghani, Benjamin H Mullish, Richard Szydlo, Eimear Brannigan, Renuka Palanicawandar, Eduardo Olavarria, Jane F Apperley, Mark R Thursz, Horace R T Williams, Julian R Marchesi, Frances Davies, Jiri Pavlu (United Kingdom)

EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY

Joyce Johnsrud, Isabelle Nguyen, Walter Domingo, Amitkumar Raval, Yuexin Tang, Janice (Wes) Brown (United States)
Scientific Programme

USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES
WORKING PARTY EBMT RETROSPECTIVE STUDY
Jan Styczynski, Gloria Tridello, Nina Knelange, Alienor Xhaard, Gerard Socie, Jakob Passweg, Stephan Mielke, Mervi Taskinen, Nicole Blilievens, Carlos Solano, Emmanouil Nikolousis, Alessandra Biffi, Andreas Groll, Christian Junghanss, Panagiotis Tsirigiotis, Bruno Lioure, Pavel Jindra, Ernst Holler, Federica Galaverna, Franca Fagioli, Rafael de la Camara, Malgorzata Mikulska, Per Ljungman (Poland)

OS14, Oral session 14 - GVHD: Clinical and translational research

Chairs:
Manuel Jurado Chacón (Spain)
Hildegard Greinix (Austria)

ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY
Mattia Algeri, Stefania Galimberti, Maria Esté Bernardo, Attilio Rovelli, Marco Zecca, Giorgio La Nasa, Sarah Marktel, Pietro Merli, Alice Bertaina, Daria Pagliara, Emilia Bocci, Francesca Del Bufalo, Stefania Gaspari, Annalisa Ruggeri, Giulia Capitoli, Maria Grazia Valsecchi, Franco Locatelli (Italy)

MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE

FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL
Barbara Fazekas de St Groth, Holly Bolton, Aster Pijning (Australia)

MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Amin Turki, Evren Bayraktar, Saskia Leserer, Ji-Hee Yi, Rashit Bogdanov, Dietrich Beelen (Germany)

SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS

A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION
Lia Perez, Hugo Fernandez, Mohamed Khargan-Dabaja, Farhad Khimani, Brian Betts, Asmita Mishra, Ernesto Ayala, Fred Locke, Leonel Ochoa, Michael Nieder, Joseph Pidala, John Powers, Eva Sahakian, Claudio Anasetti (United States)

EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS

TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE
SS9, HARMONY Alliance Project

Chairs:
Guillermo Sanz Santillana (Spain)
Pamela Bacon (Switzerland)

General Overview of the HARMONY Alliance: Progress, achievements and results
Jesús M. Hernández Rivas (Spain)

Expected contribution of the EBMT
Guillermo Sanz Santillana (Spain)
Pamela Bacon (Switzerland)

EBMT participation
Anna Sureda (Spain)

HARMONY Research Projects / Outcomes definition
Lars Bullinger (Germany)

HARMONY Platform
Ana Heredia Casanoves (Spain)

Questions & Answers

OS15, Oral session 15 - Gene therapy and experimental transplantation

Chairs:
Julián Sevilla Navarro (Spain)
Maria Ester Bernardo (Italy)

CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA
Franco Locatelli, Janet L. Kwiatkowski, Alexis A. Thompson, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, John B. Porter, Isabelle Thuret, Suradej Hongeng, Ashutosh Lal, Adrian J. Thrasher, Heidi Elliot, Ge Tao, Weijian Liu, Richard A. Colvin, Mark C. Walters (Italy)
Scientific Programme

09:11 - 09:22
LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS

Valeria Calbi, Francesca Fumagalli, Maria Sessa, Alberto Zambon, Cristina Baldoli, Federica Cugnata, Paola M.V. Rancoita, Serena Acquati, Daniela Redaelli, Fabiola De Mattia, Elena Fratini, Francesca Ferrua, Federica Barzaghi, Maria Pia Cicalese, Maddalena Migliavacca, Francesca Tucci, Vera Gallo, Francesca Ciotti, Maddalena Fraschini, Marina Sarzana, Paolo Silvani, Ivana Spiga, Marcella Facchini, Sara Locatelli, Gigioli Antoniol, Stefano Zancan, Andrea Calabria, Eugenio Montini, Giada Farinelli, Francesco Morena, Jesus Segovia, Laetitia C. Schwab, Gerald Downey, John Sharpe, Michela Gabaldo, Sabata Martino, Clelia Di Serio, Fabio Ciceri, Massimo Filippi, Maria Grazia Natali Sora, Maria Ester Bernardo, Luigi Naldini, Alessandra Biffi, Alessandro Aiuti (Italy)

09:22 - 09:33
A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES

Anthony Boitano, John Tisdale, Naoya Uchida, Robert Donahue, Bradley Pearse, Sean McDonough, Jennifer Proctor, Allen Krouse, Nathaniel Linde, Aylin Bonifacino, Rajiv Panwar, Ganapathy Sarma, Lena Kien, Kellie Latimer, Junia Dushime, Sharon Hyzy, Melissa Brooks, Rahul Palchaudhuri, Qing Li, Pranoti Sawant, Charlotte McDonagh, Michael Cooke (United States)

09:33 - 09:44
T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION

Rubiya Nadaf, Michelle Carr, Helena Lee, Denise Bonney, Helen Campbell, Hemalatha Doss, Robert Wynn (United Kingdom)

09:44 - 09:55
LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY

09:55 - 10:06
SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY

10:06 - 10:17
FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)

10:17 - 10:28
CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR

Joint Session
09:00 - 10:00

JS4, Joint session KSBMT: Status of Next Generation Sequencing for indication and monitoring in stem cell transplantation 2020

Chairs:
Nicolaus Kröger (Germany)
Hoon Kook (Korea, Republic of)
Scientific Programme

NGS for indication in myeloid malignancies 09:00 - 09:25
Jae-Sook Ahn (Korea, Republic of)

Discussion 09:25 - 09:30

Disease monitoring post transplant with NGS 09:30 - 09:55
Maximilian Christopeit (Germany)

Discussion 09:55 - 10:00

Educational 11:00 - 12:30

E12, Novel immunotherapies in Multiple Myeloma

Chairs:
Jesús San Miguel (Spain)
Ibrahim Yakoub-Agha (France)

CD38-targeting monoclonal antibodies 11:00 - 11:22
Niels van de Donk (Netherlands)

Bispecific antibodies and BiTEs 11:22 - 11:44

CAR T-cells 11:44 - 12:06
Noopur Raje (United States)

How should we position immunotherapies in the changing paradigm of myeloma treatment? 12:06 - 12:28
Meral Beksac (Turkey)

Educational 11:00 - 12:30

E13, Non-malignant paediatrics

Chairs:
Marta González-Vicent (Spain)
Paul Veys (United Kingdom)

Haplo-identical SCT in haemoglobinopathy: Taking pole position? 11:00 - 11:22
Josu de la Fuente (United Kingdom)

Mismatched family donors in inherited immune disorders: A new perspective 11:22 - 11:44
Mary A. Slatter (United Kingdom)

HSCT for inherited bone marrow failure syndromes 11:44 - 12:06
Cristina Díaz de Heredia (Spain)

Cord blood HSCT for non-malignant diseases in children 12:06 - 12:28
Vanderson Rocha (Brazil)
Scientific Programme

Workshop
11:00 - 12:30

W13, Cellular therapy beyond CAR T-cells

Chairs:
José María Moraleda (Spain)
Fred Falkenburg (Netherlands)

**Gamma-Delta T-cell Therapy**
Jürgen Kuball (Netherlands)

**Stem cell derived NK cell Therapy**
Harry Dolstra (Netherlands)

**MSC and extracellular vesicles in stem cell transplantation**
Fermín Sánchez-Guijo (Spain)

**HLA-mismatched microtransplantation**
Huisheng Ai (China)

Workshop
11:00 - 12:30

Sala Retiro

W14, Who’s the best alternative donor to a matched-sibling?

Chairs:
Fabio Ciceri (Italy)
Maria Jesús Pascual (Spain)

**A matched unrelated donor**
Bronwen Shaw (United States)

**A haploidentical donor**
Mi Kwon (Spain)

**A cord blood unit**
Guillermo Sanz Santillana (Spain)

**Do we have to challenge our current donor hierarchy for patients with hemoglobinopathies?**
Selim Corbacioglu (Germany)

Oral Session
11:00 - 12:30

OS16, Oral session 16 - Chronic leukaemias and MDS

Chairs:
Javier de la Serna (Spain)
Francesco Onida (Italy)
TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT


11:00 - 11:11

RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET

Peter Dreger, Diderik-Jan Eikema, Liesbeth de Wreede, Nina S. Knelange, Leopold Sellner, Jan M. Mideke, Antonin Vitek, Jenny L. Byrne, Christof Scheid, Nicolaus Kröger, Jürgen Finke, Jakob Passweg, Jan J. Cornelissen, Manos Nikolousis, Martin Gramatzki, Laimonas Grisvicius, Jean-Baptiste Mear, Kim Orchard, Paolo Corradini, Zafer Gülbas, Patrick Hayden, Ibrahim Jakoub-Agha, Olivier Tournilhac, Johannes Schetelig (Germany)

11:11 - 11:22

THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA

11:22 - 11:33

DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Juan Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, Dietrich Beelen, Marie Robin, Martin Bornhäuser, Emanuele Angelucci, Antonin Vitek, Igor Wolfgang Blau, Riitta Niittyvuopio, Jürgen Finke, Jan J Cornelissen, Jakob Passweg, Peter Dreger, Eefke Petersen, Lothar Kanz, Jaime Sanz, Tsila Zuckerman, Nienke Zinger, Simon Iacobelli, Patrick Hayden, Tomasz Czerw, Donal McLornan, Ibrahim Yakoub-Agha (Spain)

11:33 - 11:44

COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY

Vipul Sheth, Victoria Potter, Donal McLornan, Hugues Delavallade, Shreyans Gandhi, Austin Kulasekararaj, Francesco Dazzi, Judith Marsh, Ghulam Mufti, Antonio Pagliuca, Kavita Raj (United States)

11:44 - 11:55

Splenectomy doesn't preclude subsequent allogeneic hematopoietic cell transplantation in myelofibrosis patients: A French nationwide study using a multistate model

Jean-Baptiste Bossard, Jean-Baptiste Beuscourt, Marie Robin, Mohamad Mohty, Florenza Barraco, Patrice Chevallier, Tony Marchand, Marie-Thérèse Rubio, Amandine Charbonnier, Didier Blaise, Jacques-Olivier Bay, Carmen Botella-Garcia, Gandhi Damaj, Sébastien Maury, Patrice Ceballos, Thomas Cluzeau, Jérôme Corinon, Mathieu Meunier, Corentin Orvain, Alain Duhamel, Federico Garnier, Jean-Jacques Kiladjian, Ibrahim Yakoub-Agha (France)

11:55 - 12:06

Allogeneic hematopoietic cell transplantation of adult patients with chronic myelomonocytic leukemia: A Nordic retrospective study

Lone Smidstrup Fris, Eileen Wedge, Ingunn Dybedal, Maria Creignou, Elisabeth Ejerblad, Fryderyk Lorenz, Olle Werlenius, Mette Skov Holm, Lars Nilsson, Astrid Olsnes Kittang, Petar Antunovic, Peter Rohon, Jakob Werner Hansen, Mette Klaraskov Andersen, Martin Jädersten, Eva Hellström-Lindberg, Kirsten Grønbæk, Per Ljungman (Denmark)

12:06 - 12:17
DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS
Yan Yu, Bingyu Yang, Zhao Zeng, Lijun Wen, Suning Chen, Aining Sun (China)

12:17 - 12:28

Oral Session
11:00 - 12:30

OS17, Oral session 17 - CAR T-cell therapy 2

Chairs:
Julio Delgado (Spain)
Katy Rezvani (United States)

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2

11:00 - 11:11

SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISCO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

11:11 - 11:22

CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR RE FRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Houli Zhao, Yongxian Hu, Arnon Nagler, Alex Hongsheng Chang, He Huang (China)

11:22 - 11:33

AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)

11:33 - 11:44

THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS

11:44 - 11:55

OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT
Carlos Bachier, M. Lia Palomba, Jeremy Abramson, Charalambos Andreadis, Alison Sehgal, John Godwin, Gerhard Hildebrandt, Tanya Siddiqi, Don Stevens, Thalia Farazi, Ana Kostic, Nikolaus Trede, Lei Wang, James Lymp, Tennille Thelen, Ken Ogasawara, David Maloney (United States)

11:55 - 12:06

CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL

12:06 - 12:17
CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON

Peter Dreger, Lorenz Selberg, Sascha Dietrich, Maria-Luisa Schubert, Andrea Bondong, Mandy Wegner, Peter Stadtherr, Christoph Kimmich, Anita Schmitt, Thomas Luft, Ute Hegenbart, Anthony D. Ho, Carsten Mueller-Tidow, Michael Schmitt (Germany)

LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL

Sarit Assouline, Shen Li, Christian Gisselbrecht, Patrick Fogarty, Annette Hay, Eric van den Nest, Lois E. Shepherd, Norbert Schmitz, Armand Armand, Sue Robinson, Matthew Seftel, Caterina Stelitano, Ralph Meyer, Marina Djurfeldt, Bingshu Chen, Michael Crump (France)

EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT

Marek Trněný, Kerry J. Savage, Steven M. Horwitz, Ranjana Advani, Jacob H. Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Kensei Tobinai, Andrei R. Shustov, Sam Yuen, Pier Luigi Zinzani, Lorenz Trümper, Timothy Illidge, Owen O' Connor, Barbara Pro, Meredith Little, Veronica Bunn, Keenan Fenton, Thomas Manley, Swaminathan P. Iyer (Czech Republic)

LONG-TERM OUTCOME OF PATIENTS RECEIVING HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANTATION AS FIRST TRANSPLANT FOR HIGH-RISK HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE LYMHPOMA WORKING PARTY-EBMT

Gonzalo Gutiérrez-García, Carmen Martinez, Ariane Boumendil, Hervé Finel, Karl Peggs, Ram Maladi, Boris Afanasyev, Anna Tsoukani, Keith M.O. Wilson, Adrian Bloor, Emmanouil Nikolouis, Deborah Richardson, Lucia López-Coral, Luca Castagna, Jan Cornelissen, Mathilde Hunault, Matthew Collin, Renato Fanin, Francesca Bonifazi, Stephen Robinson, Silvia Montoto, Anna Sureda (Spain)

BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT

Scientific Programme

ALLOGENEIC STEM CELL TRANSPANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY

11:44 - 11:55

COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS

Mehdi Hamadani, Carlos Litovich, Manoj Khanal, Timothy Fenske, Kharfan-Dabaja Mohamed, Anna Sureda, Kwang Ahn (United States)

11:55 - 12:06

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE

Nieves Dorado, Gillen Oarbeascoa, Mariana Bastos, Carlos Solano, Isabel Sanchez Ortega, Lucia Lopez Corral, Christelle Ferra, Inmaculada Heras, Maria Jesus Cascon, Arancha Bermudez, Jaime Sanz, Ana Alarcon, Antonia Sampol, Jose Antonio Perez Simon, Carmen Martin, Santiago Jimbra, Pilar Herrera, Karem Humala, Victor Noriega, Jose Luis Diez-Martin, Mi Kwon (Spain)

12:06 - 12:17

ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY

NG25, Nurses Group Highlights and Summary

Nurses Group
11:00 - 12:30

NG25, Nurses Group Highlights and Summary

Chairs:
John Murray (United Kingdom)
Klara Kabatova Maxova (Czech Republic)

Outreach Project India
Veena Paulson (India)

11:00 - 11:20

Best of the Best: Presentation of NG Abstract prizes
John Murray (United Kingdom)

11:20 - 11:40

Highlights from physicians' sessions
Izaskun Zeberio (Spain)

11:40 - 12:00

Presentation of Prague 2021
Klara Kabatova Maxova (Czech Republic)

12:00 - 12:20

Oral Session
11:00 - 12:30

Sala Neptuno

OS19, Oral session 19 - Late effects and quality of life

Chairs:
Valle Gómez (Spain)
Ivan Moiseev (Russian Federation)
Scientific Programme

INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL
Anna Eichinger, Evgenia Glogova, Rita Beier, Tayfun Güngör, Daniel Stachel, Peter Lang, Martin Sauer, Brigitte Strahm, Ansgar Schulz, Bernd Gruhn, Angela Wawer, Hedwig Deubzer, Selim Corbacioglu, Ingo Müller, Christina Peters, Michael Albert (Germany)

11:00 - 11:11

EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Thomas Luft, Tobias Terzer, Ted Gooley, Chris Davis, Brenda Sandmaier, Mohamed Sorror, Olaf Penack, Nigel Shaeper, Igor W. Blau, Dietrich Beelen, Aleksandar Radujkovic, Peter Dreger, Lambros Kordelas (Germany)

11:11 - 11:22

AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR

11:22 - 11:33

RELATIVE SURVIVAL MODELS PROVIDE EVIDENCE THAT LATE NON-RELAPSE MORTALITY CANNOT BE INTERPRETED AS TREATMENT-RELATED MORTALITY FOR OLDER PATIENTS
Liesbeth C de Wreede, Johannes Schetelig, Linda Koster, Damjan Manevski, Christophe Peczynski, Emmanuelle Polge, Hein Putter, Maja Pohar Perme, Henning Baldauf, Dietrich Beelen, Nicolas Kröger, Martin Bornhäuser, Uwe Platzecker, Jürgen Finke, Igor Wolfgang Blau, Victoria Potter, Didier Blaise, Mohamed Mohty, Ibrahim Yakoub-Agha, Silvia Montoto, Zinaida Peric, Olaf Penack, Christian Koennecke, Hélène Schoemans, Grzegorz W. Basak (Netherlands)

11:33 - 11:44

ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER
Avichai Shimoni, Noga Shim-Tov, Ivetta Danylesko, Ronit Yerushalmi, Arnon Nagler (Israel)

11:44 - 12:06

EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONALWIDE SURVEY
Saiko Kurosawa, Takuhito Yamaguchi, Ayako Mori, Tomoko Matsuura, Takehiko Mori, Heiwa Kanamori, Tadakazu Kondo, Shuko Sakamoto, Nobuharu Fuji, Tatsuichinohe, Miho Nara, Tomoya Maeda, Shin Fujisawa, Yuichiro Nawa, Yukinori Nakamura, Hitoshi Minamiguchi, Yasushi Onishi, Kuniko Takano, Miyako Takahashi, Takahiro Fukuda (Japan)

FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST
Erin Sweetser, Daniel Couriel, Catherine Lee, Christopher Barnes, Christopher Noren, Kayla Woodring, Ed Wicklander (United States)

FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS

12:06 - 12:28

OS20, Oral session 20 - Conditioning regimens

Chairs:
Christelle Ferrà (Spain)
Xavier Poiré (Belgium)
Scientific Programme

**POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**


11:00 - 11:12

**FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS**

Eduardo Rodríguez-Arbolí, Myriam Labopin, Johanna Tischer, Arne Brecht, Arnold Ganser, Jürgen Fink, Igor Wolfgang Blau, Nikolaus Kröger, Peter Kalths, Edouard Forcade, Donald Bunjes, Alexandros Spyridonidis, Bipin Savani, Arnon Nagler, Mohamad Mohty (Spain)

11:12 - 11:24

**TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBластIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

Sebastian Giebel, Myriam Labopin, Emanuele Angelucci, Mutlu Arat, Mahmoud Aljurf, Simona Sicca, Jiri Pavlu, Gerard Socié, Paolo Bernasconi, Luigi Rigacci, Johanna Tischer, Antonio Risitano, Montserrat Rovira, Riccardo Saccardi, Pietro Piotelli, Gwendolyn Van Gorkom, Antonin Vitek, Zinaida Peric, Arnon Nagler, Mohamad Mohty (Poland)

11:24 - 11:36

**BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL**

Claire Seydoux, Michael Medinger, Sabine Gerull, Joerg Halter, Dominik Heim, Yves Chalandon, Stavroula Masouridou Levrat, Urs Schanz, Gayathri Nair, Patrick Simon, Jakob Robert Passweg, Nathan Cantoni (Switzerland)

11:36 - 11:48

**RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS**

Madhavi Lakkaraja, Audrey Mauguen, Farid Boulad, Barbara Spitzer, Andromachi Scarradavou, Kevin Curran, Maria Cancio, Ichelle Roessell, Elizabeth Klein, Nancy Kernan, Richard O’Reilly, Susan Prockop, Jaap Jan Boelens (United States)

11:48 - 12:00

**A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT**

12:00 - 12:12

**REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBластIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE**

Ivan Pasic, Kristjan Paulson, Graham Dozois, Kirk R. Schultz, Rajat Kumar (Canada)

12:12 - 12:24
OS21, Oral session 21 - Immunodeficiency, inborn errors and haemoglobinopathies

Chairs:
José M. Fernández Navarro (Spain)
Shahrzad Bakhtiar (Germany)

IMPACT OF DIFFERENT EX VIVO T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY
Su Han Lum, Ali Sobh, Peter McNaughton, Helen Watson, Zohreh Nademi, Stephen Owens, Eleri Williams, Marieke Emonts, Terry Flood, Sophie Hambleton, Mario Abinun, Andrew Cant, Andrew Gennery, Mary Slatter (United Kingdom)

SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS

A PHASE 2 TRIAL OF MGTA-456 CELL THERAPY DEMONSTRATES RAPID AND DURABLE LONG-TERM IMPROVEMENT IN DISEASE OUTCOMES IN INHERITED METABOLIC DISEASE (IMD) PATIENTS
Paul J Orchard, Troy C Lund, Glen D Raffel, Carolyn C Condon, Jennifer A Braun, Ryan Shanley, Ashish Gupta, Anthony E Boitano, John C Davis Jr, John E Wagner (United States)

OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS
Satoshi Miyamoto, Masakatsu Yanaigimachi, Katsutugu Umeda, Akihiro Iguchi, Yoji Sasahara, Hidetoshi Takada, Masafumi Yamada, Masataka Ishimura, Takashi Koike, Masahiro Yasui, Yoshiyuki Takahashi, Hiroshi Kawaguchi, Michiko Kajiwara, Masami Inoue, Koji Kato, Yoshiko Hashii, Yoshiko Atsuta, Hiromasa Yabe, Kohsuke Imai, Tomohiro Morio (Japan)
**46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),**
30 August - 2 September 2020, Madrid, Spain

**Scientific Programme**

**OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

Su Han Lum, Sabeena Selvarajah, Angela Deya-Martinez, Peter McNaughton, Ali Sobh, Sheila Waugh, Shirelle Burton-Fanning, Liz Newton, Julie Gandy, Zohreh Nademi, Stephen Owens, Eleri Williams, Marieke Emonts, Terry Flood, Andrew Cant, Mario Abinun, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

**12:06 - 12:17**

**OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA**

**12:17 - 12:28**

**OS22, Oral session 22 - Experimental approaches**

**Chairs:**
Javier López Jiménez (Spain)
Jean El-Cheikh (Lebanon)

**RESULTS OF A PHASE 1 TRIAL OF GDA-201, NICOTINAMIDE-EXPANDED ALLOGENEIC NATURAL KILLER CELLS (NAM-NK) IN PATIENTS WITH REFRACTORY NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA**

**11:00 - 11:11**

**GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS**

Yang Zhou, Ying-Jun Chang, Le-Qing Cao, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang (China)

**11:11 - 11:22**

**MODULATION OF CYTOSOLIC CA\(^{2+}\) REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY**

**11:22 - 11:33**

**RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCR\(\alpha\beta^+\)/CD19\(^+-\)DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK**

**11:33 - 11:44**

**PHASE II TRIAL OF FECAL MICROBIOTA TRANSPLANTATION FOR STEROID-RESISTANT GASTROINTESTINAL ACUTE GVHD**


**11:44 - 11:55**

**REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY**

Katarina Riesner, Steffen Cordes, Martina Kalupa, Constanze Schwarz, Yu Shi, Sarah Mertlitz, Christophe Peczynski, Steffie van der Werf, Zinaida Peric, Christian Konecke, Helene Schoemans, Rafael F. Duarte, Grzegorz W. Basak, Olaf Penack (Germany)

**11:55 - 12:06**
SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS 12:06 - 12:17
Florent Malard, Faezeh Legrand, Jerome Cornillon, Amandine Le Bourgeois, Jean-Baptiste Mear, Deborah Desmier, Michael Loschi, Emilie Plantamura, Ronald Carter, Thomas Cluzeau, Natacha Maillard, Thierry Lamy de la Chapelle, Patrice Chevallier, Denis Guyotat, Didier Blaise, Mohamad Mohty (France)

LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL 12:17 - 12:28

Joint Session
11:00 - 12:15
N115
JS5, Joint session LABMT: Towards an EBMT-LABMT confluence - Benefits of a mixed chimera
Chairs:
Rafael Duarte (Spain)
Gregorio Jaimovich (Argentina)

Development opportunities for LABMT and EBMT 11:00 - 11:20
Alejandro Madrigal (United Kingdom)
Amado Karduss (Colombia)

Conditioning regimens: Is less better? 11:20 - 11:40
Manuel Abecasis (Portugal)

Accreditation: Experience on implementing the “FACT-JACIE International Stepwise Accreditation Programme” in Latin America 11:40 - 12:00
Patricia Abichain (Argentina)
Raquel Espada (Spain)

Round table discussion: How to strengthen EBMT-LABMT cooperation 12:00 - 12:15

Special Session
12:30 - 13:30
N103

SS10, Best of EBMT 2020
Chairs:
Rafael Duarte (Spain)
Nicolaus Kröger (Germany)

EBMT 2020 highlights: Adults 12:30 - 12:50
Pavel Jindra (Czech Republic)

EBMT 2020 highlights: Basic 12:50 - 13:10
Sergio Querol Giner (Spain)

EBMT 2020 highlights: Paediatrics 13:10 - 13:30
Antonio Pérez-Martínez (Spain)
GS4, Closing Ceremony

**Chairs:**
- Rafael Duarte (Spain)
- Nicolaus Kröger (Germany)
- Pavel Jindra (Czech Republic)
- Petr Sedlacek (Czech Republic)

**Presentation of the Springer Nature Poster Awards**  
13:30 - 13:35  
Nicolaus Kröger (Germany)

**Presentation of the results of the EBMT Fellowship grant 2019: Cord versus marrow: Are young stem cells superior for transplantation?**  
13:35 - 13:40  
Flavia Peci (Netherlands)

**Local President Madrid 2020 closing remarks**  
13:40 - 13:50  
Rafael Duarte (Spain)

**Local Co-Presidents for EBMT 2021 Prague: Welcome**  
13:50 - 14:00  
Pavel Jindra (Czech Republic)  
Petr Sedlacek (Czech Republic)

**EBMT President closing remarks**  
14:00 - 14:05  
Nicolaus Kröger (Germany)